Evaluation of Safety and Immunogenicity of a Human Papillomavirus (HPV) Vaccine in Human Immunodeficiency Virus (HIV) Infected Females

Safety and Immunogenicity of Cervarix™ in Human Immunodeficiency Virus Infected Females

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01031069

Enrollment

873

Registered

2009-12-14

Start date

2010-10-26

Completion date

2017-04-19

Last updated

2020-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infections, Papillomavirus, Papillomavirus Vaccines

Keywords

Cervarix, Gardasil, Immunogenicity, Cervical cancer, Safety, HPV vaccine

Brief summary

Infection with human papillomavirus (HPV) has been clearly established as the central cause of cervical cancer. This Phase IV, observer-blind study is designed to evaluate the safety and immunogenicity of Cervarix in HIV infected females aged 15 to 25 years as compared to Merck's HPV vaccine (Gardasil). For comparative purposes, a group of HIV negative females will also be evaluated. All subjects will receive the HPV vaccine (either Cervarix or Gardasil) according to a three-dose schedule (Day 0, Week 6, Month 6).

Interventions

BIOLOGICALGSK Biologicals' HPV vaccine 580299

Subjects received three doses of the study vaccine administered intramuscularly according to a Day 0, Week 6, and Month 6 vaccination schedule.

BIOLOGICALMerck's Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine (Gardasil)

Subjects received three doses of the study vaccine administered intramuscularly according to a Day 0, Week 6, and Month 6 vaccination schedule.

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

PREVENTION

Masking

TRIPLE (Subject, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

FEMALE

Age

15 Years to 25 Years

Healthy volunteers

Yes

Inclusion criteria

* Subjects who the investigator believes that they and/or their parent(s)/legally acceptable representative(s) (LAR) can and will comply with the requirements of the protocol. * A female between, and including, 15 and 25 years of age at the time of the first vaccination. * Written informed consent obtained from the subject and/or from the subject's parent or LAR. * Subjects willing to undergo HIV Voluntary Counseling and Testing (VCT) and willing to be informed of their HIV infection status. * For HIV seropositive subjects: * Subjects must be HIV seropositive according to World Health Organization (WHO) case definition. * Subject must be asymptomatic (or only have persistent generalized lymphadenopathy). * Subjects should have a CD4 cell count \> 350 cells/mm3. * If currently taking antiretrovirals (ARVs), subjects must be on compliant to triple therapy (highly active ART) and have undetectable viral load on two previous clinical visits within the six months prior to study entry. * For HIV seronegative subjects: * Subjects confirmed as HIV seronegative at the screening visit. * For non-virgin female subjects: * Subjects must have no history of abnormal cytology or CIN 1/2/3. * Subjects must have had no more than six life-time sexual partners prior to enrollment. * Subjects must have no history of congenital malformations of the uterine cervix, or history of cauterization or surgical procedures involving damage to the transformation zone of the cervix or stenosis. * Female subjects of non-childbearing potential may be enrolled in the study. * Female subjects of childbearing potential may be enrolled in the study, if the subject: * has practiced adequate contraception for 30 days prior to vaccination, and * has a negative pregnancy test at screening and on the day of vaccination, and * has agreed to continue adequate contraception during the entire treatment period and for two months after completion of the vaccination series.

Exclusion criteria

* Previous vaccination against HPV, or planned administration of any HPV vaccine other than that foreseen by the study protocol during the study period (Day 0 to Month 24). * ART not compliant with the National Guidelines. * Active tuberculosis (TB) visit (criteria mandatory only for HIV+ subjects). * Current TB therapy. * Hemoglobin \< 8.0 g/dL at the screening visit. * Creatinine \> 1.5-fold the upper limit of normal (ULN) at the screening visit. * Alanine aminotransferase (ALT) \> 2.5-fold ULN at the screening visit. * Use of any investigational or non-registered product (drug or vaccine) other than the study vaccine(s) within 30 days preceding the first dose of study vaccine, or planned use during the study period (Day 0 to Month 24). * Chronic administration (defined as more than 14 consecutive days) of immunosuppressants or other immune-modifying drugs (with the exception of ART) within six months prior to the first vaccine dose. * Administration of a vaccine not foreseen by the study protocol within 30 days (Days 0 - 29) before the first dose of study vaccine/control. Enrollment will be postponed until the subject is outside the specified window. * Planned administration of a vaccine not foreseen by the study protocol within 30 days before or 30 days after (i.e., Days 0 - 29) any dose of study vaccine. * Previous administration of components of the investigational vaccine. * Cancer or autoimmune disease under treatment. * Hypersensitivity to latex. * History of allergic disease or reactions likely to be exacerbated by any component of the vaccine/control. * Acute disease and/or fever at the time of enrollment. * Acute or chronic, clinically significant pulmonary, cardiovascular, hepatic or renal functional abnormality, as determined by physical examination or laboratory testing performed at the screening visit. * History of any neurological disorders or seizures. * Pregnant or breastfeeding female. * A subject planning to become pregnant, likely to become pregnant (as determined by the investigator) or planning to discontinue contraceptive precautions during the study period, up to two months after the last vaccine dose (i.e., up to Month 8). * Concurrently participating in another clinical study, at any time during the study period (Day 0 to Month 24), in which the subject has been or will be exposed to an investigational or a non-investigational product. * Any medically diagnosed or suspected immunodeficient condition (other than HIV for HIV seropositive subjects), based on medical history, physical examination and/or laboratory tests results. * Administration of immunoglobulins and/or any blood products within the three months preceding the first dose of study vaccine/control or planned administration during the study period. Enrollment will be postponed until the subject is outside the specified window. * Administration of trimethoprim/sulphamethoxazole within seven days before the first dose of study vaccine/control, or planned administration of trimethoprim/sulphamethoxazole within seven days after the first dose of study vaccine/control. * Current drugs or alcohol abuse. * Child in care.

Design outcomes

Primary

Measure	Time frame	Description
Number of Human Immunodeficiency Virus Positive Subjects (HIV+) With Any and Grade 3 Solicited Local Symptoms	During the 7-day follow-up period (from the day of vaccination up to 6 subsequent days) after each vaccine dose and across doses	Assessed solicited local symptoms were pain, redness, swelling. Any = occurrence of the symptom regardless of intensity grade. Grade 3 pain = significant pain at rest, pain that prevented normal activity. Grade 3 redness/swelling = redness/swelling with a maximum diameter greater than 50 millimeters (mm).
Number of HIV+ Subjects With Any, Grade 3 and Related Solicited General Symptoms	During the 7-day follow-up period (from the day of vaccination up to 6 subsequent days) after each vaccine dose and across doses	Assessed solicited general symptoms were arthralgia, fatigue, gastrointestinal \[nausea, vomiting, diarrhoea and/or abdominal pain\], headache, myalgia, rash, temperature \[defined as axillary temperature higher than (\>) 37.5 degrees Celsius (°C)\] and urticaria. Any = occurrence of the symptom regardless of intensity grade and relationship. Grade 3 symptom = symptom that prevented normal activity. Grade 3 temperature = temperature \> 39.0 °C. Grade 3 urticaria = urticaria distributed on at least 4 body areas. Related = symptom assessed by the investigator as related to the vaccination.
Number of HIV+ Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs)	During the 30-day follow-up period (from the day of vaccination up to 29 subsequent days) after any vaccination	An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination. Grade 3 symptom = symptom that prevented normal activity. Related = symptom assessed by the investigator as related to the vaccination.
Number of HIV+ Subjects With Serious Adverse Events (SAEs)	From Day 0 up to Month 7 (from Day 0 up to 30 days after the last vaccination dose at Month 6)	SAEs assessed include any untoward medical occurrence that resulted in death, was life-threatening, required hospitalization or prolongation of existing hospitalization, resulted in disability/incapacity or represented a congenital anomaly/birth defect in the offspring of a study subject.
Number of HIV+ Subjects With Medically Significant Conditions (MSCs)	From Day 0 up to Month 7 (from Day 0 up to 30 days after the last vaccination dose at Month 6)	Medically significant conditions (MSCs) are defined as AEs prompting emergency room or physician visits that were not related to common diseases, or not related to routine visits for physical examination or vaccination, SAEs that were not related to common diseases.
Number of HIV+ Subjects With Potential Immune-mediated Diseases (pIMDs)	From Day 0 up to Month 7 (from Day 0 up to 30 days after the last vaccination dose at Month 6)	Potential immune-mediated diseases are a subset of AEs that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune aetiology.
Number of HIV+ Subjects Reporting Pregnancies and Outcomes of Reported Pregnancies	From Day 0 up to Month 7 (from Day 0 up to 30 days after the last vaccination dose at Month 6)	Pregnancy related outcomes were: live infant no apparent congenital anomaly, live infant congenital anomaly, elective termination (termin.) no apparent congenital anomaly, elective termination (termin.) congenital anomaly, ectopic pregnancy, spontaneous abortion no apparent congenital (congen.) anomaly, stillbirth no apparent congenital anomaly, stillbirth congenital anomaly, lost to follow-up, pregnancy ongoing, missing.
Number of HIV+ Subjects With Haematological and Biochemical Parameter Abnormalities	At Month 7 (30 days after the last vaccination dose at Month 6)	Among assessed haematological and biochemical parameters were: alanine aminotransferase \[ALAT\], basophilis \[BSPH\], creatinine \[CRT\], eosinophils \[ESPH\], haematocrit \[HTCR\], haemoglobin \[HGB\], lymphocytes \[LYMP\], monocytes \[MONO\], neutrophils \[NTPH\], platelets \[PLAT\], red blood cells \[RBC\] and white blood cells \[WBC\]. Unknown = value unknown for the specified visit and laboratory parameter; Below = value below the laboratory reference range defined for the specified visit and laboratory parameter; Within = value within the laboratory reference range defined for the specified visit and laboratory parameter; Above = value above the laboratory reference range defined for the specified visit and laboratory parameter.
Cluster of Differentiation 4 (CD4+) Cell Count in HIV+ Subjects at Month 7	At Month 7 (30 days after the last vaccination dose at Month 6)	CD4+ cell count, expressed in cells/cubic millimeter (mm3), was assessed for HIV+ subjects.
HIV Viral Load (VL) in HIV+ Subjects at Month 7	At Month 7 (30 days after the last vaccination dose at Month 6)	HIV VL, expressed in HIV copies/milliliter (mL), was assessed for HIV+ subjects.
Number of HIV+ Subjects by World Health Organization (WHO) HIV Clinical Staging	At Month 7 (30 days after the last vaccination dose at Month 6)	HIV+ subjects were categorised into clinical stages 1 through 4, as per the WHO classification \[WHO, 2009\].
Pseudovirion-Based Neutralization Assay (PBNA) Titers of Anti-HPV-16/18 Antibodies in HIV+ Subjects, Based on Adapted According-to-protocol (ATP) Cohort for Immunogenicity	At Month 7 (30 days after the last vaccination dose at Month 6)	Titers of anti-HPV-16/18 antibodies, expressed as Geometric Mean Titers (GMTs), with cut-offs greater than or equal to (≥) 40 estimated dose giving 50% signal reduction when compared to a control without serum (ED50), as assessed by the Pseudovirion-Based Neutralization Assay \[PBNA\], in HIV+ subjects. Between-group comparisons to assess non-inferiority were performed on the ATP cohort for immunogenicity (by PBNA, regardless of HPV serostatus at baseline).
Pseudovirion-Based Neutralization Assay (PBNA) Titers of Anti-HPV-16/18 Antibodies in HIV+ Subjects, Based on Total Vaccinated Cohort (TVC)	At Month 7 (30 days after the last vaccination dose at Month 6)	Titers of anti-HPV-16/18 antibodies, expressed as Geometric Mean Titers (GMTs), with cut-offs greater than or equal to (≥) 40 estimated dose giving 50% signal reduction when compared to a control without serum (ED50), as assessed by the Pseudovirion-Based Neutralization Assay \[PBNA\], in HIV+ subjects. Between-group comparisons to assess superiority were performed on the TVC (by PBNA, regardless of HPV serostatus at baseline).

Secondary

Measure	Time frame	Description
Cluster of Differentiation 4 (CD4+) Cell Count in HIV+ Subjects at Months 12, 18 and 24	At Months 12, 18 and 24	CD4+ cell count, expressed in cells/cubic millimeter (mm3), was assessed for HIV+ subjects.
HIV Viral Load (VL) in HIV+ Subjects at Months 12, 18 and 24	At Months 12, 18 and 24	HIV VL, expressed in HIV copies/milliliter (mL), was assessed for HIV+ subjects.
Number of HIV+ Subjects by WHO HIV Clinical Staging	At Months 12, 18 and 24	HIV+ subjects were categorised into clinical stages 1 through 4, as per the WHO classification \[WHO, 2009\].
Pseudovirion-Based Neutralization Assay (PBNA) Titers of Anti-HPV-16/18 Antibodies in HIV- Subjects, Based on TVC	At Month 7 (30 days after the last vaccination dose at Month 6)	Titers of anti-HPV-16/18 antibodies, expressed as Geometric Mean Titers (GMTs), with cut-offs greater than or equal to (≥) 40 estimated dose giving 50% signal reduction when compared to a control without serum (ED50), as assessed by the Pseudovirion-Based Neutralization Assay \[PBNA\], for HIV- subjects. Between-group comparisons to assess superiority were performed on the TVC (by PBNA, regardless of HPV serostatus at baseline).
Number of Subjects With SAEs	During the entire study period (from Day 0 up to Month 24)	SAEs assessed include any untoward medical occurrence that resulted in death, was life-threatening, required hospitalization or prolongation of existing hospitalization, resulted in disability/incapacity or represented a congenital anomaly/birth defect in the offspring of a study subject.
Anti-HPV-16 and Anti-HPV-18 Antibody Concentrations by ELISA in Cervicovaginal Secretion (CVS)	At Day 0, Week 6, Week 10, Month 7, Month 12, Month 18 and Month 24	Anti-HPV-16 and anti-HPV-18 antibody concentrations in CVS, are presented as Geometric Mean Concentrations (GMCs), with cut-offs greater than or equal to (≥) 0 EU/mL, as assessed by ELISA, in post-menarcheal subjects who volunteered for this procedure.
Frequency of Specific B-cells for HPV-16/18 Antigens	At Day 0, Week 6, Week 10, Month 7 and Month 12	B-cell memory was assessed by Enzyme Linked Immuno Spot (ELISPOT) assay. The assay was performed in a subset of approximately 100 subjects (50 HIV+ and 50 HIV-).
Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	At Day 0, Week 6, Week 10, Month 7 and Month 12	The combinations of cytokines expressed were CD4/8-all doubles, CD4/8-d-cluster of differentiation 40 Ligand (CD40L), CD4/8-d-interferon gamma (IFNG), CD4/8-interleukin-2 (IL-2), CD4/8-d-tumour necrosis alpha (TNFA), as assessed by Intracellular cytokine staining (ICS). The assay was performed in a subset of approximately 100 subjects (50 HIV+ and 50 HIV-).
Anti-HPV-16 and Anti-HPV-18 Antibody Concentrations by Enzyme-linked Immunosorbent Assay (ELISA) in Serum	At Day 0, Week 6, Week 10, Month 7, Month 12, Month 18 and Month 24	Anti-HPV-16 and anti-HPV-18 antibody concentrations in serum, are presented as Geometric Mean Concentrations (GMCs), with cut-offs greater than or equal to (≥) 19 ELISA units per milliliter (EU/mL) and 18 EU/mL respectively, as assessed by Enzyme-linked immunosorbent assay (ELISA), in all (HIV+ and HIV-) subjects.
Number of HIV- Subjects With Any and Grade 3 Solicited Local Symptoms	During the 7-day follow-up period (from the day of vaccination up to 6 subsequent days) after each vaccine dose and across doses	Assessed solicited local symptoms were pain, redness, swelling. Any = occurrence of the symptom regardless of intensity grade. Grade 3 pain = significant pain at rest, pain that prevented normal activity. Grade 3 redness/swelling = redness/swelling with a maximum diameter greater than 50 millimeters (mm).
Number of HIV- Subjects With Any, Grade 3 and Related Solicited General Symptoms	During the 7-day follow-up period (from the day of vaccination up to 6 subsequent days) after each vaccine dose and across doses	Assessed solicited general symptoms were arthralgia, fatigue, gastrointestinal \[nausea, vomiting, diarrhoea and/or abdominal pain\], headache, myalgia, rash, temperature \[defined as axillary temperature higher than (\>) 37.5 degrees Celsius (°C)\] and urticaria. Any = occurrence of the symptom regardless of intensity grade and relationship. Grade 3 symptom = symptom that prevented normal activity. Grade 3 temperature = temperature \> 39.0 °C. Grade 3 urticaria = urticaria distributed on at least 4 body areas. Related = symptom assessed by the investigator as related to the vaccination.
Number of HIV- Subjects With Unsolicited Adverse Events (AEs)	During the 30-day follow-up period (from the day of vaccination up to 29 subsequent days) after any vaccination	An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination. Grade 3 symptom = symptom that prevented normal activity. Related = symptom assessed by the investigator as related to the vaccination.
Number of HIV- Subjects With Serious Adverse Events (SAEs)	From Day 0 up to Month 7 (from Day 0 up to 30 days after the last vaccination dose at Month 6)	SAEs assessed include any untoward medical occurrence that resulted in death, was life-threatening, required hospitalization or prolongation of existing hospitalization, resulted in disability/incapacity or represented a congenital anomaly/birth defect in the offspring of a study subject.
Number of HIV- Subjects With Medically Significant Conditions (MSCs)	From Day 0 up to Month 7 (from Day 0 up to 30 days after the last vaccination dose at Month 6)	Medically significant conditions (MSCs) are defined as AEs prompting emergency room or physician visits that were not related to common diseases, or not related to routine visits for physical examination or vaccination, SAEs that were not related to common diseases.
Number of HIV- Subjects With Potential Immune-mediated Disease (pIMDs)	From Day 0 up to Month 7 (from Day 0 up to 30 days after the last vaccination dose at Month 6)	Potential immune-mediated diseases are a subset of AEs that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune aetiology.
Number of Subjects Reporting Pregnancies and Outcomes of Reported Pregnancies	During the entire study period (from Day 0 up to Month 24)	Pregnancy related outcomes were: live infant no apparent congenital anomaly, live infant congenital anomaly, elective termination (termin.) no apparent congenital anomaly, elective termination (termin.) congenital anomaly, ectopic pregnancy, spontaneous abortion no apparent congenital (congen.) anomaly, stillbirth no apparent congenital anomaly, stillbirth congenital anomaly, lost to follow-up, pregnancy ongoing, missing.
Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	At Day 0, Week 6, Week 10, Month 6, Month 7, Month 12, Month 18 and Month 24	Among assessed haematological and biochemical parameters were: alanine aminotransferase \[ALAT\], basophils \[BSPH\], creatinine \[CRT\], eosinophils \[ESPH\]. Unknown = value unknown for the specified visit and laboratory parameter; Below = value below the laboratory reference range defined for the specified visit and laboratory parameter; Within = value within the laboratory reference range defined for the specified visit and laboratory parameter; Above = value above the laboratory reference range defined for the specified visit and laboratory parameter.
Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	At Day 0, Week 6, Week 10, Month 6, Month 7, Month 12, Month 18 and Month 24	Among assessed haematological parameters were: haematocrit \[HTCR\], haemoglobin \[HGB\], lymphocytes \[LYMP\] and monocytes \[MONO\]. Unknown = value unknown for the specified visit and laboratory parameter; Below = value below the laboratory reference range defined for the specified visit and laboratory parameter; Within = value within the laboratory reference range defined for the specified visit and laboratory parameter; Above = value above the laboratory reference range defined for the specified visit and laboratory parameter.
Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	At Day 0, Week 6, Week 10, Month 6, Month 7, Month 12, Month 18 and Month 24	Among assessed haematological parameters were: neutrophils \[NTPH\], platelets \[PLAT\], red blood cells \[RBC\] and white blood cells \[WBC\]. Unknown = value unknown for the specified visit and laboratory parameter; Below = value below the laboratory reference range defined for the specified visit and laboratory parameter; Within = value within the laboratory reference range defined for the specified visit and laboratory parameter; Above = value above the laboratory reference range defined for the specified visit and laboratory parameter.
Number of Subjects With Medically Significant Conditions (MSCs)	From Day 0 up to Month 18 (from Day 0 up to 12 months after the last vaccination dose at Month 6)	Medically significant conditions (MSCs) are defined as AEs prompting emergency room or physician visits that were not related to common diseases, or not related to routine visits for physical examination or vaccination, SAEs that were not related to common diseases.
Number of Subjects With Potential Immune-mediated Diseases (pIMDs)	From Day 0 up to Month 18 (from Day 0 up to 12 months after the last vaccination dose at Month 6)	Potential immune-mediated diseases are a subset of AEs that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune aetiology.

Countries

Brazil, Estonia, India, Thailand

Participant flow

Recruitment details

A number of 873 subjects were enrolled, out of which 173 subjects were excluded from all statistical analysis. 154 subjects were not administered any vaccine dose (146 screen failures subjects and 8 subjects that did not participate from Visit 1).

Pre-assignment details

Screening involved: checking of inclusion/exclusion criteria, demographic data, history and physical examination, AF B sputum test and/or chest X-ray, blood sampling for HIV testing and safety, urine pregnancy testing, birth control and HIV, STI, STD counselling, checking records for concomitant medication/vaccination, subject card distribution.

Participants by arm

Arm	Count
HIV+/Cervarix Group HIV seropositive female subjects, between and including 15 and 25 years of age, who received 3 doses of Cervarix vaccine, administered intramuscularly in the deltoid muscle of the non-dominant arm, according to a three-dose schedule: at Day 0, Week 6, Month 6.	129
HIV+/Gardasil Group HIV seropositive female subjects, between and including 15 and 25 years of age, who received 3 doses of Gardasil vaccine, administered intramuscularly in the deltoid muscle of the non-dominant arm, according to a three-dose schedule: at Day 0, Week 6, Month 6.	128
HIV-/Cervarix Group HIV seronegative female subjects, between and including 15 and 25 years of age, who received 3 doses of Cervarix vaccine, administered intramuscularly in the deltoid muscle of the non-dominant arm, according to a three-dose schedule: at Day 0, Week 6, Month 6.	144
HIV-/Gardasil Group HIV seronegative female subjects, between and including 15 and 25 years of age, who received 3 doses of Gardasil vaccine, administered intramuscularly in the deltoid muscle of the non-dominant arm, according to a three-dose schedule: at Day 0, Week 6, Month 6.	145
Total	546

Withdrawals & dropouts

Period	Reason	FG000	FG001	FG002	FG003
Overall Study	Lost to Follow-up	9	5	21	15
Overall Study	Migrated/moved from study area	1	2	1	1
Overall Study	Other	0	0	1	0
Overall Study	Serious Adverse Event	0	1	0	0
Overall Study	Withdrawal by Subject	2	3	18	18

Baseline characteristics

Characteristic	HIV+/Cervarix Group	HIV+/Gardasil Group	HIV-/Cervarix Group	HIV-/Gardasil Group	Total
Age, Continuous	20.4 Years STANDARD_DEVIATION 3.4	20.1 Years STANDARD_DEVIATION 3.5	19.3 Years STANDARD_DEVIATION 3	19.6 Years STANDARD_DEVIATION 3	19.8 Years STANDARD_DEVIATION 3.2
Race/Ethnicity, Customized African Heritage/African American	10 Participants	6 Participants	4 Participants	4 Participants	24 Participants
Race/Ethnicity, Customized Asian - Central/South Asian Heritage	20 Participants	18 Participants	67 Participants	68 Participants	173 Participants
Race/Ethnicity, Customized Asian - East Asian Heritage	3 Participants	2 Participants	1 Participants	0 Participants	6 Participants
Race/Ethnicity, Customized Asian - Japanese Heritage	0 Participants	0 Participants	1 Participants	2 Participants	3 Participants
Race/Ethnicity, Customized Asian - South East Asian Heritage	40 Participants	44 Participants	39 Participants	42 Participants	165 Participants
Race/Ethnicity, Customized Unspecified	6 Participants	9 Participants	1 Participants	4 Participants	20 Participants
Race/Ethnicity, Customized White - Arabic/North African Heritage	17 Participants	12 Participants	7 Participants	6 Participants	42 Participants
Race/Ethnicity, Customized White - Caucasian/European Heritage	33 Participants	37 Participants	24 Participants	19 Participants	113 Participants
Sex: Female, Male Female	129 Participants	128 Participants	144 Participants	145 Participants	546 Participants
Sex: Female, Male Male	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants

Adverse events

Event type	EG000 affected / at risk	EG001 affected / at risk	EG002 affected / at risk	EG003 affected / at risk
deaths Total, all-cause mortality	0 / 129	1 / 128	0 / 144	0 / 145
other Total, other adverse events	123 / 129	109 / 128	136 / 144	127 / 145
serious Total, serious adverse events	9 / 129	9 / 128	4 / 144	1 / 145

Outcome results

Primary

Cluster of Differentiation 4 (CD4+) Cell Count in HIV+ Subjects at Month 7

CD4+ cell count, expressed in cells/cubic millimeter (mm3), was assessed for HIV+ subjects.

Time frame: At Month 7 (30 days after the last vaccination dose at Month 6)

Population: The analysis was performed on the Total Vaccinated cohort, which included all vaccinated subjects for whom data were available at Month 7.

Arm	Measure	Value (MEDIAN)
HIV+/Cervarix Group	Cluster of Differentiation 4 (CD4+) Cell Count in HIV+ Subjects at Month 7	554.0 cells/mm3
HIV+/Gardasil Group	Cluster of Differentiation 4 (CD4+) Cell Count in HIV+ Subjects at Month 7	568.0 cells/mm3

Primary

HIV Viral Load (VL) in HIV+ Subjects at Month 7

HIV VL, expressed in HIV copies/milliliter (mL), was assessed for HIV+ subjects.

Time frame: At Month 7 (30 days after the last vaccination dose at Month 6)

Population: The analysis was performed on the Total Vaccinated cohort, which included all vaccinated subjects for whom data were available at Month 7.

Arm	Measure	Value (MEDIAN)
HIV+/Cervarix Group	HIV Viral Load (VL) in HIV+ Subjects at Month 7	1.9 HIV copies/mL
HIV+/Gardasil Group	HIV Viral Load (VL) in HIV+ Subjects at Month 7	2.5 HIV copies/mL

Primary

Number of HIV+ Subjects by World Health Organization (WHO) HIV Clinical Staging

HIV+ subjects were categorised into clinical stages 1 through 4, as per the WHO classification \[WHO, 2009\].

Time frame: At Month 7 (30 days after the last vaccination dose at Month 6)

Population: The analysis was performed on the Total Vaccinated cohort, which included all vaccinated subjects for whom data were available at Month 7.

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
HIV+/Cervarix Group	Number of HIV+ Subjects by World Health Organization (WHO) HIV Clinical Staging	Clinical Stage 4	1 Participants
HIV+/Cervarix Group	Number of HIV+ Subjects by World Health Organization (WHO) HIV Clinical Staging	Clinical Stage 1	113 Participants
HIV+/Cervarix Group	Number of HIV+ Subjects by World Health Organization (WHO) HIV Clinical Staging	Clinical Stage 2	6 Participants
HIV+/Cervarix Group	Number of HIV+ Subjects by World Health Organization (WHO) HIV Clinical Staging	Clinical Stage 3	1 Participants
HIV+/Gardasil Group	Number of HIV+ Subjects by World Health Organization (WHO) HIV Clinical Staging	Clinical Stage 3	1 Participants
HIV+/Gardasil Group	Number of HIV+ Subjects by World Health Organization (WHO) HIV Clinical Staging	Clinical Stage 4	4 Participants
HIV+/Gardasil Group	Number of HIV+ Subjects by World Health Organization (WHO) HIV Clinical Staging	Clinical Stage 2	2 Participants
HIV+/Gardasil Group	Number of HIV+ Subjects by World Health Organization (WHO) HIV Clinical Staging	Clinical Stage 1	114 Participants

Primary

Number of HIV+ Subjects Reporting Pregnancies and Outcomes of Reported Pregnancies

Pregnancy related outcomes were: live infant no apparent congenital anomaly, live infant congenital anomaly, elective termination (termin.) no apparent congenital anomaly, elective termination (termin.) congenital anomaly, ectopic pregnancy, spontaneous abortion no apparent congenital (congen.) anomaly, stillbirth no apparent congenital anomaly, stillbirth congenital anomaly, lost to follow-up, pregnancy ongoing, missing.

Time frame: From Day 0 up to Month 7 (from Day 0 up to 30 days after the last vaccination dose at Month 6)

Population: The analysis was performed on the Total Vaccinated cohort, which included all vaccinated subjects who reported any pregnancies and outcomes of reported pregnancies.

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
HIV+/Cervarix Group	Number of HIV+ Subjects Reporting Pregnancies and Outcomes of Reported Pregnancies	Spontaneous abortion NO apparent congen. anomaly	1 Participants
HIV+/Cervarix Group	Number of HIV+ Subjects Reporting Pregnancies and Outcomes of Reported Pregnancies	Live infant congenital anomaly	0 Participants
HIV+/Cervarix Group	Number of HIV+ Subjects Reporting Pregnancies and Outcomes of Reported Pregnancies	Stillbirth NO apparent congenital anomaly	0 Participants
HIV+/Cervarix Group	Number of HIV+ Subjects Reporting Pregnancies and Outcomes of Reported Pregnancies	Elective termin. congenital anomaly	0 Participants
HIV+/Cervarix Group	Number of HIV+ Subjects Reporting Pregnancies and Outcomes of Reported Pregnancies	Stillbirth congenital anomaly	0 Participants
HIV+/Cervarix Group	Number of HIV+ Subjects Reporting Pregnancies and Outcomes of Reported Pregnancies	Live infant NO apparent congenital anomaly	3 Participants
HIV+/Cervarix Group	Number of HIV+ Subjects Reporting Pregnancies and Outcomes of Reported Pregnancies	Lost to follow-up	0 Participants
HIV+/Cervarix Group	Number of HIV+ Subjects Reporting Pregnancies and Outcomes of Reported Pregnancies	Ectopic pregnancy	0 Participants
HIV+/Cervarix Group	Number of HIV+ Subjects Reporting Pregnancies and Outcomes of Reported Pregnancies	Pregnancy ongoing	0 Participants
HIV+/Cervarix Group	Number of HIV+ Subjects Reporting Pregnancies and Outcomes of Reported Pregnancies	Missing	0 Participants
HIV+/Cervarix Group	Number of HIV+ Subjects Reporting Pregnancies and Outcomes of Reported Pregnancies	Elective termin. NO apparent congenital anomaly	0 Participants
HIV+/Gardasil Group	Number of HIV+ Subjects Reporting Pregnancies and Outcomes of Reported Pregnancies	Missing	0 Participants
HIV+/Gardasil Group	Number of HIV+ Subjects Reporting Pregnancies and Outcomes of Reported Pregnancies	Live infant NO apparent congenital anomaly	1 Participants
HIV+/Gardasil Group	Number of HIV+ Subjects Reporting Pregnancies and Outcomes of Reported Pregnancies	Live infant congenital anomaly	0 Participants
HIV+/Gardasil Group	Number of HIV+ Subjects Reporting Pregnancies and Outcomes of Reported Pregnancies	Elective termin. NO apparent congenital anomaly	0 Participants
HIV+/Gardasil Group	Number of HIV+ Subjects Reporting Pregnancies and Outcomes of Reported Pregnancies	Elective termin. congenital anomaly	0 Participants
HIV+/Gardasil Group	Number of HIV+ Subjects Reporting Pregnancies and Outcomes of Reported Pregnancies	Ectopic pregnancy	0 Participants
HIV+/Gardasil Group	Number of HIV+ Subjects Reporting Pregnancies and Outcomes of Reported Pregnancies	Spontaneous abortion NO apparent congen. anomaly	1 Participants
HIV+/Gardasil Group	Number of HIV+ Subjects Reporting Pregnancies and Outcomes of Reported Pregnancies	Stillbirth NO apparent congenital anomaly	0 Participants
HIV+/Gardasil Group	Number of HIV+ Subjects Reporting Pregnancies and Outcomes of Reported Pregnancies	Stillbirth congenital anomaly	0 Participants
HIV+/Gardasil Group	Number of HIV+ Subjects Reporting Pregnancies and Outcomes of Reported Pregnancies	Lost to follow-up	0 Participants
HIV+/Gardasil Group	Number of HIV+ Subjects Reporting Pregnancies and Outcomes of Reported Pregnancies	Pregnancy ongoing	0 Participants

Primary

Number of HIV+ Subjects With Any, Grade 3 and Related Solicited General Symptoms

Assessed solicited general symptoms were arthralgia, fatigue, gastrointestinal \[nausea, vomiting, diarrhoea and/or abdominal pain\], headache, myalgia, rash, temperature \[defined as axillary temperature higher than (\>) 37.5 degrees Celsius (°C)\] and urticaria. Any = occurrence of the symptom regardless of intensity grade and relationship. Grade 3 symptom = symptom that prevented normal activity. Grade 3 temperature = temperature \> 39.0 °C. Grade 3 urticaria = urticaria distributed on at least 4 body areas. Related = symptom assessed by the investigator as related to the vaccination.

Time frame: During the 7-day follow-up period (from the day of vaccination up to 6 subsequent days) after each vaccine dose and across doses

Population: The analysis was performed on the Total Vaccinated cohort, which included all vaccinated subjects for whom data were available and who had available symptom sheets completed.

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
HIV+/Cervarix Group	Number of HIV+ Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Urticaria, Dose 1	0 Participants
HIV+/Cervarix Group	Number of HIV+ Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Rash, Dose 2	0 Participants
HIV+/Cervarix Group	Number of HIV+ Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Temperature, Dose 3	10 Participants
HIV+/Cervarix Group	Number of HIV+ Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Temperature, Dose 3	1 Participants
HIV+/Cervarix Group	Number of HIV+ Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Arthralgia, Dose 2	0 Participants
HIV+/Cervarix Group	Number of HIV+ Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Temperature, Dose 3	7 Participants
HIV+/Cervarix Group	Number of HIV+ Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Temperature, Dose 2	11 Participants
HIV+/Cervarix Group	Number of HIV+ Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Urticaria, Dose 3	2 Participants
HIV+/Cervarix Group	Number of HIV+ Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Arthralgia, Dose 1	1 Participants
HIV+/Cervarix Group	Number of HIV+ Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Urticaria, Dose 3	0 Participants
HIV+/Cervarix Group	Number of HIV+ Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Temperature, Dose 2	0 Participants
HIV+/Cervarix Group	Number of HIV+ Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Fatigue, Dose 2	38 Participants
HIV+/Cervarix Group	Number of HIV+ Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Arthralgia, Across Doses	41 Participants
HIV+/Cervarix Group	Number of HIV+ Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Temperature, Dose 2	9 Participants
HIV+/Cervarix Group	Number of HIV+ Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Arthralgia, Across Doses	3 Participants
HIV+/Cervarix Group	Number of HIV+ Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Rash, Across Doses	11 Participants
HIV+/Cervarix Group	Number of HIV+ Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Arthralgia, Across Doses	31 Participants
HIV+/Cervarix Group	Number of HIV+ Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Urticaria, Dose 2	5 Participants
HIV+/Cervarix Group	Number of HIV+ Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Fatigue, Across Doses	73 Participants
HIV+/Cervarix Group	Number of HIV+ Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Fatigue, Dose 2	2 Participants
HIV+/Cervarix Group	Number of HIV+ Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Fatigue, Across Doses	6 Participants
HIV+/Cervarix Group	Number of HIV+ Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Urticaria, Dose 2	1 Participants
HIV+/Cervarix Group	Number of HIV+ Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Fatigue, Across Doses	50 Participants
HIV+/Cervarix Group	Number of HIV+ Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Gastrointestinal, Dose 2	15 Participants
HIV+/Cervarix Group	Number of HIV+ Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Gastrointestinal, Across Doses	41 Participants
HIV+/Cervarix Group	Number of HIV+ Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Urticaria, Dose 2	4 Participants
HIV+/Cervarix Group	Number of HIV+ Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Gastrointestinal, Across Doses	3 Participants
HIV+/Cervarix Group	Number of HIV+ Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Myalgia, Dose 1	49 Participants
HIV+/Cervarix Group	Number of HIV+ Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Gastrointestinal, Across Doses	27 Participants
HIV+/Cervarix Group	Number of HIV+ Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Arthralgia, Dose 3	17 Participants
HIV+/Cervarix Group	Number of HIV+ Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Headache, Across Doses	88 Participants
HIV+/Cervarix Group	Number of HIV+ Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Gastrointestinal, Dose 2	0 Participants
HIV+/Cervarix Group	Number of HIV+ Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Headache, Across Doses	11 Participants
HIV+/Cervarix Group	Number of HIV+ Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Arthralgia, Dose 3	2 Participants
HIV+/Cervarix Group	Number of HIV+ Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Headache, Across Doses	65 Participants
HIV+/Cervarix Group	Number of HIV+ Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Rash, Dose 2	0 Participants
HIV+/Cervarix Group	Number of HIV+ Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Arthralgia, Dose 3	13 Participants
HIV+/Cervarix Group	Number of HIV+ Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Myalgia, Across Doses	7 Participants
HIV+/Cervarix Group	Number of HIV+ Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Gastrointestinal, Dose 2	11 Participants
HIV+/Cervarix Group	Number of HIV+ Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Myalgia, Across Doses	52 Participants
HIV+/Cervarix Group	Number of HIV+ Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Fatigue, Dose 3	40 Participants
HIV+/Cervarix Group	Number of HIV+ Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Urticaria, Across Doses	10 Participants
HIV+/Cervarix Group	Number of HIV+ Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Myalgia, Dose 1	35 Participants
HIV+/Cervarix Group	Number of HIV+ Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Rash, Across Doses	5 Participants
HIV+/Cervarix Group	Number of HIV+ Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Fatigue, Dose 3	1 Participants
HIV+/Cervarix Group	Number of HIV+ Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Temperature, Across Doses	23 Participants
HIV+/Cervarix Group	Number of HIV+ Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Headache, Dose 2	48 Participants
HIV+/Cervarix Group	Number of HIV+ Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Temperature, Across Doses	1 Participants
HIV+/Cervarix Group	Number of HIV+ Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Fatigue, Dose 3	30 Participants
HIV+/Cervarix Group	Number of HIV+ Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Temperature, Across Doses	18 Participants
HIV+/Cervarix Group	Number of HIV+ Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Rash, Across Doses	1 Participants
HIV+/Cervarix Group	Number of HIV+ Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Urticaria, Across Doses	13 Participants
HIV+/Cervarix Group	Number of HIV+ Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Urticaria, Across Doses	1 Participants
HIV+/Cervarix Group	Number of HIV+ Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Gastrointestinal, Dose 3	13 Participants
HIV+/Cervarix Group	Number of HIV+ Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Rash, Dose 1	7 Participants
HIV+/Cervarix Group	Number of HIV+ Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Headache, Dose 2	5 Participants
HIV+/Cervarix Group	Number of HIV+ Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Arthralgia, Dose 1	29 Participants
HIV+/Cervarix Group	Number of HIV+ Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Gastrointestinal, Dose 3	1 Participants
HIV+/Cervarix Group	Number of HIV+ Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Arthralgia, Dose 1	19 Participants
HIV+/Cervarix Group	Number of HIV+ Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Fatigue, Dose 1	50 Participants
HIV+/Cervarix Group	Number of HIV+ Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Rash, Dose 1	1 Participants
HIV+/Cervarix Group	Number of HIV+ Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Fatigue, Dose 1	4 Participants
HIV+/Cervarix Group	Number of HIV+ Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Gastrointestinal, Dose 3	9 Participants
HIV+/Cervarix Group	Number of HIV+ Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Fatigue, Dose 1	30 Participants
HIV+/Cervarix Group	Number of HIV+ Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Headache, Dose 2	30 Participants
HIV+/Cervarix Group	Number of HIV+ Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Gastrointestinal, Dose 1	30 Participants
HIV+/Cervarix Group	Number of HIV+ Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Headache, Dose 3	48 Participants
HIV+/Cervarix Group	Number of HIV+ Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Gastrointestinal, Dose 1	2 Participants
HIV+/Cervarix Group	Number of HIV+ Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Urticaria, Dose 3	2 Participants
HIV+/Cervarix Group	Number of HIV+ Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Gastrointestinal, Dose 1	19 Participants
HIV+/Cervarix Group	Number of HIV+ Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Headache, Dose 3	2 Participants
HIV+/Cervarix Group	Number of HIV+ Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Headache, Dose 1	61 Participants
HIV+/Cervarix Group	Number of HIV+ Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Myalgia, Dose 2	36 Participants
HIV+/Cervarix Group	Number of HIV+ Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Headache, Dose 1	4 Participants
HIV+/Cervarix Group	Number of HIV+ Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Headache, Dose 3	39 Participants
HIV+/Cervarix Group	Number of HIV+ Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Headache, Dose 1	39 Participants
HIV+/Cervarix Group	Number of HIV+ Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Rash, Dose 1	4 Participants
HIV+/Cervarix Group	Number of HIV+ Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Myalgia, Dose 1	2 Participants
HIV+/Cervarix Group	Number of HIV+ Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Myalgia, Dose 3	30 Participants
HIV+/Cervarix Group	Number of HIV+ Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Myalgia, Dose 2	2 Participants
HIV+/Cervarix Group	Number of HIV+ Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Temperature, Dose 1	9 Participants
HIV+/Cervarix Group	Number of HIV+ Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Myalgia, Dose 3	4 Participants
HIV+/Cervarix Group	Number of HIV+ Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Temperature, Dose 1	0 Participants
HIV+/Cervarix Group	Number of HIV+ Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Urticaria, Dose 1	8 Participants
HIV+/Cervarix Group	Number of HIV+ Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Temperature, Dose 1	7 Participants
HIV+/Cervarix Group	Number of HIV+ Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Myalgia, Dose 3	26 Participants
HIV+/Cervarix Group	Number of HIV+ Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Myalgia, Dose 2	25 Participants
HIV+/Cervarix Group	Number of HIV+ Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Urticaria, Dose 1	6 Participants
HIV+/Cervarix Group	Number of HIV+ Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Rash, Dose 3	2 Participants
HIV+/Cervarix Group	Number of HIV+ Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Arthralgia, Dose 2	18 Participants
HIV+/Cervarix Group	Number of HIV+ Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Myalgia, Across Doses	68 Participants
HIV+/Cervarix Group	Number of HIV+ Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Arthralgia, Dose 2	11 Participants
HIV+/Cervarix Group	Number of HIV+ Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Rash, Dose 3	0 Participants
HIV+/Cervarix Group	Number of HIV+ Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Rash, Dose 2	2 Participants
HIV+/Cervarix Group	Number of HIV+ Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Fatigue, Dose 2	20 Participants
HIV+/Cervarix Group	Number of HIV+ Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Rash, Dose 3	1 Participants
HIV+/Gardasil Group	Number of HIV+ Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Urticaria, Across Doses	0 Participants
HIV+/Gardasil Group	Number of HIV+ Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Temperature, Dose 3	12 Participants
HIV+/Gardasil Group	Number of HIV+ Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Rash, Across Doses	5 Participants
HIV+/Gardasil Group	Number of HIV+ Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Urticaria, Across Doses	9 Participants
HIV+/Gardasil Group	Number of HIV+ Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Arthralgia, Dose 1	20 Participants
HIV+/Gardasil Group	Number of HIV+ Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Arthralgia, Dose 1	13 Participants
HIV+/Gardasil Group	Number of HIV+ Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Myalgia, Dose 1	34 Participants
HIV+/Gardasil Group	Number of HIV+ Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Myalgia, Dose 1	25 Participants
HIV+/Gardasil Group	Number of HIV+ Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Rash, Dose 1	0 Participants
HIV+/Gardasil Group	Number of HIV+ Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Urticaria, Dose 1	3 Participants
HIV+/Gardasil Group	Number of HIV+ Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Arthralgia, Dose 2	3 Participants
HIV+/Gardasil Group	Number of HIV+ Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Fatigue, Dose 2	40 Participants
HIV+/Gardasil Group	Number of HIV+ Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Gastrointestinal, Dose 2	17 Participants
HIV+/Gardasil Group	Number of HIV+ Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Gastrointestinal, Dose 2	0 Participants
HIV+/Gardasil Group	Number of HIV+ Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Gastrointestinal, Dose 2	11 Participants
HIV+/Gardasil Group	Number of HIV+ Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Headache, Dose 2	37 Participants
HIV+/Gardasil Group	Number of HIV+ Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Headache, Dose 2	3 Participants
HIV+/Gardasil Group	Number of HIV+ Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Headache, Dose 2	20 Participants
HIV+/Gardasil Group	Number of HIV+ Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Myalgia, Dose 2	26 Participants
HIV+/Gardasil Group	Number of HIV+ Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Myalgia, Dose 2	4 Participants
HIV+/Gardasil Group	Number of HIV+ Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Myalgia, Dose 2	19 Participants
HIV+/Gardasil Group	Number of HIV+ Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Rash, Dose 2	1 Participants
HIV+/Gardasil Group	Number of HIV+ Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Rash, Dose 2	0 Participants
HIV+/Gardasil Group	Number of HIV+ Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Temperature, Dose 2	4 Participants
HIV+/Gardasil Group	Number of HIV+ Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Temperature, Dose 2	0 Participants
HIV+/Gardasil Group	Number of HIV+ Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Temperature, Dose 2	2 Participants
HIV+/Gardasil Group	Number of HIV+ Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Urticaria, Dose 2	4 Participants
HIV+/Gardasil Group	Number of HIV+ Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Urticaria, Dose 2	0 Participants
HIV+/Gardasil Group	Number of HIV+ Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Urticaria, Dose 2	4 Participants
HIV+/Gardasil Group	Number of HIV+ Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Arthralgia, Dose 3	15 Participants
HIV+/Gardasil Group	Number of HIV+ Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Arthralgia, Dose 3	1 Participants
HIV+/Gardasil Group	Number of HIV+ Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Arthralgia, Dose 3	12 Participants
HIV+/Gardasil Group	Number of HIV+ Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Fatigue, Dose 3	31 Participants
HIV+/Gardasil Group	Number of HIV+ Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Fatigue, Dose 3	1 Participants
HIV+/Gardasil Group	Number of HIV+ Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Fatigue, Dose 3	22 Participants
HIV+/Gardasil Group	Number of HIV+ Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Gastrointestinal, Dose 3	17 Participants
HIV+/Gardasil Group	Number of HIV+ Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Gastrointestinal, Dose 3	1 Participants
HIV+/Gardasil Group	Number of HIV+ Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Gastrointestinal, Dose 3	13 Participants
HIV+/Gardasil Group	Number of HIV+ Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Headache, Dose 3	27 Participants
HIV+/Gardasil Group	Number of HIV+ Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Headache, Dose 3	2 Participants
HIV+/Gardasil Group	Number of HIV+ Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Headache, Dose 3	16 Participants
HIV+/Gardasil Group	Number of HIV+ Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Myalgia, Dose 3	21 Participants
HIV+/Gardasil Group	Number of HIV+ Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Myalgia, Dose 3	1 Participants
HIV+/Gardasil Group	Number of HIV+ Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Myalgia, Dose 3	17 Participants
HIV+/Gardasil Group	Number of HIV+ Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Rash, Dose 3	1 Participants
HIV+/Gardasil Group	Number of HIV+ Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Rash, Dose 3	0 Participants
HIV+/Gardasil Group	Number of HIV+ Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Rash, Dose 2	0 Participants
HIV+/Gardasil Group	Number of HIV+ Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Rash, Dose 3	0 Participants
HIV+/Gardasil Group	Number of HIV+ Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Temperature, Dose 3	1 Participants
HIV+/Gardasil Group	Number of HIV+ Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Temperature, Dose 3	6 Participants
HIV+/Gardasil Group	Number of HIV+ Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Urticaria, Dose 3	4 Participants
HIV+/Gardasil Group	Number of HIV+ Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Urticaria, Dose 3	0 Participants
HIV+/Gardasil Group	Number of HIV+ Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Urticaria, Dose 3	2 Participants
HIV+/Gardasil Group	Number of HIV+ Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Arthralgia, Across Doses	38 Participants
HIV+/Gardasil Group	Number of HIV+ Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Arthralgia, Across Doses	4 Participants
HIV+/Gardasil Group	Number of HIV+ Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Arthralgia, Across Doses	28 Participants
HIV+/Gardasil Group	Number of HIV+ Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Fatigue, Across Doses	59 Participants
HIV+/Gardasil Group	Number of HIV+ Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Fatigue, Across Doses	2 Participants
HIV+/Gardasil Group	Number of HIV+ Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Fatigue, Across Doses	39 Participants
HIV+/Gardasil Group	Number of HIV+ Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Gastrointestinal, Across Doses	35 Participants
HIV+/Gardasil Group	Number of HIV+ Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Gastrointestinal, Across Doses	1 Participants
HIV+/Gardasil Group	Number of HIV+ Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Gastrointestinal, Across Doses	23 Participants
HIV+/Gardasil Group	Number of HIV+ Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Headache, Across Doses	63 Participants
HIV+/Gardasil Group	Number of HIV+ Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Headache, Across Doses	4 Participants
HIV+/Gardasil Group	Number of HIV+ Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Headache, Across Doses	39 Participants
HIV+/Gardasil Group	Number of HIV+ Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Myalgia, Across Doses	51 Participants
HIV+/Gardasil Group	Number of HIV+ Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Myalgia, Across Doses	4 Participants
HIV+/Gardasil Group	Number of HIV+ Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Myalgia, Across Doses	37 Participants
HIV+/Gardasil Group	Number of HIV+ Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Rash, Across Doses	0 Participants
HIV+/Gardasil Group	Number of HIV+ Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Rash, Across Doses	0 Participants
HIV+/Gardasil Group	Number of HIV+ Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Temperature, Across Doses	19 Participants
HIV+/Gardasil Group	Number of HIV+ Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Temperature, Across Doses	1 Participants
HIV+/Gardasil Group	Number of HIV+ Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Temperature, Across Doses	10 Participants
HIV+/Gardasil Group	Number of HIV+ Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Urticaria, Across Doses	8 Participants
HIV+/Gardasil Group	Number of HIV+ Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Rash, Dose 1	4 Participants
HIV+/Gardasil Group	Number of HIV+ Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Arthralgia, Dose 1	1 Participants
HIV+/Gardasil Group	Number of HIV+ Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Fatigue, Dose 1	47 Participants
HIV+/Gardasil Group	Number of HIV+ Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Fatigue, Dose 1	0 Participants
HIV+/Gardasil Group	Number of HIV+ Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Fatigue, Dose 1	29 Participants
HIV+/Gardasil Group	Number of HIV+ Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Gastrointestinal, Dose 1	21 Participants
HIV+/Gardasil Group	Number of HIV+ Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Gastrointestinal, Dose 1	0 Participants
HIV+/Gardasil Group	Number of HIV+ Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Gastrointestinal, Dose 1	15 Participants
HIV+/Gardasil Group	Number of HIV+ Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Headache, Dose 1	48 Participants
HIV+/Gardasil Group	Number of HIV+ Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Headache, Dose 1	1 Participants
HIV+/Gardasil Group	Number of HIV+ Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Headache, Dose 1	27 Participants
HIV+/Gardasil Group	Number of HIV+ Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Myalgia, Dose 1	1 Participants
HIV+/Gardasil Group	Number of HIV+ Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Rash, Dose 1	0 Participants
HIV+/Gardasil Group	Number of HIV+ Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Temperature, Dose 1	5 Participants
HIV+/Gardasil Group	Number of HIV+ Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Temperature, Dose 1	0 Participants
HIV+/Gardasil Group	Number of HIV+ Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Temperature, Dose 1	4 Participants
HIV+/Gardasil Group	Number of HIV+ Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Urticaria, Dose 1	0 Participants
HIV+/Gardasil Group	Number of HIV+ Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Urticaria, Dose 1	3 Participants
HIV+/Gardasil Group	Number of HIV+ Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Arthralgia, Dose 2	21 Participants
HIV+/Gardasil Group	Number of HIV+ Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Arthralgia, Dose 2	14 Participants
HIV+/Gardasil Group	Number of HIV+ Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Fatigue, Dose 2	1 Participants
HIV+/Gardasil Group	Number of HIV+ Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Fatigue, Dose 2	25 Participants

Primary

Number of HIV+ Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs)

An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination. Grade 3 symptom = symptom that prevented normal activity. Related = symptom assessed by the investigator as related to the vaccination.

Time frame: During the 30-day follow-up period (from the day of vaccination up to 29 subsequent days) after any vaccination

Population: The analysis was performed on the Total Vaccinated cohort for analysis of safety, which included all subjects with at least one vaccine administration documented.

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
HIV+/Cervarix Group	Number of HIV+ Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs)	Any AE(s)	41 Participants
HIV+/Cervarix Group	Number of HIV+ Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs)	Grade 3 AE(s)	7 Participants
HIV+/Cervarix Group	Number of HIV+ Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs)	Related AE(s)	9 Participants
HIV+/Gardasil Group	Number of HIV+ Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs)	Any AE(s)	41 Participants
HIV+/Gardasil Group	Number of HIV+ Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs)	Grade 3 AE(s)	4 Participants
HIV+/Gardasil Group	Number of HIV+ Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs)	Related AE(s)	8 Participants

Primary

Number of HIV+ Subjects With Haematological and Biochemical Parameter Abnormalities

Among assessed haematological and biochemical parameters were: alanine aminotransferase \[ALAT\], basophilis \[BSPH\], creatinine \[CRT\], eosinophils \[ESPH\], haematocrit \[HTCR\], haemoglobin \[HGB\], lymphocytes \[LYMP\], monocytes \[MONO\], neutrophils \[NTPH\], platelets \[PLAT\], red blood cells \[RBC\] and white blood cells \[WBC\]. Unknown = value unknown for the specified visit and laboratory parameter; Below = value below the laboratory reference range defined for the specified visit and laboratory parameter; Within = value within the laboratory reference range defined for the specified visit and laboratory parameter; Above = value above the laboratory reference range defined for the specified visit and laboratory parameter.

Time frame: At Month 7 (30 days after the last vaccination dose at Month 6)

Population: The analysis was performed on the Total Vaccinated cohort, which included all vaccinated subjects for whom data were available at Month 7.

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
HIV+/Cervarix Group	Number of HIV+ Subjects With Haematological and Biochemical Parameter Abnormalities	HGB, Below	28 Participants
HIV+/Cervarix Group	Number of HIV+ Subjects With Haematological and Biochemical Parameter Abnormalities	BSPH, Unknown	0 Participants
HIV+/Cervarix Group	Number of HIV+ Subjects With Haematological and Biochemical Parameter Abnormalities	HGB, Within	92 Participants
HIV+/Cervarix Group	Number of HIV+ Subjects With Haematological and Biochemical Parameter Abnormalities	CRT, Unknown	0 Participants
HIV+/Cervarix Group	Number of HIV+ Subjects With Haematological and Biochemical Parameter Abnormalities	HGB, Above	1 Participants
HIV+/Cervarix Group	Number of HIV+ Subjects With Haematological and Biochemical Parameter Abnormalities	HGB, Unknown	0 Participants
HIV+/Cervarix Group	Number of HIV+ Subjects With Haematological and Biochemical Parameter Abnormalities	LYMP, Unknown	0 Participants
HIV+/Cervarix Group	Number of HIV+ Subjects With Haematological and Biochemical Parameter Abnormalities	BSPH, Within	120 Participants
HIV+/Cervarix Group	Number of HIV+ Subjects With Haematological and Biochemical Parameter Abnormalities	LYMP, Below	12 Participants
HIV+/Cervarix Group	Number of HIV+ Subjects With Haematological and Biochemical Parameter Abnormalities	BSPH, Below	0 Participants
HIV+/Cervarix Group	Number of HIV+ Subjects With Haematological and Biochemical Parameter Abnormalities	LYMP, Within	96 Participants
HIV+/Cervarix Group	Number of HIV+ Subjects With Haematological and Biochemical Parameter Abnormalities	BSPH, Above	1 Participants
HIV+/Cervarix Group	Number of HIV+ Subjects With Haematological and Biochemical Parameter Abnormalities	LYMP, Above	13 Participants
HIV+/Cervarix Group	Number of HIV+ Subjects With Haematological and Biochemical Parameter Abnormalities	CRT, Below	29 Participants
HIV+/Cervarix Group	Number of HIV+ Subjects With Haematological and Biochemical Parameter Abnormalities	MONO, Below	4 Participants
HIV+/Cervarix Group	Number of HIV+ Subjects With Haematological and Biochemical Parameter Abnormalities	MONO, Unknown	0 Participants
HIV+/Cervarix Group	Number of HIV+ Subjects With Haematological and Biochemical Parameter Abnormalities	MONO, Within	106 Participants
HIV+/Cervarix Group	Number of HIV+ Subjects With Haematological and Biochemical Parameter Abnormalities	PLAT, Above	2 Participants
HIV+/Cervarix Group	Number of HIV+ Subjects With Haematological and Biochemical Parameter Abnormalities	MONO, Above	11 Participants
HIV+/Cervarix Group	Number of HIV+ Subjects With Haematological and Biochemical Parameter Abnormalities	CRT, Above	1 Participants
HIV+/Cervarix Group	Number of HIV+ Subjects With Haematological and Biochemical Parameter Abnormalities	NTPH, Unknown	0 Participants
HIV+/Cervarix Group	Number of HIV+ Subjects With Haematological and Biochemical Parameter Abnormalities	RBC, Above	3 Participants
HIV+/Cervarix Group	Number of HIV+ Subjects With Haematological and Biochemical Parameter Abnormalities	ESPH, Unknown	0 Participants
HIV+/Cervarix Group	Number of HIV+ Subjects With Haematological and Biochemical Parameter Abnormalities	NTPH, Below	16 Participants
HIV+/Cervarix Group	Number of HIV+ Subjects With Haematological and Biochemical Parameter Abnormalities	WBC, Below	10 Participants
HIV+/Cervarix Group	Number of HIV+ Subjects With Haematological and Biochemical Parameter Abnormalities	NTPH, Within	97 Participants
HIV+/Cervarix Group	Number of HIV+ Subjects With Haematological and Biochemical Parameter Abnormalities	WBC, Above	5 Participants
HIV+/Cervarix Group	Number of HIV+ Subjects With Haematological and Biochemical Parameter Abnormalities	NTPH, Above	8 Participants
HIV+/Cervarix Group	Number of HIV+ Subjects With Haematological and Biochemical Parameter Abnormalities	ESPH, Within	108 Participants
HIV+/Cervarix Group	Number of HIV+ Subjects With Haematological and Biochemical Parameter Abnormalities	PLAT, Unknown	0 Participants
HIV+/Cervarix Group	Number of HIV+ Subjects With Haematological and Biochemical Parameter Abnormalities	ALAT, Unknown	0 Participants
HIV+/Cervarix Group	Number of HIV+ Subjects With Haematological and Biochemical Parameter Abnormalities	PLAT, Below	1 Participants
HIV+/Cervarix Group	Number of HIV+ Subjects With Haematological and Biochemical Parameter Abnormalities	ESPH, Above	4 Participants
HIV+/Cervarix Group	Number of HIV+ Subjects With Haematological and Biochemical Parameter Abnormalities	PLAT, Within	118 Participants
HIV+/Cervarix Group	Number of HIV+ Subjects With Haematological and Biochemical Parameter Abnormalities	HTCR, Unknown	0 Participants
HIV+/Cervarix Group	Number of HIV+ Subjects With Haematological and Biochemical Parameter Abnormalities	CRT, Within	91 Participants
HIV+/Cervarix Group	Number of HIV+ Subjects With Haematological and Biochemical Parameter Abnormalities	RBC, Unknown	0 Participants
HIV+/Cervarix Group	Number of HIV+ Subjects With Haematological and Biochemical Parameter Abnormalities	HTCR, Below	19 Participants
HIV+/Cervarix Group	Number of HIV+ Subjects With Haematological and Biochemical Parameter Abnormalities	RBC, Below	36 Participants
HIV+/Cervarix Group	Number of HIV+ Subjects With Haematological and Biochemical Parameter Abnormalities	RBC, Within	82 Participants
HIV+/Cervarix Group	Number of HIV+ Subjects With Haematological and Biochemical Parameter Abnormalities	HTCR, Within	101 Participants
HIV+/Cervarix Group	Number of HIV+ Subjects With Haematological and Biochemical Parameter Abnormalities	ALAT, Below	4 Participants
HIV+/Cervarix Group	Number of HIV+ Subjects With Haematological and Biochemical Parameter Abnormalities	WBC, Unknown	0 Participants
HIV+/Cervarix Group	Number of HIV+ Subjects With Haematological and Biochemical Parameter Abnormalities	HTCR, Above	1 Participants
HIV+/Cervarix Group	Number of HIV+ Subjects With Haematological and Biochemical Parameter Abnormalities	ESPH, Below	9 Participants
HIV+/Cervarix Group	Number of HIV+ Subjects With Haematological and Biochemical Parameter Abnormalities	WBC, Within	106 Participants
HIV+/Cervarix Group	Number of HIV+ Subjects With Haematological and Biochemical Parameter Abnormalities	ALAT, Within	110 Participants
HIV+/Cervarix Group	Number of HIV+ Subjects With Haematological and Biochemical Parameter Abnormalities	ALAT, Above	7 Participants
HIV+/Gardasil Group	Number of HIV+ Subjects With Haematological and Biochemical Parameter Abnormalities	WBC, Above	4 Participants
HIV+/Gardasil Group	Number of HIV+ Subjects With Haematological and Biochemical Parameter Abnormalities	ALAT, Above	13 Participants
HIV+/Gardasil Group	Number of HIV+ Subjects With Haematological and Biochemical Parameter Abnormalities	BSPH, Above	0 Participants
HIV+/Gardasil Group	Number of HIV+ Subjects With Haematological and Biochemical Parameter Abnormalities	CRT, Unknown	0 Participants
HIV+/Gardasil Group	Number of HIV+ Subjects With Haematological and Biochemical Parameter Abnormalities	ESPH, Above	5 Participants
HIV+/Gardasil Group	Number of HIV+ Subjects With Haematological and Biochemical Parameter Abnormalities	HTCR, Below	27 Participants
HIV+/Gardasil Group	Number of HIV+ Subjects With Haematological and Biochemical Parameter Abnormalities	LYMP, Above	13 Participants
HIV+/Gardasil Group	Number of HIV+ Subjects With Haematological and Biochemical Parameter Abnormalities	ALAT, Unknown	0 Participants
HIV+/Gardasil Group	Number of HIV+ Subjects With Haematological and Biochemical Parameter Abnormalities	ALAT, Below	3 Participants
HIV+/Gardasil Group	Number of HIV+ Subjects With Haematological and Biochemical Parameter Abnormalities	ALAT, Within	105 Participants
HIV+/Gardasil Group	Number of HIV+ Subjects With Haematological and Biochemical Parameter Abnormalities	BSPH, Unknown	0 Participants
HIV+/Gardasil Group	Number of HIV+ Subjects With Haematological and Biochemical Parameter Abnormalities	BSPH, Below	0 Participants
HIV+/Gardasil Group	Number of HIV+ Subjects With Haematological and Biochemical Parameter Abnormalities	BSPH, Within	121 Participants
HIV+/Gardasil Group	Number of HIV+ Subjects With Haematological and Biochemical Parameter Abnormalities	CRT, Below	36 Participants
HIV+/Gardasil Group	Number of HIV+ Subjects With Haematological and Biochemical Parameter Abnormalities	CRT, Within	84 Participants
HIV+/Gardasil Group	Number of HIV+ Subjects With Haematological and Biochemical Parameter Abnormalities	CRT, Above	0 Participants
HIV+/Gardasil Group	Number of HIV+ Subjects With Haematological and Biochemical Parameter Abnormalities	ESPH, Unknown	0 Participants
HIV+/Gardasil Group	Number of HIV+ Subjects With Haematological and Biochemical Parameter Abnormalities	ESPH, Below	10 Participants
HIV+/Gardasil Group	Number of HIV+ Subjects With Haematological and Biochemical Parameter Abnormalities	ESPH, Within	106 Participants
HIV+/Gardasil Group	Number of HIV+ Subjects With Haematological and Biochemical Parameter Abnormalities	HTCR, Unknown	0 Participants
HIV+/Gardasil Group	Number of HIV+ Subjects With Haematological and Biochemical Parameter Abnormalities	HTCR, Within	92 Participants
HIV+/Gardasil Group	Number of HIV+ Subjects With Haematological and Biochemical Parameter Abnormalities	HTCR, Above	2 Participants
HIV+/Gardasil Group	Number of HIV+ Subjects With Haematological and Biochemical Parameter Abnormalities	HGB, Unknown	0 Participants
HIV+/Gardasil Group	Number of HIV+ Subjects With Haematological and Biochemical Parameter Abnormalities	HGB, Below	37 Participants
HIV+/Gardasil Group	Number of HIV+ Subjects With Haematological and Biochemical Parameter Abnormalities	HGB, Within	83 Participants
HIV+/Gardasil Group	Number of HIV+ Subjects With Haematological and Biochemical Parameter Abnormalities	HGB, Above	1 Participants
HIV+/Gardasil Group	Number of HIV+ Subjects With Haematological and Biochemical Parameter Abnormalities	LYMP, Unknown	0 Participants
HIV+/Gardasil Group	Number of HIV+ Subjects With Haematological and Biochemical Parameter Abnormalities	LYMP, Below	11 Participants
HIV+/Gardasil Group	Number of HIV+ Subjects With Haematological and Biochemical Parameter Abnormalities	LYMP, Within	97 Participants
HIV+/Gardasil Group	Number of HIV+ Subjects With Haematological and Biochemical Parameter Abnormalities	MONO, Unknown	0 Participants
HIV+/Gardasil Group	Number of HIV+ Subjects With Haematological and Biochemical Parameter Abnormalities	MONO, Below	7 Participants
HIV+/Gardasil Group	Number of HIV+ Subjects With Haematological and Biochemical Parameter Abnormalities	MONO, Within	97 Participants
HIV+/Gardasil Group	Number of HIV+ Subjects With Haematological and Biochemical Parameter Abnormalities	MONO, Above	17 Participants
HIV+/Gardasil Group	Number of HIV+ Subjects With Haematological and Biochemical Parameter Abnormalities	NTPH, Unknown	0 Participants
HIV+/Gardasil Group	Number of HIV+ Subjects With Haematological and Biochemical Parameter Abnormalities	RBC, Below	34 Participants
HIV+/Gardasil Group	Number of HIV+ Subjects With Haematological and Biochemical Parameter Abnormalities	NTPH, Below	17 Participants
HIV+/Gardasil Group	Number of HIV+ Subjects With Haematological and Biochemical Parameter Abnormalities	NTPH, Within	93 Participants
HIV+/Gardasil Group	Number of HIV+ Subjects With Haematological and Biochemical Parameter Abnormalities	NTPH, Above	11 Participants
HIV+/Gardasil Group	Number of HIV+ Subjects With Haematological and Biochemical Parameter Abnormalities	PLAT, Unknown	0 Participants
HIV+/Gardasil Group	Number of HIV+ Subjects With Haematological and Biochemical Parameter Abnormalities	PLAT, Below	3 Participants
HIV+/Gardasil Group	Number of HIV+ Subjects With Haematological and Biochemical Parameter Abnormalities	PLAT, Within	114 Participants
HIV+/Gardasil Group	Number of HIV+ Subjects With Haematological and Biochemical Parameter Abnormalities	PLAT, Above	4 Participants
HIV+/Gardasil Group	Number of HIV+ Subjects With Haematological and Biochemical Parameter Abnormalities	RBC, Unknown	0 Participants
HIV+/Gardasil Group	Number of HIV+ Subjects With Haematological and Biochemical Parameter Abnormalities	RBC, Within	84 Participants
HIV+/Gardasil Group	Number of HIV+ Subjects With Haematological and Biochemical Parameter Abnormalities	RBC, Above	3 Participants
HIV+/Gardasil Group	Number of HIV+ Subjects With Haematological and Biochemical Parameter Abnormalities	WBC, Unknown	0 Participants
HIV+/Gardasil Group	Number of HIV+ Subjects With Haematological and Biochemical Parameter Abnormalities	WBC, Below	9 Participants
HIV+/Gardasil Group	Number of HIV+ Subjects With Haematological and Biochemical Parameter Abnormalities	WBC, Within	108 Participants

Primary

Number of HIV+ Subjects With Medically Significant Conditions (MSCs)

Medically significant conditions (MSCs) are defined as AEs prompting emergency room or physician visits that were not related to common diseases, or not related to routine visits for physical examination or vaccination, SAEs that were not related to common diseases.

Time frame: From Day 0 up to Month 7 (from Day 0 up to 30 days after the last vaccination dose at Month 6)

Population: The analysis was performed on the Total Vaccinated cohort for analysis of safety, which included all subjects with at least one vaccine administration documented.

Arm	Measure	Value (COUNT_OF_PARTICIPANTS)
HIV+/Cervarix Group	Number of HIV+ Subjects With Medically Significant Conditions (MSCs)	17 Participants
HIV+/Gardasil Group	Number of HIV+ Subjects With Medically Significant Conditions (MSCs)	27 Participants

Primary

Number of HIV+ Subjects With Potential Immune-mediated Diseases (pIMDs)

Potential immune-mediated diseases are a subset of AEs that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune aetiology.

Time frame: From Day 0 up to Month 7 (from Day 0 up to 30 days after the last vaccination dose at Month 6)

Population: The analysis was performed on the Total Vaccinated cohort for analysis of safety, which included all subjects with at least one vaccine administration documented.

Arm	Measure	Value (COUNT_OF_PARTICIPANTS)
HIV+/Cervarix Group	Number of HIV+ Subjects With Potential Immune-mediated Diseases (pIMDs)	1 Participants
HIV+/Gardasil Group	Number of HIV+ Subjects With Potential Immune-mediated Diseases (pIMDs)	0 Participants

Primary

Number of HIV+ Subjects With Serious Adverse Events (SAEs)

SAEs assessed include any untoward medical occurrence that resulted in death, was life-threatening, required hospitalization or prolongation of existing hospitalization, resulted in disability/incapacity or represented a congenital anomaly/birth defect in the offspring of a study subject.

Time frame: From Day 0 up to Month 7 (from Day 0 up to 30 days after the last vaccination dose at Month 6)

Population: The analysis was performed on the Total Vaccinated cohort for analysis of safety, which included all subjects with at least one vaccine administration documented.

Arm	Measure	Value (COUNT_OF_PARTICIPANTS)
HIV+/Cervarix Group	Number of HIV+ Subjects With Serious Adverse Events (SAEs)	6 Participants
HIV+/Gardasil Group	Number of HIV+ Subjects With Serious Adverse Events (SAEs)	6 Participants

Primary

Number of Human Immunodeficiency Virus Positive Subjects (HIV+) With Any and Grade 3 Solicited Local Symptoms

Assessed solicited local symptoms were pain, redness, swelling. Any = occurrence of the symptom regardless of intensity grade. Grade 3 pain = significant pain at rest, pain that prevented normal activity. Grade 3 redness/swelling = redness/swelling with a maximum diameter greater than 50 millimeters (mm).

Time frame: During the 7-day follow-up period (from the day of vaccination up to 6 subsequent days) after each vaccine dose and across doses

Population: The analysis was performed on the Total Vaccinated cohort, which included all vaccinated subjects for whom data were available and who had available symptom sheets completed.

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
HIV+/Cervarix Group	Number of Human Immunodeficiency Virus Positive Subjects (HIV+) With Any and Grade 3 Solicited Local Symptoms	Any Swelling, Across Doses	38 Participants
HIV+/Cervarix Group	Number of Human Immunodeficiency Virus Positive Subjects (HIV+) With Any and Grade 3 Solicited Local Symptoms	Any Redness, Dose 2	18 Participants
HIV+/Cervarix Group	Number of Human Immunodeficiency Virus Positive Subjects (HIV+) With Any and Grade 3 Solicited Local Symptoms	Any Redness, Dose 1	24 Participants
HIV+/Cervarix Group	Number of Human Immunodeficiency Virus Positive Subjects (HIV+) With Any and Grade 3 Solicited Local Symptoms	Grade 3 Redness, Dose 2	1 Participants
HIV+/Cervarix Group	Number of Human Immunodeficiency Virus Positive Subjects (HIV+) With Any and Grade 3 Solicited Local Symptoms	Grade 3 Pain, Dose 1	4 Participants
HIV+/Cervarix Group	Number of Human Immunodeficiency Virus Positive Subjects (HIV+) With Any and Grade 3 Solicited Local Symptoms	Grade 3 Pain, Across Doses	11 Participants
HIV+/Cervarix Group	Number of Human Immunodeficiency Virus Positive Subjects (HIV+) With Any and Grade 3 Solicited Local Symptoms	Grade 3 Swelling, Dose 2	0 Participants
HIV+/Cervarix Group	Number of Human Immunodeficiency Virus Positive Subjects (HIV+) With Any and Grade 3 Solicited Local Symptoms	Any Redness, Across Doses	41 Participants
HIV+/Cervarix Group	Number of Human Immunodeficiency Virus Positive Subjects (HIV+) With Any and Grade 3 Solicited Local Symptoms	Any Pain, Dose 3	87 Participants
HIV+/Cervarix Group	Number of Human Immunodeficiency Virus Positive Subjects (HIV+) With Any and Grade 3 Solicited Local Symptoms	Any Swelling, Dose 1	25 Participants
HIV+/Cervarix Group	Number of Human Immunodeficiency Virus Positive Subjects (HIV+) With Any and Grade 3 Solicited Local Symptoms	Grade 3 Pain, Dose 3	5 Participants
HIV+/Cervarix Group	Number of Human Immunodeficiency Virus Positive Subjects (HIV+) With Any and Grade 3 Solicited Local Symptoms	Grade 3 Redness, Dose 1	0 Participants
HIV+/Cervarix Group	Number of Human Immunodeficiency Virus Positive Subjects (HIV+) With Any and Grade 3 Solicited Local Symptoms	Any Redness, Dose 3	17 Participants
HIV+/Cervarix Group	Number of Human Immunodeficiency Virus Positive Subjects (HIV+) With Any and Grade 3 Solicited Local Symptoms	Grade 3 Swelling, Dose 1	2 Participants
HIV+/Cervarix Group	Number of Human Immunodeficiency Virus Positive Subjects (HIV+) With Any and Grade 3 Solicited Local Symptoms	Grade 3 Redness, Dose 3	0 Participants
HIV+/Cervarix Group	Number of Human Immunodeficiency Virus Positive Subjects (HIV+) With Any and Grade 3 Solicited Local Symptoms	Grade 3 Redness, Across Doses	1 Participants
HIV+/Cervarix Group	Number of Human Immunodeficiency Virus Positive Subjects (HIV+) With Any and Grade 3 Solicited Local Symptoms	Any Swelling, Dose 3	19 Participants
HIV+/Cervarix Group	Number of Human Immunodeficiency Virus Positive Subjects (HIV+) With Any and Grade 3 Solicited Local Symptoms	Any Pain, Dose 2	98 Participants
HIV+/Cervarix Group	Number of Human Immunodeficiency Virus Positive Subjects (HIV+) With Any and Grade 3 Solicited Local Symptoms	Grade 3 Swelling, Dose 3	1 Participants
HIV+/Cervarix Group	Number of Human Immunodeficiency Virus Positive Subjects (HIV+) With Any and Grade 3 Solicited Local Symptoms	Any Swelling, Dose 2	16 Participants
HIV+/Cervarix Group	Number of Human Immunodeficiency Virus Positive Subjects (HIV+) With Any and Grade 3 Solicited Local Symptoms	Any Pain, Across Doses	120 Participants
HIV+/Cervarix Group	Number of Human Immunodeficiency Virus Positive Subjects (HIV+) With Any and Grade 3 Solicited Local Symptoms	Grade 3 Pain, Dose 2	5 Participants
HIV+/Cervarix Group	Number of Human Immunodeficiency Virus Positive Subjects (HIV+) With Any and Grade 3 Solicited Local Symptoms	Grade 3 Swelling, Across Doses	2 Participants
HIV+/Cervarix Group	Number of Human Immunodeficiency Virus Positive Subjects (HIV+) With Any and Grade 3 Solicited Local Symptoms	Any Pain, Dose 1	115 Participants
HIV+/Gardasil Group	Number of Human Immunodeficiency Virus Positive Subjects (HIV+) With Any and Grade 3 Solicited Local Symptoms	Grade 3 Swelling, Across Doses	0 Participants
HIV+/Gardasil Group	Number of Human Immunodeficiency Virus Positive Subjects (HIV+) With Any and Grade 3 Solicited Local Symptoms	Any Pain, Dose 1	58 Participants
HIV+/Gardasil Group	Number of Human Immunodeficiency Virus Positive Subjects (HIV+) With Any and Grade 3 Solicited Local Symptoms	Any Redness, Dose 1	19 Participants
HIV+/Gardasil Group	Number of Human Immunodeficiency Virus Positive Subjects (HIV+) With Any and Grade 3 Solicited Local Symptoms	Any Pain, Across Doses	85 Participants
HIV+/Gardasil Group	Number of Human Immunodeficiency Virus Positive Subjects (HIV+) With Any and Grade 3 Solicited Local Symptoms	Any Redness, Across Doses	34 Participants
HIV+/Gardasil Group	Number of Human Immunodeficiency Virus Positive Subjects (HIV+) With Any and Grade 3 Solicited Local Symptoms	Grade 3 Redness, Across Doses	0 Participants
HIV+/Gardasil Group	Number of Human Immunodeficiency Virus Positive Subjects (HIV+) With Any and Grade 3 Solicited Local Symptoms	Any Swelling, Across Doses	20 Participants
HIV+/Gardasil Group	Number of Human Immunodeficiency Virus Positive Subjects (HIV+) With Any and Grade 3 Solicited Local Symptoms	Grade 3 Pain, Dose 1	0 Participants
HIV+/Gardasil Group	Number of Human Immunodeficiency Virus Positive Subjects (HIV+) With Any and Grade 3 Solicited Local Symptoms	Grade 3 Redness, Dose 1	0 Participants
HIV+/Gardasil Group	Number of Human Immunodeficiency Virus Positive Subjects (HIV+) With Any and Grade 3 Solicited Local Symptoms	Any Swelling, Dose 1	6 Participants
HIV+/Gardasil Group	Number of Human Immunodeficiency Virus Positive Subjects (HIV+) With Any and Grade 3 Solicited Local Symptoms	Grade 3 Swelling, Dose 1	0 Participants
HIV+/Gardasil Group	Number of Human Immunodeficiency Virus Positive Subjects (HIV+) With Any and Grade 3 Solicited Local Symptoms	Any Pain, Dose 2	56 Participants
HIV+/Gardasil Group	Number of Human Immunodeficiency Virus Positive Subjects (HIV+) With Any and Grade 3 Solicited Local Symptoms	Grade 3 Pain, Dose 2	6 Participants
HIV+/Gardasil Group	Number of Human Immunodeficiency Virus Positive Subjects (HIV+) With Any and Grade 3 Solicited Local Symptoms	Any Redness, Dose 2	13 Participants
HIV+/Gardasil Group	Number of Human Immunodeficiency Virus Positive Subjects (HIV+) With Any and Grade 3 Solicited Local Symptoms	Grade 3 Redness, Dose 2	0 Participants
HIV+/Gardasil Group	Number of Human Immunodeficiency Virus Positive Subjects (HIV+) With Any and Grade 3 Solicited Local Symptoms	Any Swelling, Dose 2	11 Participants
HIV+/Gardasil Group	Number of Human Immunodeficiency Virus Positive Subjects (HIV+) With Any and Grade 3 Solicited Local Symptoms	Grade 3 Swelling, Dose 2	0 Participants
HIV+/Gardasil Group	Number of Human Immunodeficiency Virus Positive Subjects (HIV+) With Any and Grade 3 Solicited Local Symptoms	Any Pain, Dose 3	60 Participants
HIV+/Gardasil Group	Number of Human Immunodeficiency Virus Positive Subjects (HIV+) With Any and Grade 3 Solicited Local Symptoms	Grade 3 Pain, Dose 3	2 Participants
HIV+/Gardasil Group	Number of Human Immunodeficiency Virus Positive Subjects (HIV+) With Any and Grade 3 Solicited Local Symptoms	Any Redness, Dose 3	18 Participants
HIV+/Gardasil Group	Number of Human Immunodeficiency Virus Positive Subjects (HIV+) With Any and Grade 3 Solicited Local Symptoms	Grade 3 Redness, Dose 3	0 Participants
HIV+/Gardasil Group	Number of Human Immunodeficiency Virus Positive Subjects (HIV+) With Any and Grade 3 Solicited Local Symptoms	Any Swelling, Dose 3	10 Participants
HIV+/Gardasil Group	Number of Human Immunodeficiency Virus Positive Subjects (HIV+) With Any and Grade 3 Solicited Local Symptoms	Grade 3 Swelling, Dose 3	0 Participants
HIV+/Gardasil Group	Number of Human Immunodeficiency Virus Positive Subjects (HIV+) With Any and Grade 3 Solicited Local Symptoms	Grade 3 Pain, Across Doses	6 Participants

Primary

Pseudovirion-Based Neutralization Assay (PBNA) Titers of Anti-HPV-16/18 Antibodies in HIV+ Subjects, Based on Adapted According-to-protocol (ATP) Cohort for Immunogenicity

Titers of anti-HPV-16/18 antibodies, expressed as Geometric Mean Titers (GMTs), with cut-offs greater than or equal to (≥) 40 estimated dose giving 50% signal reduction when compared to a control without serum (ED50), as assessed by the Pseudovirion-Based Neutralization Assay \[PBNA\], in HIV+ subjects. Between-group comparisons to assess non-inferiority were performed on the ATP cohort for immunogenicity (by PBNA, regardless of HPV serostatus at baseline).

Time frame: At Month 7 (30 days after the last vaccination dose at Month 6)

Population: The analysis was performed on the Adapted ATP cohort for immunogenicity, which included all evaluable subjects who met all eligibility criteria and for whom Month 7 data concerning immunogenicity endpoint measures obtained from the ATP cohort for immunogenicity at Month 7 were available.

Arm	Measure	Group	Value (GEOMETRIC_MEAN)
HIV+/Cervarix Group	Pseudovirion-Based Neutralization Assay (PBNA) Titers of Anti-HPV-16/18 Antibodies in HIV+ Subjects, Based on Adapted According-to-protocol (ATP) Cohort for Immunogenicity	Anti-HPV-16	23436.1 Titers
HIV+/Cervarix Group	Pseudovirion-Based Neutralization Assay (PBNA) Titers of Anti-HPV-16/18 Antibodies in HIV+ Subjects, Based on Adapted According-to-protocol (ATP) Cohort for Immunogenicity	Anti-HPV-18	12490.9 Titers
HIV+/Gardasil Group	Pseudovirion-Based Neutralization Assay (PBNA) Titers of Anti-HPV-16/18 Antibodies in HIV+ Subjects, Based on Adapted According-to-protocol (ATP) Cohort for Immunogenicity	Anti-HPV-16	7507.0 Titers
HIV+/Gardasil Group	Pseudovirion-Based Neutralization Assay (PBNA) Titers of Anti-HPV-16/18 Antibodies in HIV+ Subjects, Based on Adapted According-to-protocol (ATP) Cohort for Immunogenicity	Anti-HPV-18	1459.6 Titers

Comparison: Adjusted GMT ratios for anti-HPV-16 neutra antibody (ED50): To demonstrate that the immunogenicity of Cervarix vaccine (HIV+/Cervarix Group) was non-inferior to that of Gardasil vaccine (HIV+/Gardasil Group), in terms of geometric mean titers (GMTs) against HPV-16, measured by Pseudovirion-based neutralization assay (PBNA) one month after the administration of the third dose of vaccine in HIV+ subjects.95% CI: [1.92, 4.52]

Comparison: Adjusted GMT ratios for anti-HPV-18 neutra antibody (ED50): To demonstrate that the immunogenicity of Cervarix vaccine (HIV+/Cervarix Group) was non-inferior to that of Gardasil vaccine (HIV+/Gardasil Group), in terms of geometric mean titers (GMTs) against HPV-18, measured by Pseudovirion-based neutralization assay (PBNA) one month after the administration of the third dose of vaccine in HIV+ subjects.95% CI: [4.84, 12.66]

Primary

Pseudovirion-Based Neutralization Assay (PBNA) Titers of Anti-HPV-16/18 Antibodies in HIV+ Subjects, Based on Total Vaccinated Cohort (TVC)

Titers of anti-HPV-16/18 antibodies, expressed as Geometric Mean Titers (GMTs), with cut-offs greater than or equal to (≥) 40 estimated dose giving 50% signal reduction when compared to a control without serum (ED50), as assessed by the Pseudovirion-Based Neutralization Assay \[PBNA\], in HIV+ subjects. Between-group comparisons to assess superiority were performed on the TVC (by PBNA, regardless of HPV serostatus at baseline).

Time frame: At Month 7 (30 days after the last vaccination dose at Month 6)

Population: The analysis was performed on the TVC for analysis of immunogenicity, which included vaccinated subjects for whom data concerning immunogenicity endpoint measures were available at Month 7.

Arm	Measure	Group	Value (GEOMETRIC_MEAN)
HIV+/Cervarix Group	Pseudovirion-Based Neutralization Assay (PBNA) Titers of Anti-HPV-16/18 Antibodies in HIV+ Subjects, Based on Total Vaccinated Cohort (TVC)	Anti-HPV-16	21106.6 Titers
HIV+/Cervarix Group	Pseudovirion-Based Neutralization Assay (PBNA) Titers of Anti-HPV-16/18 Antibodies in HIV+ Subjects, Based on Total Vaccinated Cohort (TVC)	Anti-HPV-18	11580.5 Titers
HIV+/Gardasil Group	Pseudovirion-Based Neutralization Assay (PBNA) Titers of Anti-HPV-16/18 Antibodies in HIV+ Subjects, Based on Total Vaccinated Cohort (TVC)	Anti-HPV-18	1451.9 Titers
HIV+/Gardasil Group	Pseudovirion-Based Neutralization Assay (PBNA) Titers of Anti-HPV-16/18 Antibodies in HIV+ Subjects, Based on Total Vaccinated Cohort (TVC)	Anti-HPV-16	7533.7 Titers

Comparison: Adjusted GMT ratios for anti-HPV-18 neutra antibody (ED50): To demonstrate that the immunogenicity of Cervarix vaccine (HIV+/Cervarix Group) was superior to that of Gardasil vaccine (HIV+/Gardasil Group), in terms of geometric mean titers (GMTs) against HPV-18, measured by Pseudovirion-based neutralization assay (PBNA) in HIV+ subjects, assessed following a sequential approach.p-value: <0.000195% CI: [4.79, 11.54]ANOVA

Comparison: Adjusted GMT ratios for anti-HPV-16 neutra antibody (ED50): To demonstrate that the immunogenicity of Cervarix vaccine (HIV+/Cervarix Group) was superior to that of Gardasil vaccine (HIV+/Gardasil Group), in terms of geometric mean titers (GMTs) against HPV-16, measured by Pseudovirion-based neutralization assay (PBNA) in HIV+ subjects, following a sequential approach.p-value: <0.000195% CI: [1.83, 4.11]ANOVA

Secondary

Anti-HPV-16 and Anti-HPV-18 Antibody Concentrations by ELISA in Cervicovaginal Secretion (CVS)

Anti-HPV-16 and anti-HPV-18 antibody concentrations in CVS, are presented as Geometric Mean Concentrations (GMCs), with cut-offs greater than or equal to (≥) 0 EU/mL, as assessed by ELISA, in post-menarcheal subjects who volunteered for this procedure.

Time frame: At Day 0, Week 6, Week 10, Month 7, Month 12, Month 18 and Month 24

Population: The analysis was performed on the Adapted ATP cohort for immunogenicity, which included post-menarcheal subjects who volunteered for this procedure, met all eligibility criteria and for whom data concerning immunogenicity endpoint measures obtained from the ATP cohort for immunogenicity corresponding to each time point were available.

Arm	Measure	Group	Value (GEOMETRIC_MEAN)
HIV+/Cervarix Group	Anti-HPV-16 and Anti-HPV-18 Antibody Concentrations by ELISA in Cervicovaginal Secretion (CVS)	anti-HPV-18, Day 0	1.2 EU/mL
HIV+/Cervarix Group	Anti-HPV-16 and Anti-HPV-18 Antibody Concentrations by ELISA in Cervicovaginal Secretion (CVS)	anti-HPV-16, Week 6	31.5 EU/mL
HIV+/Cervarix Group	Anti-HPV-16 and Anti-HPV-18 Antibody Concentrations by ELISA in Cervicovaginal Secretion (CVS)	anti-HPV-18, Week 10	22.9 EU/mL
HIV+/Cervarix Group	Anti-HPV-16 and Anti-HPV-18 Antibody Concentrations by ELISA in Cervicovaginal Secretion (CVS)	anti-HPV-16, Month 7	23.6 EU/mL
HIV+/Cervarix Group	Anti-HPV-16 and Anti-HPV-18 Antibody Concentrations by ELISA in Cervicovaginal Secretion (CVS)	anti-HPV-16, Week 10	38.8 EU/mL
HIV+/Cervarix Group	Anti-HPV-16 and Anti-HPV-18 Antibody Concentrations by ELISA in Cervicovaginal Secretion (CVS)	anti-HPV-18, Month 7	10.1 EU/mL
HIV+/Cervarix Group	Anti-HPV-16 and Anti-HPV-18 Antibody Concentrations by ELISA in Cervicovaginal Secretion (CVS)	anti-HPV-18, Week 6	16.8 EU/mL
HIV+/Cervarix Group	Anti-HPV-16 and Anti-HPV-18 Antibody Concentrations by ELISA in Cervicovaginal Secretion (CVS)	anti-HPV-16, Month 24	8.1 EU/mL
HIV+/Cervarix Group	Anti-HPV-16 and Anti-HPV-18 Antibody Concentrations by ELISA in Cervicovaginal Secretion (CVS)	anti-HPV-18, Month 12	23.9 EU/mL
HIV+/Cervarix Group	Anti-HPV-16 and Anti-HPV-18 Antibody Concentrations by ELISA in Cervicovaginal Secretion (CVS)	anti-HPV-18, Month 24	8.8 EU/mL
HIV+/Cervarix Group	Anti-HPV-16 and Anti-HPV-18 Antibody Concentrations by ELISA in Cervicovaginal Secretion (CVS)	anti-HPV-16, Month 12	18.7 EU/mL
HIV+/Cervarix Group	Anti-HPV-16 and Anti-HPV-18 Antibody Concentrations by ELISA in Cervicovaginal Secretion (CVS)	anti-HPV-16, Day 0	1.5 EU/mL
HIV+/Gardasil Group	Anti-HPV-16 and Anti-HPV-18 Antibody Concentrations by ELISA in Cervicovaginal Secretion (CVS)	anti-HPV-18, Day 0	1.0 EU/mL
HIV+/Gardasil Group	Anti-HPV-16 and Anti-HPV-18 Antibody Concentrations by ELISA in Cervicovaginal Secretion (CVS)	anti-HPV-16, Day 0	1.4 EU/mL
HIV+/Gardasil Group	Anti-HPV-16 and Anti-HPV-18 Antibody Concentrations by ELISA in Cervicovaginal Secretion (CVS)	anti-HPV-16, Week 6	3.1 EU/mL
HIV+/Gardasil Group	Anti-HPV-16 and Anti-HPV-18 Antibody Concentrations by ELISA in Cervicovaginal Secretion (CVS)	anti-HPV-18, Month 12	2.4 EU/mL
HIV+/Gardasil Group	Anti-HPV-16 and Anti-HPV-18 Antibody Concentrations by ELISA in Cervicovaginal Secretion (CVS)	anti-HPV-18, Week 6	1.7 EU/mL
HIV+/Gardasil Group	Anti-HPV-16 and Anti-HPV-18 Antibody Concentrations by ELISA in Cervicovaginal Secretion (CVS)	anti-HPV-16, Month 12	6.8 EU/mL
HIV+/Gardasil Group	Anti-HPV-16 and Anti-HPV-18 Antibody Concentrations by ELISA in Cervicovaginal Secretion (CVS)	anti-HPV-16, Week 10	15.7 EU/mL
HIV+/Gardasil Group	Anti-HPV-16 and Anti-HPV-18 Antibody Concentrations by ELISA in Cervicovaginal Secretion (CVS)	anti-HPV-18, Week 10	2.3 EU/mL
HIV+/Gardasil Group	Anti-HPV-16 and Anti-HPV-18 Antibody Concentrations by ELISA in Cervicovaginal Secretion (CVS)	anti-HPV-16, Month 24	4.3 EU/mL
HIV+/Gardasil Group	Anti-HPV-16 and Anti-HPV-18 Antibody Concentrations by ELISA in Cervicovaginal Secretion (CVS)	anti-HPV-16, Month 7	5.4 EU/mL
HIV+/Gardasil Group	Anti-HPV-16 and Anti-HPV-18 Antibody Concentrations by ELISA in Cervicovaginal Secretion (CVS)	anti-HPV-18, Month 7	2.2 EU/mL
HIV+/Gardasil Group	Anti-HPV-16 and Anti-HPV-18 Antibody Concentrations by ELISA in Cervicovaginal Secretion (CVS)	anti-HPV-18, Month 24	1.5 EU/mL
HIV-/Cervarix Group	Anti-HPV-16 and Anti-HPV-18 Antibody Concentrations by ELISA in Cervicovaginal Secretion (CVS)	anti-HPV-16, Day 0	1.0 EU/mL
HIV-/Cervarix Group	Anti-HPV-16 and Anti-HPV-18 Antibody Concentrations by ELISA in Cervicovaginal Secretion (CVS)	anti-HPV-18, Week 6	3.0 EU/mL
HIV-/Cervarix Group	Anti-HPV-16 and Anti-HPV-18 Antibody Concentrations by ELISA in Cervicovaginal Secretion (CVS)	anti-HPV-18, Month 7	44.2 EU/mL
HIV-/Cervarix Group	Anti-HPV-16 and Anti-HPV-18 Antibody Concentrations by ELISA in Cervicovaginal Secretion (CVS)	anti-HPV-18, Month 12	32.7 EU/mL
HIV-/Cervarix Group	Anti-HPV-16 and Anti-HPV-18 Antibody Concentrations by ELISA in Cervicovaginal Secretion (CVS)	anti-HPV-18, Month 24	13.8 EU/mL
HIV-/Cervarix Group	Anti-HPV-16 and Anti-HPV-18 Antibody Concentrations by ELISA in Cervicovaginal Secretion (CVS)	anti-HPV-18, Day 0	1.0 EU/mL
HIV-/Cervarix Group	Anti-HPV-16 and Anti-HPV-18 Antibody Concentrations by ELISA in Cervicovaginal Secretion (CVS)	anti-HPV-16, Week 6	27.1 EU/mL
HIV-/Cervarix Group	Anti-HPV-16 and Anti-HPV-18 Antibody Concentrations by ELISA in Cervicovaginal Secretion (CVS)	anti-HPV-16, Month 7	104.2 EU/mL
HIV-/Cervarix Group	Anti-HPV-16 and Anti-HPV-18 Antibody Concentrations by ELISA in Cervicovaginal Secretion (CVS)	anti-HPV-16, Month 12	107.6 EU/mL
HIV-/Cervarix Group	Anti-HPV-16 and Anti-HPV-18 Antibody Concentrations by ELISA in Cervicovaginal Secretion (CVS)	anti-HPV-16, Month 24	49.0 EU/mL
HIV-/Gardasil Group	Anti-HPV-16 and Anti-HPV-18 Antibody Concentrations by ELISA in Cervicovaginal Secretion (CVS)	anti-HPV-16, Month 24	1.0 EU/mL
HIV-/Gardasil Group	Anti-HPV-16 and Anti-HPV-18 Antibody Concentrations by ELISA in Cervicovaginal Secretion (CVS)	anti-HPV-16, Month 7	53.5 EU/mL
HIV-/Gardasil Group	Anti-HPV-16 and Anti-HPV-18 Antibody Concentrations by ELISA in Cervicovaginal Secretion (CVS)	anti-HPV-18, Month 24	1.0 EU/mL
HIV-/Gardasil Group	Anti-HPV-16 and Anti-HPV-18 Antibody Concentrations by ELISA in Cervicovaginal Secretion (CVS)	anti-HPV-18, Month 12	16.3 EU/mL
HIV-/Gardasil Group	Anti-HPV-16 and Anti-HPV-18 Antibody Concentrations by ELISA in Cervicovaginal Secretion (CVS)	anti-HPV-18, Week 6	1.0 EU/mL
HIV-/Gardasil Group	Anti-HPV-16 and Anti-HPV-18 Antibody Concentrations by ELISA in Cervicovaginal Secretion (CVS)	anti-HPV-16, Month 12	34.7 EU/mL
HIV-/Gardasil Group	Anti-HPV-16 and Anti-HPV-18 Antibody Concentrations by ELISA in Cervicovaginal Secretion (CVS)	anti-HPV-18, Month 7	16.3 EU/mL
HIV-/Gardasil Group	Anti-HPV-16 and Anti-HPV-18 Antibody Concentrations by ELISA in Cervicovaginal Secretion (CVS)	anti-HPV-18, Week 10	21.6 EU/mL
HIV-/Gardasil Group	Anti-HPV-16 and Anti-HPV-18 Antibody Concentrations by ELISA in Cervicovaginal Secretion (CVS)	anti-HPV-18, Day 0	1.0 EU/mL
HIV-/Gardasil Group	Anti-HPV-16 and Anti-HPV-18 Antibody Concentrations by ELISA in Cervicovaginal Secretion (CVS)	anti-HPV-16, Week 10	159.8 EU/mL
HIV-/Gardasil Group	Anti-HPV-16 and Anti-HPV-18 Antibody Concentrations by ELISA in Cervicovaginal Secretion (CVS)	anti-HPV-16, Week 6	2.7 EU/mL
HIV-/Gardasil Group	Anti-HPV-16 and Anti-HPV-18 Antibody Concentrations by ELISA in Cervicovaginal Secretion (CVS)	anti-HPV-16, Day 0	1.0 EU/mL

Secondary

Anti-HPV-16 and Anti-HPV-18 Antibody Concentrations by Enzyme-linked Immunosorbent Assay (ELISA) in Serum

Anti-HPV-16 and anti-HPV-18 antibody concentrations in serum, are presented as Geometric Mean Concentrations (GMCs), with cut-offs greater than or equal to (≥) 19 ELISA units per milliliter (EU/mL) and 18 EU/mL respectively, as assessed by Enzyme-linked immunosorbent assay (ELISA), in all (HIV+ and HIV-) subjects.

Time frame: At Day 0, Week 6, Week 10, Month 7, Month 12, Month 18 and Month 24

Population: The analysis was performed on the Adapted ATP cohort for immunogenicity, which included all evaluable subjects who met all eligibility criteria and for whom data concerning immunogenicity endpoint measures obtained from the ATP cohort for immunogenicity corresponding to each time point were available.

Arm	Measure	Group	Value (GEOMETRIC_MEAN)
HIV+/Cervarix Group	Anti-HPV-16 and Anti-HPV-18 Antibody Concentrations by Enzyme-linked Immunosorbent Assay (ELISA) in Serum	anti-HPV-18, Week 6	205.6 EU/mL
HIV+/Cervarix Group	Anti-HPV-16 and Anti-HPV-18 Antibody Concentrations by Enzyme-linked Immunosorbent Assay (ELISA) in Serum	anti-HPV-18, Day 0	13.4 EU/mL
HIV+/Cervarix Group	Anti-HPV-16 and Anti-HPV-18 Antibody Concentrations by Enzyme-linked Immunosorbent Assay (ELISA) in Serum	anti-HPV-16, Month 12	1392.3 EU/mL
HIV+/Cervarix Group	Anti-HPV-16 and Anti-HPV-18 Antibody Concentrations by Enzyme-linked Immunosorbent Assay (ELISA) in Serum	anti-HPV-18, Month 24	295.2 EU/mL
HIV+/Cervarix Group	Anti-HPV-16 and Anti-HPV-18 Antibody Concentrations by Enzyme-linked Immunosorbent Assay (ELISA) in Serum	anti-HPV-16, Month 24	664.6 EU/mL
HIV+/Cervarix Group	Anti-HPV-16 and Anti-HPV-18 Antibody Concentrations by Enzyme-linked Immunosorbent Assay (ELISA) in Serum	anti-HPV-16, Month 18	861.3 EU/mL
HIV+/Cervarix Group	Anti-HPV-16 and Anti-HPV-18 Antibody Concentrations by Enzyme-linked Immunosorbent Assay (ELISA) in Serum	anti-HPV-18, Month 12	676.9 EU/mL
HIV+/Cervarix Group	Anti-HPV-16 and Anti-HPV-18 Antibody Concentrations by Enzyme-linked Immunosorbent Assay (ELISA) in Serum	anti-HPV-16, Day 0	17.2 EU/mL
HIV+/Cervarix Group	Anti-HPV-16 and Anti-HPV-18 Antibody Concentrations by Enzyme-linked Immunosorbent Assay (ELISA) in Serum	anti-HPV-16, Week 10	2191.2 EU/mL
HIV+/Cervarix Group	Anti-HPV-16 and Anti-HPV-18 Antibody Concentrations by Enzyme-linked Immunosorbent Assay (ELISA) in Serum	anti-HPV-18, Month 18	408.7 EU/mL
HIV+/Cervarix Group	Anti-HPV-16 and Anti-HPV-18 Antibody Concentrations by Enzyme-linked Immunosorbent Assay (ELISA) in Serum	anti-HPV-18, Month 7	2540.8 EU/mL
HIV+/Cervarix Group	Anti-HPV-16 and Anti-HPV-18 Antibody Concentrations by Enzyme-linked Immunosorbent Assay (ELISA) in Serum	anti-HPV-18, Week 10	1432.4 EU/mL
HIV+/Cervarix Group	Anti-HPV-16 and Anti-HPV-18 Antibody Concentrations by Enzyme-linked Immunosorbent Assay (ELISA) in Serum	anti-HPV-16, Month 7	4896.0 EU/mL
HIV+/Cervarix Group	Anti-HPV-16 and Anti-HPV-18 Antibody Concentrations by Enzyme-linked Immunosorbent Assay (ELISA) in Serum	anti-HPV-16, Week 6	452.9 EU/mL
HIV+/Gardasil Group	Anti-HPV-16 and Anti-HPV-18 Antibody Concentrations by Enzyme-linked Immunosorbent Assay (ELISA) in Serum	anti-HPV-18, Month 7	493.8 EU/mL
HIV+/Gardasil Group	Anti-HPV-16 and Anti-HPV-18 Antibody Concentrations by Enzyme-linked Immunosorbent Assay (ELISA) in Serum	anti-HPV-16, Day 0	15.0 EU/mL
HIV+/Gardasil Group	Anti-HPV-16 and Anti-HPV-18 Antibody Concentrations by Enzyme-linked Immunosorbent Assay (ELISA) in Serum	anti-HPV-16, Week 6	280.2 EU/mL
HIV+/Gardasil Group	Anti-HPV-16 and Anti-HPV-18 Antibody Concentrations by Enzyme-linked Immunosorbent Assay (ELISA) in Serum	anti-HPV-16, Week 10	1565.5 EU/mL
HIV+/Gardasil Group	Anti-HPV-16 and Anti-HPV-18 Antibody Concentrations by Enzyme-linked Immunosorbent Assay (ELISA) in Serum	anti-HPV-16, Month 7	2145.2 EU/mL
HIV+/Gardasil Group	Anti-HPV-16 and Anti-HPV-18 Antibody Concentrations by Enzyme-linked Immunosorbent Assay (ELISA) in Serum	anti-HPV-16, Month 12	608.8 EU/mL
HIV+/Gardasil Group	Anti-HPV-16 and Anti-HPV-18 Antibody Concentrations by Enzyme-linked Immunosorbent Assay (ELISA) in Serum	anti-HPV-16, Month 18	311.4 EU/mL
HIV+/Gardasil Group	Anti-HPV-16 and Anti-HPV-18 Antibody Concentrations by Enzyme-linked Immunosorbent Assay (ELISA) in Serum	anti-HPV-16, Month 24	243.5 EU/mL
HIV+/Gardasil Group	Anti-HPV-16 and Anti-HPV-18 Antibody Concentrations by Enzyme-linked Immunosorbent Assay (ELISA) in Serum	anti-HPV-18, Day 0	10.7 EU/mL
HIV+/Gardasil Group	Anti-HPV-16 and Anti-HPV-18 Antibody Concentrations by Enzyme-linked Immunosorbent Assay (ELISA) in Serum	anti-HPV-18, Week 6	53.2 EU/mL
HIV+/Gardasil Group	Anti-HPV-16 and Anti-HPV-18 Antibody Concentrations by Enzyme-linked Immunosorbent Assay (ELISA) in Serum	anti-HPV-18, Week 10	277.2 EU/mL
HIV+/Gardasil Group	Anti-HPV-16 and Anti-HPV-18 Antibody Concentrations by Enzyme-linked Immunosorbent Assay (ELISA) in Serum	anti-HPV-18, Month 12	116.2 EU/mL
HIV+/Gardasil Group	Anti-HPV-16 and Anti-HPV-18 Antibody Concentrations by Enzyme-linked Immunosorbent Assay (ELISA) in Serum	anti-HPV-18, Month 18	55.6 EU/mL
HIV+/Gardasil Group	Anti-HPV-16 and Anti-HPV-18 Antibody Concentrations by Enzyme-linked Immunosorbent Assay (ELISA) in Serum	anti-HPV-18, Month 24	52.4 EU/mL
HIV-/Cervarix Group	Anti-HPV-16 and Anti-HPV-18 Antibody Concentrations by Enzyme-linked Immunosorbent Assay (ELISA) in Serum	anti-HPV-18, Month 7	6779.3 EU/mL
HIV-/Cervarix Group	Anti-HPV-16 and Anti-HPV-18 Antibody Concentrations by Enzyme-linked Immunosorbent Assay (ELISA) in Serum	anti-HPV-18, Month 18	895.5 EU/mL
HIV-/Cervarix Group	Anti-HPV-16 and Anti-HPV-18 Antibody Concentrations by Enzyme-linked Immunosorbent Assay (ELISA) in Serum	anti-HPV-16, Week 6	390.6 EU/mL
HIV-/Cervarix Group	Anti-HPV-16 and Anti-HPV-18 Antibody Concentrations by Enzyme-linked Immunosorbent Assay (ELISA) in Serum	anti-HPV-16, Month 7	15493.0 EU/mL
HIV-/Cervarix Group	Anti-HPV-16 and Anti-HPV-18 Antibody Concentrations by Enzyme-linked Immunosorbent Assay (ELISA) in Serum	anti-HPV-18, Month 12	1747.7 EU/mL
HIV-/Cervarix Group	Anti-HPV-16 and Anti-HPV-18 Antibody Concentrations by Enzyme-linked Immunosorbent Assay (ELISA) in Serum	anti-HPV-16, Day 0	10.2 EU/mL
HIV-/Cervarix Group	Anti-HPV-16 and Anti-HPV-18 Antibody Concentrations by Enzyme-linked Immunosorbent Assay (ELISA) in Serum	anti-HPV-18, Week 10	3174.4 EU/mL
HIV-/Cervarix Group	Anti-HPV-16 and Anti-HPV-18 Antibody Concentrations by Enzyme-linked Immunosorbent Assay (ELISA) in Serum	anti-HPV-18, Day 0	9.3 EU/mL
HIV-/Cervarix Group	Anti-HPV-16 and Anti-HPV-18 Antibody Concentrations by Enzyme-linked Immunosorbent Assay (ELISA) in Serum	anti-HPV-16, Month 18	2294.1 EU/mL
HIV-/Cervarix Group	Anti-HPV-16 and Anti-HPV-18 Antibody Concentrations by Enzyme-linked Immunosorbent Assay (ELISA) in Serum	anti-HPV-16, Week 10	4512.7 EU/mL
HIV-/Cervarix Group	Anti-HPV-16 and Anti-HPV-18 Antibody Concentrations by Enzyme-linked Immunosorbent Assay (ELISA) in Serum	anti-HPV-16, Month 12	4389.3 EU/mL
HIV-/Cervarix Group	Anti-HPV-16 and Anti-HPV-18 Antibody Concentrations by Enzyme-linked Immunosorbent Assay (ELISA) in Serum	anti-HPV-18, Month 24	761.9 EU/mL
HIV-/Cervarix Group	Anti-HPV-16 and Anti-HPV-18 Antibody Concentrations by Enzyme-linked Immunosorbent Assay (ELISA) in Serum	anti-HPV-16, Month 24	1893.6 EU/mL
HIV-/Cervarix Group	Anti-HPV-16 and Anti-HPV-18 Antibody Concentrations by Enzyme-linked Immunosorbent Assay (ELISA) in Serum	anti-HPV-18, Week 6	277.3 EU/mL
HIV-/Gardasil Group	Anti-HPV-16 and Anti-HPV-18 Antibody Concentrations by Enzyme-linked Immunosorbent Assay (ELISA) in Serum	anti-HPV-16, Month 24	601.9 EU/mL
HIV-/Gardasil Group	Anti-HPV-16 and Anti-HPV-18 Antibody Concentrations by Enzyme-linked Immunosorbent Assay (ELISA) in Serum	anti-HPV-18, Day 0	9.2 EU/mL
HIV-/Gardasil Group	Anti-HPV-16 and Anti-HPV-18 Antibody Concentrations by Enzyme-linked Immunosorbent Assay (ELISA) in Serum	anti-HPV-18, Month 18	160.1 EU/mL
HIV-/Gardasil Group	Anti-HPV-16 and Anti-HPV-18 Antibody Concentrations by Enzyme-linked Immunosorbent Assay (ELISA) in Serum	anti-HPV-18, Week 6	60.4 EU/mL
HIV-/Gardasil Group	Anti-HPV-16 and Anti-HPV-18 Antibody Concentrations by Enzyme-linked Immunosorbent Assay (ELISA) in Serum	anti-HPV-16, Week 10	2993.2 EU/mL
HIV-/Gardasil Group	Anti-HPV-16 and Anti-HPV-18 Antibody Concentrations by Enzyme-linked Immunosorbent Assay (ELISA) in Serum	anti-HPV-18, Week 10	666.1 EU/mL
HIV-/Gardasil Group	Anti-HPV-16 and Anti-HPV-18 Antibody Concentrations by Enzyme-linked Immunosorbent Assay (ELISA) in Serum	anti-HPV-16, Week 6	303.2 EU/mL
HIV-/Gardasil Group	Anti-HPV-16 and Anti-HPV-18 Antibody Concentrations by Enzyme-linked Immunosorbent Assay (ELISA) in Serum	anti-HPV-18, Month 7	1516.5 EU/mL
HIV-/Gardasil Group	Anti-HPV-16 and Anti-HPV-18 Antibody Concentrations by Enzyme-linked Immunosorbent Assay (ELISA) in Serum	anti-HPV-18, Month 24	116.2 EU/mL
HIV-/Gardasil Group	Anti-HPV-16 and Anti-HPV-18 Antibody Concentrations by Enzyme-linked Immunosorbent Assay (ELISA) in Serum	anti-HPV-18, Month 12	338.3 EU/mL
HIV-/Gardasil Group	Anti-HPV-16 and Anti-HPV-18 Antibody Concentrations by Enzyme-linked Immunosorbent Assay (ELISA) in Serum	anti-HPV-16, Month 12	1772.2 EU/mL
HIV-/Gardasil Group	Anti-HPV-16 and Anti-HPV-18 Antibody Concentrations by Enzyme-linked Immunosorbent Assay (ELISA) in Serum	anti-HPV-16, Day 0	10.9 EU/mL
HIV-/Gardasil Group	Anti-HPV-16 and Anti-HPV-18 Antibody Concentrations by Enzyme-linked Immunosorbent Assay (ELISA) in Serum	anti-HPV-16, Month 18	798.0 EU/mL
HIV-/Gardasil Group	Anti-HPV-16 and Anti-HPV-18 Antibody Concentrations by Enzyme-linked Immunosorbent Assay (ELISA) in Serum	anti-HPV-16, Month 7	5960.9 EU/mL

Secondary

Cluster of Differentiation 4 (CD4+) Cell Count in HIV+ Subjects at Months 12, 18 and 24

CD4+ cell count, expressed in cells/cubic millimeter (mm3), was assessed for HIV+ subjects.

Time frame: At Months 12, 18 and 24

Population: The analysis was performed on the Total Vaccinated cohort, which included all vaccinated subjects for whom data were available at Months 12, 18 and 24.

Arm	Measure	Group	Value (MEDIAN)
HIV+/Cervarix Group	Cluster of Differentiation 4 (CD4+) Cell Count in HIV+ Subjects at Months 12, 18 and 24	CD4+ cell counts, Month 12	584.5 cells/mm3
HIV+/Cervarix Group	Cluster of Differentiation 4 (CD4+) Cell Count in HIV+ Subjects at Months 12, 18 and 24	CD4+ cell counts, Month 18	621.0 cells/mm3
HIV+/Cervarix Group	Cluster of Differentiation 4 (CD4+) Cell Count in HIV+ Subjects at Months 12, 18 and 24	CD4+ cell counts, Month 24	568.0 cells/mm3
HIV+/Gardasil Group	Cluster of Differentiation 4 (CD4+) Cell Count in HIV+ Subjects at Months 12, 18 and 24	CD4+ cell counts, Month 12	602.0 cells/mm3
HIV+/Gardasil Group	Cluster of Differentiation 4 (CD4+) Cell Count in HIV+ Subjects at Months 12, 18 and 24	CD4+ cell counts, Month 18	572.0 cells/mm3
HIV+/Gardasil Group	Cluster of Differentiation 4 (CD4+) Cell Count in HIV+ Subjects at Months 12, 18 and 24	CD4+ cell counts, Month 24	598.0 cells/mm3

Secondary

Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response

The combinations of cytokines expressed were CD4/8-all doubles, CD4/8-d-cluster of differentiation 40 Ligand (CD40L), CD4/8-d-interferon gamma (IFNG), CD4/8-interleukin-2 (IL-2), CD4/8-d-tumour necrosis alpha (TNFA), as assessed by Intracellular cytokine staining (ICS). The assay was performed in a subset of approximately 100 subjects (50 HIV+ and 50 HIV-).

Time frame: At Day 0, Week 6, Week 10, Month 7 and Month 12

Population: The analysis was performed on the Adapted ATP cohort for immunogenicity,which included subjects in a subset of approximately 100 subjects(50 HIV+ and 50 HIV-) who met all eligibility criteria and for whom data concerning immunogenicity endpoint measures obtained from the ATP cohort for immunogenicity corresponding to each time point were available.

Arm	Measure	Group	Value (MEDIAN)
HIV+/Cervarix Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD8-d-CD40L, Anti-HPV-16, Month 7	26.0 CD4 cells/million T-cells
HIV+/Cervarix Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD8-d-CD40L, Anti-HPV-18, Week 10	10.5 CD4 cells/million T-cells
HIV+/Cervarix Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD4-d-TNFA, Anti-HPV-18, Day 0	1.0 CD4 cells/million T-cells
HIV+/Cervarix Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD4-All doubles,Anti-HPV-18,Week 6	396.0 CD4 cells/million T-cells
HIV+/Cervarix Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD8-d-CD40L, Anti-HPV-16, Week 10	18.5 CD4 cells/million T-cells
HIV+/Cervarix Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD8-d-CD40L, Anti-HPV-18, Week 6	9.5 CD4 cells/million T-cells
HIV+/Cervarix Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD4-d-TNFA, Anti-HPV-16, Week 6	326.5 CD4 cells/million T-cells
HIV+/Cervarix Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD4-d-IFNG, Anti-HPV-16, Week 6	222.5 CD4 cells/million T-cells
HIV+/Cervarix Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD8-d-CD40L, Anti-HPV-16, Week 6	1.0 CD4 cells/million T-cells
HIV+/Cervarix Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD8-d-CD40L, Anti-HPV-18, Day 0	1.0 CD4 cells/million T-cells
HIV+/Cervarix Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD4-d-TNFA, Anti-HPV-18, Week 6	234.0 CD4 cells/million T-cells
HIV+/Cervarix Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD4-d-CD40L, Anti-HPV-18, Month 7	1839.0 CD4 cells/million T-cells
HIV+/Cervarix Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD8-d-CD40L, Anti-HPV-16, Day 0	1.0 CD4 cells/million T-cells
HIV+/Cervarix Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD8-All doubles,Anti-HPV-18, Month 12	25.0 CD4 cells/million T-cells
HIV+/Cervarix Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD4-d-TNFA, Anti-HPV-16, Week 10	2086.0 CD4 cells/million T-cells
HIV+/Cervarix Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD4-All doubles,Anti-HPV-16,Week 6	445.5 CD4 cells/million T-cells
HIV+/Cervarix Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD8-All doubles,Anti-HPV-16, Month 12	1.0 CD4 cells/million T-cells
HIV+/Cervarix Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD8-All doubles,Anti-HPV-18,Month 7	41.0 CD4 cells/million T-cells
HIV+/Cervarix Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD4-d-TNFA, Anti-HPV-18, Week 10	1493.5 CD4 cells/million T-cells
HIV+/Cervarix Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD4-All doubles,Anti-HPV-18,Day 0	7.0 CD4 cells/million T-cells
HIV+/Cervarix Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD8-All doubles,Anti-HPV-16,Month 7	51.0 CD4 cells/million T-cells
HIV+/Cervarix Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD8-All doubles,Anti-HPV-18,Week 10	11.0 CD4 cells/million T-cells
HIV+/Cervarix Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD4-d-TNFA, Anti-HPV-16, Month 7	2688.0 CD4 cells/million T-cells
HIV+/Cervarix Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD4-d-IFNG, Anti-HPV-18, Week 6	98.0 CD4 cells/million T-cells
HIV+/Cervarix Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD8-All doubles,Anti-HPV-16,Week 10	41.0 CD4 cells/million T-cells
HIV+/Cervarix Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD8-All doubles,Anti-HPV-18,Week 6	37.5 CD4 cells/million T-cells
HIV+/Cervarix Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD4-d-TNFA, Anti-HPV-18, Month 7	1366.0 CD4 cells/million T-cells
HIV+/Cervarix Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD4-d-IL-2, Anti-HPV-18, Week 10	1668.5 CD4 cells/million T-cells
HIV+/Cervarix Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD8-All doubles,Anti-HPV-16,Week 6	2.0 CD4 cells/million T-cells
HIV+/Cervarix Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD8-All doubles,Anti-HPV-18, Day 0	6.0 CD4 cells/million T-cells
HIV+/Cervarix Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD4-d-TNFA, Anti-HPV-16, Month 12	1937.0 CD4 cells/million T-cells
HIV+/Cervarix Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD4-All doubles,Anti-HPV-16,Day 0	41.0 CD4 cells/million T-cells
HIV+/Cervarix Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD8-All doubles,Anti-HPV-16, Day 0	1.0 CD4 cells/million T-cells
HIV+/Cervarix Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD4-d-TNFA, Anti-HPV-18, Month 12	1264.0 CD4 cells/million T-cells
HIV+/Cervarix Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD8-d-TNFA, Anti-HPV-18, Month 12	30.0 CD4 cells/million T-cells
HIV+/Cervarix Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD4-d-IFNG, Anti-HPV-16, Week 10	1220.0 CD4 cells/million T-cells
HIV+/Cervarix Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD4-d-CD40L, Anti-HPV-16, Week 6	426.0 CD4 cells/million T-cells
HIV+/Cervarix Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD8-d-TNFA, Anti-HPV-16, Month 12	1.0 CD4 cells/million T-cells
HIV+/Cervarix Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD8-d-TNFA, Anti-HPV-18, Month 7	41.0 CD4 cells/million T-cells
HIV+/Cervarix Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD4-d-IFNG, Anti-HPV-18, Week 10	694.0 CD4 cells/million T-cells
HIV+/Cervarix Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD4-d-CD40L, Anti-HPV-18, Day 0	36.0 CD4 cells/million T-cells
HIV+/Cervarix Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD8-d-TNFA, Anti-HPV-16, Month 7	34.0 CD4 cells/million T-cells
HIV+/Cervarix Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD8-d-TNFA, Anti-HPV-18, Week 10	17.5 CD4 cells/million T-cells
HIV+/Cervarix Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD4-d-IFNG, Anti-HPV-16, Month 7	1513.0 CD4 cells/million T-cells
HIV+/Cervarix Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD4-d-CD40L, Anti-HPV-16, Month 12	2266.0 CD4 cells/million T-cells
HIV+/Cervarix Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD8-d-TNFA, Anti-HPV-16, Week 10	1.5 CD4 cells/million T-cells
HIV+/Cervarix Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD8-d-TNFA, Anti-HPV-18, Week 6	19.0 CD4 cells/million T-cells
HIV+/Cervarix Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD4-d-IFNG, Anti-HPV-18, Month 7	694.0 CD4 cells/million T-cells
HIV+/Cervarix Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD4-d-CD40L, Anti-HPV-18, Week 10	2015.0 CD4 cells/million T-cells
HIV+/Cervarix Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD8-d-TNFA, Anti-HPV-16, Week 6	1.0 CD4 cells/million T-cells
HIV+/Cervarix Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD8-d-TNFA, Anti-HPV-18, Day 0	6.0 CD4 cells/million T-cells
HIV+/Cervarix Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD4-d-IFNG, Anti-HPV-16, Month 12	452.0 CD4 cells/million T-cells
HIV+/Cervarix Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD4-d-CD40L, Anti-HPV-16, Day 0	22.0 CD4 cells/million T-cells
HIV+/Cervarix Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD8-d-TNFA, Anti-HPV-16, Day 0	1.0 CD4 cells/million T-cells
HIV+/Cervarix Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD8-d-IL-2, Anti-HPV-18, Month 12	1.0 CD4 cells/million T-cells
HIV+/Cervarix Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD4-d-IFNG, Anti-HPV-18, Month 12	402.0 CD4 cells/million T-cells
HIV+/Cervarix Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD4-All doubles, Anti-HPV-18, Month 12	1654.0 CD4 cells/million T-cells
HIV+/Cervarix Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD8-d-IL-2, Anti-HPV-16, Month 12	1.0 CD4 cells/million T-cells
HIV+/Cervarix Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD8-d-IL-2, Anti-HPV-18, Month 7	1.0 CD4 cells/million T-cells
HIV+/Cervarix Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD4-d-IL-2, Anti-HPV-16, Day 0	43.0 CD4 cells/million T-cells
HIV+/Cervarix Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD4-d-CD40L, Anti-HPV-18, Month 12	1668.0 CD4 cells/million T-cells
HIV+/Cervarix Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD8-d-IL-2, Anti-HPV-16, Month 7	1.0 CD4 cells/million T-cells
HIV+/Cervarix Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD8-d-IL-2, Anti-HPV-18, Week 10	1.0 CD4 cells/million T-cells
HIV+/Cervarix Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD4-d-IL-2, Anti-HPV-18, Day 0	46.0 CD4 cells/million T-cells
HIV+/Cervarix Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD4-d-CD40L, Anti-HPV-16, Month 7	3658.0 CD4 cells/million T-cells
HIV+/Cervarix Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD8-d-IL-2, Anti-HPV-16, Week 10	1.0 CD4 cells/million T-cells
HIV+/Cervarix Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD8-d-IL-2, Anti-HPV-18, Week 6	1.0 CD4 cells/million T-cells
HIV+/Cervarix Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD4-d-IL-2, Anti-HPV-16, Week 6	361.0 CD4 cells/million T-cells
HIV+/Cervarix Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD4-All doubles, Anti-HPV-16, Month 12	2328.0 CD4 cells/million T-cells
HIV+/Cervarix Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD8-d-IL-2, Anti-HPV-16, Week 6	1.0 CD4 cells/million T-cells
HIV+/Cervarix Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD8-d-IL-2, Anti-HPV-18, Day 0	1.0 CD4 cells/million T-cells
HIV+/Cervarix Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD4-d-IL-2, Anti-HPV-18, Week 6	364.5 CD4 cells/million T-cells
HIV+/Cervarix Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD4-All doubles,Anti-HPV-18,Month 7	1866.0 CD4 cells/million T-cells
HIV+/Cervarix Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD8-d-IL-2, Anti-HPV-16, Day 0	1.0 CD4 cells/million T-cells
HIV+/Cervarix Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD8-d-IFNG, Anti-HPV-18, Month 12	23.0 CD4 cells/million T-cells
HIV+/Cervarix Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD4-d-IL-2, Anti-HPV-16, Week 10	2503.0 CD4 cells/million T-cells
HIV+/Cervarix Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD4-d-IFNG, Anti-HPV-16, Day 0	27.0 CD4 cells/million T-cells
HIV+/Cervarix Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD8-d-IFNG, Anti-HPV-16, Month 12	1.0 CD4 cells/million T-cells
HIV+/Cervarix Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD8-d-IFNG, Anti-HPV-18, Month 7	41.0 CD4 cells/million T-cells
HIV+/Cervarix Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD4-d-CD40L, Anti-HPV-16, Week 10	2893.5 CD4 cells/million T-cells
HIV+/Cervarix Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD8-d-IFNG, Anti-HPV-16, Month 7	46.0 CD4 cells/million T-cells
HIV+/Cervarix Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD8-d-IFNG, Anti-HPV-18, Week 10	3.0 CD4 cells/million T-cells
HIV+/Cervarix Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD4-d-IL-2, Anti-HPV-16, Month 7	2847.0 CD4 cells/million T-cells
HIV+/Cervarix Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD4-All doubles,Anti-HPV-16,Month 7	3693.0 CD4 cells/million T-cells
HIV+/Cervarix Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD8-d-IFNG, Anti-HPV-16, Week 10	34.0 CD4 cells/million T-cells
HIV+/Cervarix Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD8-d-IFNG, Anti-HPV-18, Week 6	27.5 CD4 cells/million T-cells
HIV+/Cervarix Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD4-d-IL-2, Anti-HPV-18, Month 7	1522.0 CD4 cells/million T-cells
HIV+/Cervarix Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD4-All doubles,Anti-HPV-18,Week 10	2036.5 CD4 cells/million T-cells
HIV+/Cervarix Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD8-d-IFNG, Anti-HPV-16, Week 6	2.5 CD4 cells/million T-cells
HIV+/Cervarix Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD8-d-IFNG, Anti-HPV-18, Day 0	6.0 CD4 cells/million T-cells
HIV+/Cervarix Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD4-d-IL-2, Anti-HPV-16, Month 12	1792.0 CD4 cells/million T-cells
HIV+/Cervarix Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD4-d-IFNG, Anti-HPV-18, Day 0	4.0 CD4 cells/million T-cells
HIV+/Cervarix Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD8-d-IFNG, Anti-HPV-16, Day 0	1.0 CD4 cells/million T-cells
HIV+/Cervarix Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD8-d-CD40L, Anti-HPV-18, Month 12	23.0 CD4 cells/million T-cells
HIV+/Cervarix Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD4-d-IL-2, Anti-HPV-18, Month 12	1170.0 CD4 cells/million T-cells
HIV+/Cervarix Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD4-d-CD40L, Anti-HPV-18, Week 6	403.5 CD4 cells/million T-cells
HIV+/Cervarix Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD8-d-CD40L, Anti-HPV-16, Month 12	1.0 CD4 cells/million T-cells
HIV+/Cervarix Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD8-d-CD40L, Anti-HPV-18, Month 7	4.0 CD4 cells/million T-cells
HIV+/Cervarix Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD4-d-TNFA, Anti-HPV-16, Day 0	1.0 CD4 cells/million T-cells
HIV+/Cervarix Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD4-All doubles,Anti-HPV-16,Week 10	2955.5 CD4 cells/million T-cells
HIV+/Gardasil Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD8-d-TNFA, Anti-HPV-16, Day 0	1.0 CD4 cells/million T-cells
HIV+/Gardasil Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD4-d-CD40L, Anti-HPV-16, Month 7	1619.5 CD4 cells/million T-cells
HIV+/Gardasil Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD4-d-CD40L, Anti-HPV-18, Month 7	833.5 CD4 cells/million T-cells
HIV+/Gardasil Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD4-d-CD40L, Anti-HPV-16, Month 12	1278.0 CD4 cells/million T-cells
HIV+/Gardasil Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD4-d-CD40L, Anti-HPV-18, Month 12	808.5 CD4 cells/million T-cells
HIV+/Gardasil Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD4-d-IFNG, Anti-HPV-16, Day 0	30.0 CD4 cells/million T-cells
HIV+/Gardasil Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD4-d-IFNG, Anti-HPV-18, Day 0	51.0 CD4 cells/million T-cells
HIV+/Gardasil Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD4-d-IFNG, Anti-HPV-16, Week 6	116.0 CD4 cells/million T-cells
HIV+/Gardasil Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD4-d-IFNG, Anti-HPV-18, Week 6	104.5 CD4 cells/million T-cells
HIV+/Gardasil Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD4-d-IFNG, Anti-HPV-16, Week 10	450.0 CD4 cells/million T-cells
HIV+/Gardasil Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD4-d-IFNG, Anti-HPV-18, Week 10	326.5 CD4 cells/million T-cells
HIV+/Gardasil Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD4-d-IFNG, Anti-HPV-16, Month 7	585.5 CD4 cells/million T-cells
HIV+/Gardasil Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD4-d-IFNG, Anti-HPV-18, Month 7	306.0 CD4 cells/million T-cells
HIV+/Gardasil Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD4-d-IFNG, Anti-HPV-16, Month 12	432.0 CD4 cells/million T-cells
HIV+/Gardasil Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD4-d-IFNG, Anti-HPV-18, Month 12	253.5 CD4 cells/million T-cells
HIV+/Gardasil Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD4-d-IL-2, Anti-HPV-16, Day 0	30.0 CD4 cells/million T-cells
HIV+/Gardasil Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD4-d-IL-2, Anti-HPV-18, Day 0	37.0 CD4 cells/million T-cells
HIV+/Gardasil Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD4-d-IL-2, Anti-HPV-16, Week 6	300.0 CD4 cells/million T-cells
HIV+/Gardasil Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD4-d-IL-2, Anti-HPV-18, Week 6	193.5 CD4 cells/million T-cells
HIV+/Gardasil Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD4-d-IL-2, Anti-HPV-16, Week 10	1221.0 CD4 cells/million T-cells
HIV+/Gardasil Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD4-d-IL-2, Anti-HPV-18, Week 10	555.5 CD4 cells/million T-cells
HIV+/Gardasil Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD4-d-IL-2, Anti-HPV-16, Month 7	1318.5 CD4 cells/million T-cells
HIV+/Gardasil Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD4-d-IL-2, Anti-HPV-18, Month 7	615.0 CD4 cells/million T-cells
HIV+/Gardasil Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD4-d-IL-2, Anti-HPV-16, Month 12	1040.5 CD4 cells/million T-cells
HIV+/Gardasil Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD4-d-IL-2, Anti-HPV-18, Month 12	601.5 CD4 cells/million T-cells
HIV+/Gardasil Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD4-d-TNFA, Anti-HPV-16, Day 0	71.0 CD4 cells/million T-cells
HIV+/Gardasil Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD4-d-TNFA, Anti-HPV-18, Day 0	35.0 CD4 cells/million T-cells
HIV+/Gardasil Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD4-d-TNFA, Anti-HPV-16, Week 6	171.0 CD4 cells/million T-cells
HIV+/Gardasil Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD4-d-TNFA, Anti-HPV-18, Week 6	204.0 CD4 cells/million T-cells
HIV+/Gardasil Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD4-d-TNFA, Anti-HPV-16, Week 10	903.5 CD4 cells/million T-cells
HIV+/Gardasil Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD4-d-TNFA, Anti-HPV-18, Week 10	443.0 CD4 cells/million T-cells
HIV+/Gardasil Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD4-d-TNFA, Anti-HPV-16, Month 7	1109.0 CD4 cells/million T-cells
HIV+/Gardasil Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD4-d-TNFA, Anti-HPV-18, Month 7	598.0 CD4 cells/million T-cells
HIV+/Gardasil Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD4-d-TNFA, Anti-HPV-16, Month 12	1011.5 CD4 cells/million T-cells
HIV+/Gardasil Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD4-d-TNFA, Anti-HPV-18, Month 12	527.0 CD4 cells/million T-cells
HIV+/Gardasil Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD8-All doubles,Anti-HPV-16, Day 0	1.0 CD4 cells/million T-cells
HIV+/Gardasil Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD8-All doubles,Anti-HPV-18, Day 0	23.0 CD4 cells/million T-cells
HIV+/Gardasil Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD8-All doubles,Anti-HPV-16,Week 6	13.0 CD4 cells/million T-cells
HIV+/Gardasil Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD8-All doubles,Anti-HPV-18,Week 6	2.0 CD4 cells/million T-cells
HIV+/Gardasil Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD8-All doubles,Anti-HPV-16,Week 10	3.5 CD4 cells/million T-cells
HIV+/Gardasil Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD8-All doubles,Anti-HPV-18,Week 10	1.0 CD4 cells/million T-cells
HIV+/Gardasil Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD8-All doubles,Anti-HPV-16,Month 7	9.5 CD4 cells/million T-cells
HIV+/Gardasil Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD8-All doubles,Anti-HPV-18,Month 7	30.0 CD4 cells/million T-cells
HIV+/Gardasil Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD8-All doubles,Anti-HPV-16, Month 12	34.0 CD4 cells/million T-cells
HIV+/Gardasil Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD8-All doubles,Anti-HPV-18, Month 12	1.0 CD4 cells/million T-cells
HIV+/Gardasil Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD8-d-CD40L, Anti-HPV-16, Day 0	1.0 CD4 cells/million T-cells
HIV+/Gardasil Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD8-d-CD40L, Anti-HPV-18, Day 0	1.0 CD4 cells/million T-cells
HIV+/Gardasil Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD8-d-CD40L, Anti-HPV-16, Week 6	1.0 CD4 cells/million T-cells
HIV+/Gardasil Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD8-d-CD40L, Anti-HPV-18, Week 6	1.0 CD4 cells/million T-cells
HIV+/Gardasil Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD8-d-CD40L, Anti-HPV-16, Week 10	1.0 CD4 cells/million T-cells
HIV+/Gardasil Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD8-d-CD40L, Anti-HPV-18, Week 10	2.5 CD4 cells/million T-cells
HIV+/Gardasil Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD8-d-CD40L, Anti-HPV-16, Month 7	3.0 CD4 cells/million T-cells
HIV+/Gardasil Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD8-d-CD40L, Anti-HPV-18, Month 7	15.0 CD4 cells/million T-cells
HIV+/Gardasil Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD8-d-CD40L, Anti-HPV-16, Month 12	31.0 CD4 cells/million T-cells
HIV+/Gardasil Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD8-d-CD40L, Anti-HPV-18, Month 12	1.0 CD4 cells/million T-cells
HIV+/Gardasil Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD8-d-IFNG, Anti-HPV-16, Day 0	1.0 CD4 cells/million T-cells
HIV+/Gardasil Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD8-d-IFNG, Anti-HPV-18, Day 0	19.0 CD4 cells/million T-cells
HIV+/Gardasil Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD8-d-IFNG, Anti-HPV-16, Week 6	17.5 CD4 cells/million T-cells
HIV+/Gardasil Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD8-d-IFNG, Anti-HPV-18, Week 6	1.0 CD4 cells/million T-cells
HIV+/Gardasil Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD8-d-IFNG, Anti-HPV-16, Week 10	25.0 CD4 cells/million T-cells
HIV+/Gardasil Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD8-d-IFNG, Anti-HPV-18, Week 10	7.5 CD4 cells/million T-cells
HIV+/Gardasil Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD8-d-IFNG, Anti-HPV-16, Month 7	1.0 CD4 cells/million T-cells
HIV+/Gardasil Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD8-d-IFNG, Anti-HPV-18, Month 7	21.0 CD4 cells/million T-cells
HIV+/Gardasil Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD8-d-IFNG, Anti-HPV-16, Month 12	25.0 CD4 cells/million T-cells
HIV+/Gardasil Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD8-d-IFNG, Anti-HPV-18, Month 12	1.0 CD4 cells/million T-cells
HIV+/Gardasil Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD8-d-IL-2, Anti-HPV-16, Day 0	1.0 CD4 cells/million T-cells
HIV+/Gardasil Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD8-d-IL-2, Anti-HPV-18, Day 0	1.0 CD4 cells/million T-cells
HIV+/Gardasil Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD8-d-IL-2, Anti-HPV-16, Week 6	1.0 CD4 cells/million T-cells
HIV+/Gardasil Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD8-d-IL-2, Anti-HPV-18, Week 6	1.0 CD4 cells/million T-cells
HIV+/Gardasil Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD8-d-IL-2, Anti-HPV-16, Week 10	1.0 CD4 cells/million T-cells
HIV+/Gardasil Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD8-d-IL-2, Anti-HPV-18, Week 10	1.0 CD4 cells/million T-cells
HIV+/Gardasil Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD8-d-IL-2, Anti-HPV-16, Month 7	1.0 CD4 cells/million T-cells
HIV+/Gardasil Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD8-d-IL-2, Anti-HPV-18, Month 7	1.0 CD4 cells/million T-cells
HIV+/Gardasil Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD8-d-IL-2, Anti-HPV-16, Month 12	1.0 CD4 cells/million T-cells
HIV+/Gardasil Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD8-d-IL-2, Anti-HPV-18, Month 12	1.0 CD4 cells/million T-cells
HIV+/Gardasil Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD8-d-TNFA, Anti-HPV-18, Day 0	7.0 CD4 cells/million T-cells
HIV+/Gardasil Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD8-d-TNFA, Anti-HPV-16, Week 6	1.0 CD4 cells/million T-cells
HIV+/Gardasil Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD8-d-TNFA, Anti-HPV-18, Week 6	1.0 CD4 cells/million T-cells
HIV+/Gardasil Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD8-d-TNFA, Anti-HPV-16, Week 10	1.0 CD4 cells/million T-cells
HIV+/Gardasil Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD8-d-TNFA, Anti-HPV-18, Week 10	14.0 CD4 cells/million T-cells
HIV+/Gardasil Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD8-d-TNFA, Anti-HPV-16, Month 7	13.0 CD4 cells/million T-cells
HIV+/Gardasil Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD8-d-TNFA, Anti-HPV-18, Month 7	26.5 CD4 cells/million T-cells
HIV+/Gardasil Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD8-d-TNFA, Anti-HPV-16, Month 12	1.0 CD4 cells/million T-cells
HIV+/Gardasil Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD8-d-TNFA, Anti-HPV-18, Month 12	1.0 CD4 cells/million T-cells
HIV+/Gardasil Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD4-All doubles,Anti-HPV-16,Day 0	101.0 CD4 cells/million T-cells
HIV+/Gardasil Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD4-All doubles,Anti-HPV-18,Day 0	87.0 CD4 cells/million T-cells
HIV+/Gardasil Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD4-All doubles,Anti-HPV-16,Week 6	345.5 CD4 cells/million T-cells
HIV+/Gardasil Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD4-All doubles,Anti-HPV-18,Week 6	309.5 CD4 cells/million T-cells
HIV+/Gardasil Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD4-All doubles,Anti-HPV-16,Week 10	1449.0 CD4 cells/million T-cells
HIV+/Gardasil Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD4-All doubles,Anti-HPV-18,Week 10	602.0 CD4 cells/million T-cells
HIV+/Gardasil Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD4-All doubles,Anti-HPV-16,Month 7	1679.5 CD4 cells/million T-cells
HIV+/Gardasil Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD4-All doubles,Anti-HPV-18,Month 7	840.5 CD4 cells/million T-cells
HIV+/Gardasil Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD4-All doubles, Anti-HPV-16, Month 12	1288.0 CD4 cells/million T-cells
HIV+/Gardasil Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD4-All doubles, Anti-HPV-18, Month 12	808.5 CD4 cells/million T-cells
HIV+/Gardasil Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD4-d-CD40L, Anti-HPV-16, Day 0	99.0 CD4 cells/million T-cells
HIV+/Gardasil Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD4-d-CD40L, Anti-HPV-18, Day 0	89.0 CD4 cells/million T-cells
HIV+/Gardasil Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD4-d-CD40L, Anti-HPV-16, Week 6	326.5 CD4 cells/million T-cells
HIV+/Gardasil Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD4-d-CD40L, Anti-HPV-18, Week 6	296.0 CD4 cells/million T-cells
HIV+/Gardasil Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD4-d-CD40L, Anti-HPV-16, Week 10	1440.0 CD4 cells/million T-cells
HIV+/Gardasil Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD4-d-CD40L, Anti-HPV-18, Week 10	564.5 CD4 cells/million T-cells
HIV-/Cervarix Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD8-d-CD40L, Anti-HPV-18, Week 10	26.0 CD4 cells/million T-cells
HIV-/Cervarix Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD4-d-TNFA, Anti-HPV-16, Day 0	32.0 CD4 cells/million T-cells
HIV-/Cervarix Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD4-All doubles,Anti-HPV-18,Week 6	237.0 CD4 cells/million T-cells
HIV-/Cervarix Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD8-d-CD40L, Anti-HPV-16, Month 7	2.0 CD4 cells/million T-cells
HIV-/Cervarix Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD8-d-CD40L, Anti-HPV-18, Month 7	38.0 CD4 cells/million T-cells
HIV-/Cervarix Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD4-d-IL-2, Anti-HPV-18, Month 12	1342.0 CD4 cells/million T-cells
HIV-/Cervarix Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD4-d-IFNG, Anti-HPV-18, Day 0	1.0 CD4 cells/million T-cells
HIV-/Cervarix Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD8-d-CD40L, Anti-HPV-16, Month 12	3.0 CD4 cells/million T-cells
HIV-/Cervarix Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD8-d-CD40L, Anti-HPV-18, Month 12	1.0 CD4 cells/million T-cells
HIV-/Cervarix Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD4-d-IL-2, Anti-HPV-16, Month 12	1861.0 CD4 cells/million T-cells
HIV-/Cervarix Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD4-All doubles,Anti-HPV-16,Week 10	1767.0 CD4 cells/million T-cells
HIV-/Cervarix Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD8-d-IFNG, Anti-HPV-16, Day 0	1.0 CD4 cells/million T-cells
HIV-/Cervarix Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD8-d-IFNG, Anti-HPV-18, Day 0	21.0 CD4 cells/million T-cells
HIV-/Cervarix Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD4-d-IL-2, Anti-HPV-18, Month 7	1442.0 CD4 cells/million T-cells
HIV-/Cervarix Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD8-d-IFNG, Anti-HPV-16, Week 6	1.0 CD4 cells/million T-cells
HIV-/Cervarix Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD8-d-IFNG, Anti-HPV-18, Week 6	1.0 CD4 cells/million T-cells
HIV-/Cervarix Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD4-d-IL-2, Anti-HPV-16, Month 7	2608.5 CD4 cells/million T-cells
HIV-/Cervarix Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD4-All doubles,Anti-HPV-18,Week 10	1243.0 CD4 cells/million T-cells
HIV-/Cervarix Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD8-d-IFNG, Anti-HPV-16, Week 10	1.0 CD4 cells/million T-cells
HIV-/Cervarix Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD8-d-IFNG, Anti-HPV-18, Week 10	24.0 CD4 cells/million T-cells
HIV-/Cervarix Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD4-d-IL-2, Anti-HPV-18, Week 10	1183.0 CD4 cells/million T-cells
HIV-/Cervarix Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD4-d-IFNG, Anti-HPV-16, Day 0	1.0 CD4 cells/million T-cells
HIV-/Cervarix Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD8-d-IFNG, Anti-HPV-16, Month 7	1.0 CD4 cells/million T-cells
HIV-/Cervarix Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD8-d-TNFA, Anti-HPV-16, Month 12	28.0 CD4 cells/million T-cells
HIV-/Cervarix Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD8-d-IFNG, Anti-HPV-18, Month 7	4.0 CD4 cells/million T-cells
HIV-/Cervarix Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD4-d-IL-2, Anti-HPV-16, Week 10	1542.0 CD4 cells/million T-cells
HIV-/Cervarix Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD4-All doubles,Anti-HPV-16,Month 7	3414.5 CD4 cells/million T-cells
HIV-/Cervarix Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD8-d-IFNG, Anti-HPV-16, Month 12	1.0 CD4 cells/million T-cells
HIV-/Cervarix Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD8-d-IFNG, Anti-HPV-18, Month 12	1.0 CD4 cells/million T-cells
HIV-/Cervarix Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD4-d-IL-2, Anti-HPV-18, Week 6	227.5 CD4 cells/million T-cells
HIV-/Cervarix Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD8-d-IL-2, Anti-HPV-16, Day 0	1.0 CD4 cells/million T-cells
HIV-/Cervarix Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD4-d-CD40L, Anti-HPV-18, Week 6	242.5 CD4 cells/million T-cells
HIV-/Cervarix Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD8-d-IL-2, Anti-HPV-18, Day 0	1.0 CD4 cells/million T-cells
HIV-/Cervarix Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD4-d-IL-2, Anti-HPV-16, Week 6	245.5 CD4 cells/million T-cells
HIV-/Cervarix Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD4-All doubles,Anti-HPV-18,Month 7	2084.5 CD4 cells/million T-cells
HIV-/Cervarix Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD8-d-IL-2, Anti-HPV-16, Week 6	1.0 CD4 cells/million T-cells
HIV-/Cervarix Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD8-d-IL-2, Anti-HPV-18, Week 6	1.0 CD4 cells/million T-cells
HIV-/Cervarix Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD4-d-IL-2, Anti-HPV-18, Day 0	1.0 CD4 cells/million T-cells
HIV-/Cervarix Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD4-d-CD40L, Anti-HPV-18, Month 12	1641.0 CD4 cells/million T-cells
HIV-/Cervarix Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD8-d-IL-2, Anti-HPV-16, Week 10	1.0 CD4 cells/million T-cells
HIV-/Cervarix Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD8-d-IL-2, Anti-HPV-18, Week 10	1.0 CD4 cells/million T-cells
HIV-/Cervarix Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD4-d-IL-2, Anti-HPV-16, Day 0	1.0 CD4 cells/million T-cells
HIV-/Cervarix Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD4-All doubles, Anti-HPV-16, Month 12	2543.0 CD4 cells/million T-cells
HIV-/Cervarix Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD8-d-IL-2, Anti-HPV-16, Month 7	1.0 CD4 cells/million T-cells
HIV-/Cervarix Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD8-d-IL-2, Anti-HPV-18, Month 7	1.0 CD4 cells/million T-cells
HIV-/Cervarix Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD4-d-IFNG, Anti-HPV-18, Month 12	273.0 CD4 cells/million T-cells
HIV-/Cervarix Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD8-d-IL-2, Anti-HPV-16, Month 12	1.0 CD4 cells/million T-cells
HIV-/Cervarix Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD4-d-CD40L, Anti-HPV-16, Month 7	3290.0 CD4 cells/million T-cells
HIV-/Cervarix Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD8-d-IL-2, Anti-HPV-18, Month 12	1.0 CD4 cells/million T-cells
HIV-/Cervarix Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD4-d-IFNG, Anti-HPV-16, Month 12	621.0 CD4 cells/million T-cells
HIV-/Cervarix Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD8-d-TNFA, Anti-HPV-16, Day 0	1.0 CD4 cells/million T-cells
HIV-/Cervarix Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD4-All doubles, Anti-HPV-18, Month 12	1641.0 CD4 cells/million T-cells
HIV-/Cervarix Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD8-d-TNFA, Anti-HPV-18, Day 0	1.0 CD4 cells/million T-cells
HIV-/Cervarix Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD4-d-IFNG, Anti-HPV-18, Month 7	414.5 CD4 cells/million T-cells
HIV-/Cervarix Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD8-d-TNFA, Anti-HPV-16, Week 6	1.0 CD4 cells/million T-cells
HIV-/Cervarix Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD4-d-CD40L, Anti-HPV-16, Month 12	2519.0 CD4 cells/million T-cells
HIV-/Cervarix Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD8-d-TNFA, Anti-HPV-18, Week 6	1.0 CD4 cells/million T-cells
HIV-/Cervarix Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD4-d-IFNG, Anti-HPV-16, Month 7	731.0 CD4 cells/million T-cells
HIV-/Cervarix Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD4-d-CD40L, Anti-HPV-18, Week 10	1051.0 CD4 cells/million T-cells
HIV-/Cervarix Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD8-d-TNFA, Anti-HPV-16, Week 10	1.0 CD4 cells/million T-cells
HIV-/Cervarix Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD4-d-CD40L, Anti-HPV-16, Day 0	1.0 CD4 cells/million T-cells
HIV-/Cervarix Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD8-d-TNFA, Anti-HPV-18, Week 10	5.0 CD4 cells/million T-cells
HIV-/Cervarix Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD4-d-IFNG, Anti-HPV-18, Week 10	222.0 CD4 cells/million T-cells
HIV-/Cervarix Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD8-d-TNFA, Anti-HPV-16, Month 7	1.0 CD4 cells/million T-cells
HIV-/Cervarix Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD8-d-TNFA, Anti-HPV-18, Month 7	1.0 CD4 cells/million T-cells
HIV-/Cervarix Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD4-d-IFNG, Anti-HPV-16, Week 10	332.0 CD4 cells/million T-cells
HIV-/Cervarix Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD4-d-CD40L, Anti-HPV-16, Week 10	1678.0 CD4 cells/million T-cells
HIV-/Cervarix Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD4-d-CD40L, Anti-HPV-18, Day 0	1.0 CD4 cells/million T-cells
HIV-/Cervarix Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD4-d-TNFA, Anti-HPV-18, Month 12	1480.0 CD4 cells/million T-cells
HIV-/Cervarix Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD4-d-TNFA, Anti-HPV-16, Month 12	2344.0 CD4 cells/million T-cells
HIV-/Cervarix Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD8-d-TNFA, Anti-HPV-18, Month 12	1.0 CD4 cells/million T-cells
HIV-/Cervarix Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD8-All doubles,Anti-HPV-16, Day 0	1.0 CD4 cells/million T-cells
HIV-/Cervarix Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD8-All doubles,Anti-HPV-18, Day 0	21.0 CD4 cells/million T-cells
HIV-/Cervarix Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD4-d-TNFA, Anti-HPV-18, Month 7	1614.0 CD4 cells/million T-cells
HIV-/Cervarix Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD4-d-IFNG, Anti-HPV-18, Week 6	1.0 CD4 cells/million T-cells
HIV-/Cervarix Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD8-All doubles,Anti-HPV-16,Week 6	1.0 CD4 cells/million T-cells
HIV-/Cervarix Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD8-All doubles,Anti-HPV-18,Week 6	1.0 CD4 cells/million T-cells
HIV-/Cervarix Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD4-d-TNFA, Anti-HPV-16, Month 7	2621.0 CD4 cells/million T-cells
HIV-/Cervarix Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD4-All doubles,Anti-HPV-16,Day 0	1.0 CD4 cells/million T-cells
HIV-/Cervarix Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD8-All doubles,Anti-HPV-16,Week 10	1.0 CD4 cells/million T-cells
HIV-/Cervarix Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD8-All doubles,Anti-HPV-18,Week 10	5.0 CD4 cells/million T-cells
HIV-/Cervarix Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD4-d-TNFA, Anti-HPV-18, Week 10	899.0 CD4 cells/million T-cells
HIV-/Cervarix Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD8-All doubles,Anti-HPV-16,Month 7	1.0 CD4 cells/million T-cells
HIV-/Cervarix Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD4-d-CD40L, Anti-HPV-18, Month 7	2014.0 CD4 cells/million T-cells
HIV-/Cervarix Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD8-All doubles,Anti-HPV-18,Month 7	15.5 CD4 cells/million T-cells
HIV-/Cervarix Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD4-d-TNFA, Anti-HPV-16, Week 10	1260.0 CD4 cells/million T-cells
HIV-/Cervarix Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD4-All doubles,Anti-HPV-18,Day 0	1.0 CD4 cells/million T-cells
HIV-/Cervarix Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD8-All doubles,Anti-HPV-16, Month 12	23.0 CD4 cells/million T-cells
HIV-/Cervarix Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD8-All doubles,Anti-HPV-18, Month 12	1.0 CD4 cells/million T-cells
HIV-/Cervarix Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD4-d-TNFA, Anti-HPV-18, Week 6	162.5 CD4 cells/million T-cells
HIV-/Cervarix Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD4-d-IFNG, Anti-HPV-16, Week 6	42.5 CD4 cells/million T-cells
HIV-/Cervarix Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD8-d-CD40L, Anti-HPV-16, Day 0	1.0 CD4 cells/million T-cells
HIV-/Cervarix Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD8-d-CD40L, Anti-HPV-18, Day 0	1.0 CD4 cells/million T-cells
HIV-/Cervarix Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD4-d-TNFA, Anti-HPV-16, Week 6	237.0 CD4 cells/million T-cells
HIV-/Cervarix Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD4-All doubles,Anti-HPV-16,Week 6	298.0 CD4 cells/million T-cells
HIV-/Cervarix Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD8-d-CD40L, Anti-HPV-16, Week 6	1.0 CD4 cells/million T-cells
HIV-/Cervarix Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD8-d-CD40L, Anti-HPV-18, Week 6	1.0 CD4 cells/million T-cells
HIV-/Cervarix Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD4-d-TNFA, Anti-HPV-18, Day 0	25.0 CD4 cells/million T-cells
HIV-/Cervarix Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD8-d-CD40L, Anti-HPV-16, Week 10	1.0 CD4 cells/million T-cells
HIV-/Cervarix Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD4-d-CD40L, Anti-HPV-16, Week 6	298.0 CD4 cells/million T-cells
HIV-/Gardasil Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD4-d-TNFA, Anti-HPV-16, Month 7	1215.0 CD4 cells/million T-cells
HIV-/Gardasil Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD8-d-CD40L, Anti-HPV-18, Week 10	1.0 CD4 cells/million T-cells
HIV-/Gardasil Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD8-d-TNFA, Anti-HPV-16, Day 0	1.0 CD4 cells/million T-cells
HIV-/Gardasil Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD4-d-IFNG, Anti-HPV-18, Month 7	198.0 CD4 cells/million T-cells
HIV-/Gardasil Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD4-d-CD40L, Anti-HPV-18, Day 0	13.5 CD4 cells/million T-cells
HIV-/Gardasil Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD8-d-CD40L, Anti-HPV-16, Month 7	1.0 CD4 cells/million T-cells
HIV-/Gardasil Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD4-d-IL-2, Anti-HPV-18, Month 12	337.0 CD4 cells/million T-cells
HIV-/Gardasil Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD4-All doubles,Anti-HPV-18,Week 6	320.5 CD4 cells/million T-cells
HIV-/Gardasil Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD4-d-IFNG, Anti-HPV-18, Day 0	21.0 CD4 cells/million T-cells
HIV-/Gardasil Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD8-d-CD40L, Anti-HPV-18, Month 7	4.0 CD4 cells/million T-cells
HIV-/Gardasil Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD8-d-TNFA, Anti-HPV-18, Day 0	1.0 CD4 cells/million T-cells
HIV-/Gardasil Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD8-All doubles,Anti-HPV-18,Week 6	30.5 CD4 cells/million T-cells
HIV-/Gardasil Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD4-All doubles, Anti-HPV-18, Month 12	428.0 CD4 cells/million T-cells
HIV-/Gardasil Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD8-d-CD40L, Anti-HPV-16, Month 12	1.0 CD4 cells/million T-cells
HIV-/Gardasil Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD4-d-IL-2, Anti-HPV-16, Month 12	723.0 CD4 cells/million T-cells
HIV-/Gardasil Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD4-d-CD40L, Anti-HPV-16, Week 6	582.0 CD4 cells/million T-cells
HIV-/Gardasil Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD8-All doubles,Anti-HPV-18, Month 12	1.0 CD4 cells/million T-cells
HIV-/Gardasil Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD8-d-CD40L, Anti-HPV-18, Month 12	1.0 CD4 cells/million T-cells
HIV-/Gardasil Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD8-d-TNFA, Anti-HPV-16, Week 6	1.0 CD4 cells/million T-cells
HIV-/Gardasil Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD4-d-IFNG, Anti-HPV-16, Month 7	495.0 CD4 cells/million T-cells
HIV-/Gardasil Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD8-d-CD40L, Anti-HPV-16, Week 6	1.0 CD4 cells/million T-cells
HIV-/Gardasil Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD8-d-IFNG, Anti-HPV-16, Day 0	1.0 CD4 cells/million T-cells
HIV-/Gardasil Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD4-d-IL-2, Anti-HPV-18, Month 7	537.0 CD4 cells/million T-cells
HIV-/Gardasil Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD4-All doubles,Anti-HPV-16,Week 10	1268.5 CD4 cells/million T-cells
HIV-/Gardasil Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD4-d-TNFA, Anti-HPV-18, Day 0	15.5 CD4 cells/million T-cells
HIV-/Gardasil Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD8-d-IFNG, Anti-HPV-18, Day 0	4.0 CD4 cells/million T-cells
HIV-/Gardasil Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD8-d-TNFA, Anti-HPV-18, Week 6	1.0 CD4 cells/million T-cells
HIV-/Gardasil Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD4-d-IFNG, Anti-HPV-16, Day 0	39.0 CD4 cells/million T-cells
HIV-/Gardasil Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD8-All doubles,Anti-HPV-16,Week 10	1.0 CD4 cells/million T-cells
HIV-/Gardasil Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD8-d-IFNG, Anti-HPV-16, Week 6	1.0 CD4 cells/million T-cells
HIV-/Gardasil Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD4-d-IL-2, Anti-HPV-16, Month 7	1128.0 CD4 cells/million T-cells
HIV-/Gardasil Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD4-d-CD40L, Anti-HPV-16, Month 7	1389.0 CD4 cells/million T-cells
HIV-/Gardasil Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD4-d-TNFA, Anti-HPV-18, Week 10	334.5 CD4 cells/million T-cells
HIV-/Gardasil Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD8-d-IFNG, Anti-HPV-18, Week 6	35.5 CD4 cells/million T-cells
HIV-/Gardasil Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD4-All doubles,Anti-HPV-16,Day 0	54.5 CD4 cells/million T-cells
HIV-/Gardasil Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD8-d-TNFA, Anti-HPV-16, Week 10	1.0 CD4 cells/million T-cells
HIV-/Gardasil Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD4-d-IFNG, Anti-HPV-18, Week 10	202.0 CD4 cells/million T-cells
HIV-/Gardasil Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD8-d-IFNG, Anti-HPV-16, Week 10	1.0 CD4 cells/million T-cells
HIV-/Gardasil Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD4-d-IL-2, Anti-HPV-18, Week 10	411.0 CD4 cells/million T-cells
HIV-/Gardasil Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD4-All doubles,Anti-HPV-18,Week 10	515.5 CD4 cells/million T-cells
HIV-/Gardasil Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD4-All doubles,Anti-HPV-16,Week 6	661.0 CD4 cells/million T-cells
HIV-/Gardasil Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD8-d-IFNG, Anti-HPV-18, Week 10	1.0 CD4 cells/million T-cells
HIV-/Gardasil Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD8-All doubles,Anti-HPV-18,Week 10	1.0 CD4 cells/million T-cells
HIV-/Gardasil Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD8-d-TNFA, Anti-HPV-18, Week 10	1.0 CD4 cells/million T-cells
HIV-/Gardasil Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD8-d-CD40L, Anti-HPV-16, Day 0	1.0 CD4 cells/million T-cells
HIV-/Gardasil Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD8-d-IFNG, Anti-HPV-16, Month 7	1.0 CD4 cells/million T-cells
HIV-/Gardasil Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD4-d-IL-2, Anti-HPV-16, Week 10	929.5 CD4 cells/million T-cells
HIV-/Gardasil Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD4-d-CD40L, Anti-HPV-16, Day 0	46.0 CD4 cells/million T-cells
HIV-/Gardasil Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD4-d-IFNG, Anti-HPV-16, Week 6	241.5 CD4 cells/million T-cells
HIV-/Gardasil Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD8-d-IFNG, Anti-HPV-18, Month 7	3.0 CD4 cells/million T-cells
HIV-/Gardasil Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD8-d-TNFA, Anti-HPV-16, Month 7	2.0 CD4 cells/million T-cells
HIV-/Gardasil Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD4-d-IFNG, Anti-HPV-16, Week 10	442.0 CD4 cells/million T-cells
HIV-/Gardasil Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD4-d-CD40L, Anti-HPV-18, Month 7	647.0 CD4 cells/million T-cells
HIV-/Gardasil Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD8-d-IFNG, Anti-HPV-16, Month 12	1.0 CD4 cells/million T-cells
HIV-/Gardasil Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD4-d-IL-2, Anti-HPV-18, Week 6	286.0 CD4 cells/million T-cells
HIV-/Gardasil Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD4-All doubles,Anti-HPV-16,Month 7	1505.0 CD4 cells/million T-cells
HIV-/Gardasil Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD4-d-TNFA, Anti-HPV-16, Week 6	337.5 CD4 cells/million T-cells
HIV-/Gardasil Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD8-d-IFNG, Anti-HPV-18, Month 12	1.0 CD4 cells/million T-cells
HIV-/Gardasil Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD8-d-TNFA, Anti-HPV-18, Month 7	1.0 CD4 cells/million T-cells
HIV-/Gardasil Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD4-d-CD40L, Anti-HPV-18, Month 12	394.0 CD4 cells/million T-cells
HIV-/Gardasil Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD8-All doubles,Anti-HPV-16,Month 7	2.0 CD4 cells/million T-cells
HIV-/Gardasil Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD8-d-IL-2, Anti-HPV-16, Day 0	1.0 CD4 cells/million T-cells
HIV-/Gardasil Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD4-d-IL-2, Anti-HPV-16, Week 6	454.5 CD4 cells/million T-cells
HIV-/Gardasil Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD4-d-TNFA, Anti-HPV-16, Week 10	865.5 CD4 cells/million T-cells
HIV-/Gardasil Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD8-d-TNFA, Anti-HPV-16, Month 12	1.0 CD4 cells/million T-cells
HIV-/Gardasil Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD8-d-IL-2, Anti-HPV-18, Day 0	1.0 CD4 cells/million T-cells
HIV-/Gardasil Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD4-d-IFNG, Anti-HPV-18, Week 6	129.5 CD4 cells/million T-cells
HIV-/Gardasil Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD4-d-TNFA, Anti-HPV-16, Month 12	646.0 CD4 cells/million T-cells
HIV-/Gardasil Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD4-d-CD40L, Anti-HPV-16, Week 10	1239.0 CD4 cells/million T-cells
HIV-/Gardasil Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD8-d-IL-2, Anti-HPV-16, Week 6	1.0 CD4 cells/million T-cells
HIV-/Gardasil Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD4-d-IL-2, Anti-HPV-18, Day 0	13.5 CD4 cells/million T-cells
HIV-/Gardasil Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD4-All doubles,Anti-HPV-18,Month 7	669.0 CD4 cells/million T-cells
HIV-/Gardasil Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD4-d-TNFA, Anti-HPV-16, Day 0	34.0 CD4 cells/million T-cells
HIV-/Gardasil Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD8-d-IL-2, Anti-HPV-18, Week 6	1.0 CD4 cells/million T-cells
HIV-/Gardasil Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD4-d-TNFA, Anti-HPV-18, Month 12	358.0 CD4 cells/million T-cells
HIV-/Gardasil Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD8-All doubles,Anti-HPV-18,Month 7	24.0 CD4 cells/million T-cells
HIV-/Gardasil Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD8-d-CD40L, Anti-HPV-18, Day 0	1.0 CD4 cells/million T-cells
HIV-/Gardasil Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD8-d-IL-2, Anti-HPV-16, Week 10	1.0 CD4 cells/million T-cells
HIV-/Gardasil Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD4-d-IL-2, Anti-HPV-16, Day 0	1.0 CD4 cells/million T-cells
HIV-/Gardasil Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD4-d-CD40L, Anti-HPV-18, Week 6	310.0 CD4 cells/million T-cells
HIV-/Gardasil Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD8-d-CD40L, Anti-HPV-18, Week 6	1.0 CD4 cells/million T-cells
HIV-/Gardasil Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD8-d-IL-2, Anti-HPV-18, Week 10	1.0 CD4 cells/million T-cells
HIV-/Gardasil Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD8-All doubles,Anti-HPV-16, Day 0	1.0 CD4 cells/million T-cells
HIV-/Gardasil Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD4-d-TNFA, Anti-HPV-18, Month 7	505.0 CD4 cells/million T-cells
HIV-/Gardasil Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD8-d-TNFA, Anti-HPV-18, Month 12	1.0 CD4 cells/million T-cells
HIV-/Gardasil Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD8-d-IL-2, Anti-HPV-16, Month 7	1.0 CD4 cells/million T-cells
HIV-/Gardasil Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD4-d-IFNG, Anti-HPV-18, Month 12	98.0 CD4 cells/million T-cells
HIV-/Gardasil Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD4-All doubles, Anti-HPV-16, Month 12	830.0 CD4 cells/million T-cells
HIV-/Gardasil Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD8-d-CD40L, Anti-HPV-16, Week 10	1.0 CD4 cells/million T-cells
HIV-/Gardasil Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD8-d-IL-2, Anti-HPV-18, Month 7	1.0 CD4 cells/million T-cells
HIV-/Gardasil Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD8-All doubles,Anti-HPV-18, Day 0	1.0 CD4 cells/million T-cells
HIV-/Gardasil Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD4-d-CD40L, Anti-HPV-16, Month 12	862.0 CD4 cells/million T-cells
HIV-/Gardasil Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD8-All doubles,Anti-HPV-16, Month 12	1.0 CD4 cells/million T-cells
HIV-/Gardasil Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD8-d-IL-2, Anti-HPV-16, Month 12	1.0 CD4 cells/million T-cells
HIV-/Gardasil Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD4-d-IFNG, Anti-HPV-16, Month 12	302.0 CD4 cells/million T-cells
HIV-/Gardasil Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD4-d-TNFA, Anti-HPV-18, Week 6	156.5 CD4 cells/million T-cells
HIV-/Gardasil Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD4-All doubles,Anti-HPV-18,Day 0	1.0 CD4 cells/million T-cells
HIV-/Gardasil Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD8-d-IL-2, Anti-HPV-18, Month 12	1.0 CD4 cells/million T-cells
HIV-/Gardasil Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD8-All doubles,Anti-HPV-16,Week 6	1.0 CD4 cells/million T-cells
HIV-/Gardasil Group	Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response	CD4-d-CD40L, Anti-HPV-18, Week 10	474.5 CD4 cells/million T-cells

Secondary

Frequency of Specific B-cells for HPV-16/18 Antigens

B-cell memory was assessed by Enzyme Linked Immuno Spot (ELISPOT) assay. The assay was performed in a subset of approximately 100 subjects (50 HIV+ and 50 HIV-).

Time frame: At Day 0, Week 6, Week 10, Month 7 and Month 12

Population: The analysis was performed on the Adapted ATP cohort for immunogenicity,which included subjects in a subset of approximately 100 subjects(50 HIV+ and 50 HIV-),who met all eligibility criteria and for whom data concerning immunogenicity endpoint measures obtained from the ATP cohort for immunogenicity corresponding to each time point were available.

Arm	Measure	Group	Value (MEDIAN)
HIV+/Cervarix Group	Frequency of Specific B-cells for HPV-16/18 Antigens	HPV-16, Day 0	1.0 B-cells/million cells
HIV+/Cervarix Group	Frequency of Specific B-cells for HPV-16/18 Antigens	HPV-18, Day 0	1.0 B-cells/million cells
HIV+/Cervarix Group	Frequency of Specific B-cells for HPV-16/18 Antigens	HPV-16, Week 6	91.0 B-cells/million cells
HIV+/Cervarix Group	Frequency of Specific B-cells for HPV-16/18 Antigens	HPV-18, Week 6	39.5 B-cells/million cells
HIV+/Cervarix Group	Frequency of Specific B-cells for HPV-16/18 Antigens	HPV-16, Week 10	558.0 B-cells/million cells
HIV+/Cervarix Group	Frequency of Specific B-cells for HPV-16/18 Antigens	HPV-18, Week 10	150.0 B-cells/million cells
HIV+/Cervarix Group	Frequency of Specific B-cells for HPV-16/18 Antigens	HPV-16, Month 7	624.0 B-cells/million cells
HIV+/Cervarix Group	Frequency of Specific B-cells for HPV-16/18 Antigens	HPV-18, Month 7	332.0 B-cells/million cells
HIV+/Cervarix Group	Frequency of Specific B-cells for HPV-16/18 Antigens	HPV-16, Month 12	256.5 B-cells/million cells
HIV+/Cervarix Group	Frequency of Specific B-cells for HPV-16/18 Antigens	HPV-18, Month 12	101.0 B-cells/million cells
HIV+/Gardasil Group	Frequency of Specific B-cells for HPV-16/18 Antigens	HPV-16, Week 6	1.0 B-cells/million cells
HIV+/Gardasil Group	Frequency of Specific B-cells for HPV-16/18 Antigens	HPV-16, Month 12	121.0 B-cells/million cells
HIV+/Gardasil Group	Frequency of Specific B-cells for HPV-16/18 Antigens	HPV-18, Week 6	1.0 B-cells/million cells
HIV+/Gardasil Group	Frequency of Specific B-cells for HPV-16/18 Antigens	HPV-16, Week 10	198.0 B-cells/million cells
HIV+/Gardasil Group	Frequency of Specific B-cells for HPV-16/18 Antigens	HPV-18, Week 10	1.0 B-cells/million cells
HIV+/Gardasil Group	Frequency of Specific B-cells for HPV-16/18 Antigens	HPV-16, Month 7	213.0 B-cells/million cells
HIV+/Gardasil Group	Frequency of Specific B-cells for HPV-16/18 Antigens	HPV-18, Month 12	1.0 B-cells/million cells
HIV+/Gardasil Group	Frequency of Specific B-cells for HPV-16/18 Antigens	HPV-18, Month 7	1.0 B-cells/million cells
HIV+/Gardasil Group	Frequency of Specific B-cells for HPV-16/18 Antigens	HPV-16, Day 0	1.0 B-cells/million cells
HIV+/Gardasil Group	Frequency of Specific B-cells for HPV-16/18 Antigens	HPV-18, Day 0	1.0 B-cells/million cells
HIV-/Cervarix Group	Frequency of Specific B-cells for HPV-16/18 Antigens	HPV-18, Month 7	513.5 B-cells/million cells
HIV-/Cervarix Group	Frequency of Specific B-cells for HPV-16/18 Antigens	HPV-16, Month 7	1504.0 B-cells/million cells
HIV-/Cervarix Group	Frequency of Specific B-cells for HPV-16/18 Antigens	HPV-18, Month 12	250.5 B-cells/million cells
HIV-/Cervarix Group	Frequency of Specific B-cells for HPV-16/18 Antigens	HPV-16, Day 0	1.0 B-cells/million cells
HIV-/Cervarix Group	Frequency of Specific B-cells for HPV-16/18 Antigens	HPV-18, Week 6	155.0 B-cells/million cells
HIV-/Cervarix Group	Frequency of Specific B-cells for HPV-16/18 Antigens	HPV-18, Week 10	211.0 B-cells/million cells
HIV-/Cervarix Group	Frequency of Specific B-cells for HPV-16/18 Antigens	HPV-16, Month 12	414.5 B-cells/million cells
HIV-/Cervarix Group	Frequency of Specific B-cells for HPV-16/18 Antigens	HPV-18, Day 0	1.0 B-cells/million cells
HIV-/Cervarix Group	Frequency of Specific B-cells for HPV-16/18 Antigens	HPV-16, Week 10	494.0 B-cells/million cells
HIV-/Cervarix Group	Frequency of Specific B-cells for HPV-16/18 Antigens	HPV-16, Week 6	22.0 B-cells/million cells
HIV-/Gardasil Group	Frequency of Specific B-cells for HPV-16/18 Antigens	HPV-16, Week 10	150.5 B-cells/million cells
HIV-/Gardasil Group	Frequency of Specific B-cells for HPV-16/18 Antigens	HPV-18, Month 7	65.0 B-cells/million cells
HIV-/Gardasil Group	Frequency of Specific B-cells for HPV-16/18 Antigens	HPV-18, Week 10	29.5 B-cells/million cells
HIV-/Gardasil Group	Frequency of Specific B-cells for HPV-16/18 Antigens	HPV-18, Month 12	58.0 B-cells/million cells
HIV-/Gardasil Group	Frequency of Specific B-cells for HPV-16/18 Antigens	HPV-16, Month 7	448.0 B-cells/million cells
HIV-/Gardasil Group	Frequency of Specific B-cells for HPV-16/18 Antigens	HPV-18, Day 0	1.0 B-cells/million cells
HIV-/Gardasil Group	Frequency of Specific B-cells for HPV-16/18 Antigens	HPV-16, Week 6	1.0 B-cells/million cells
HIV-/Gardasil Group	Frequency of Specific B-cells for HPV-16/18 Antigens	HPV-18, Week 6	33.0 B-cells/million cells
HIV-/Gardasil Group	Frequency of Specific B-cells for HPV-16/18 Antigens	HPV-16, Day 0	1.0 B-cells/million cells
HIV-/Gardasil Group	Frequency of Specific B-cells for HPV-16/18 Antigens	HPV-16, Month 12	256.0 B-cells/million cells

Secondary

HIV Viral Load (VL) in HIV+ Subjects at Months 12, 18 and 24

HIV VL, expressed in HIV copies/milliliter (mL), was assessed for HIV+ subjects.

Time frame: At Months 12, 18 and 24

Population: The analysis was performed on the Total Vaccinated cohort, which included all vaccinated subjects for whom data were available at Months 12, 18 and 24.

Arm	Measure	Group	Value (MEDIAN)
HIV+/Cervarix Group	HIV Viral Load (VL) in HIV+ Subjects at Months 12, 18 and 24	HIV viral load, Month 12	1.6 HIV copies/mL
HIV+/Cervarix Group	HIV Viral Load (VL) in HIV+ Subjects at Months 12, 18 and 24	HIV viral load, Month 18	1.7 HIV copies/mL
HIV+/Cervarix Group	HIV Viral Load (VL) in HIV+ Subjects at Months 12, 18 and 24	HIV viral load, Month 24	1.6 HIV copies/mL
HIV+/Gardasil Group	HIV Viral Load (VL) in HIV+ Subjects at Months 12, 18 and 24	HIV viral load, Month 12	2.3 HIV copies/mL
HIV+/Gardasil Group	HIV Viral Load (VL) in HIV+ Subjects at Months 12, 18 and 24	HIV viral load, Month 18	2.2 HIV copies/mL
HIV+/Gardasil Group	HIV Viral Load (VL) in HIV+ Subjects at Months 12, 18 and 24	HIV viral load, Month 24	2.1 HIV copies/mL

Secondary

Number of HIV+ Subjects by WHO HIV Clinical Staging

HIV+ subjects were categorised into clinical stages 1 through 4, as per the WHO classification \[WHO, 2009\].

Time frame: At Months 12, 18 and 24

Population: The analysis was performed on the Total Vaccinated cohort, which included all vaccinated subjects for whom data were available at Months 12, 18 and 24.

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
HIV+/Cervarix Group	Number of HIV+ Subjects by WHO HIV Clinical Staging	Clinical stage 1, Month 12	113 Participants
HIV+/Cervarix Group	Number of HIV+ Subjects by WHO HIV Clinical Staging	Clinical stage 2, Month 12	7 Participants
HIV+/Cervarix Group	Number of HIV+ Subjects by WHO HIV Clinical Staging	Clinical stage 3, Month 12	1 Participants
HIV+/Cervarix Group	Number of HIV+ Subjects by WHO HIV Clinical Staging	Clinical stage 4, Month 12	2 Participants
HIV+/Cervarix Group	Number of HIV+ Subjects by WHO HIV Clinical Staging	Clinical stage 1, Month 18	112 Participants
HIV+/Cervarix Group	Number of HIV+ Subjects by WHO HIV Clinical Staging	Clinical stage 2, Month 18	7 Participants
HIV+/Cervarix Group	Number of HIV+ Subjects by WHO HIV Clinical Staging	Clinical stage 3, Month 18	1 Participants
HIV+/Cervarix Group	Number of HIV+ Subjects by WHO HIV Clinical Staging	Clinical stage 4, Month 18	2 Participants
HIV+/Cervarix Group	Number of HIV+ Subjects by WHO HIV Clinical Staging	Clinical stage 1, Month 24	107 Participants
HIV+/Cervarix Group	Number of HIV+ Subjects by WHO HIV Clinical Staging	Clinical stage 2, Month 24	7 Participants
HIV+/Cervarix Group	Number of HIV+ Subjects by WHO HIV Clinical Staging	Clinical stage 3, Month 24	1 Participants
HIV+/Cervarix Group	Number of HIV+ Subjects by WHO HIV Clinical Staging	Clinical stage 4, Month 24	2 Participants
HIV+/Gardasil Group	Number of HIV+ Subjects by WHO HIV Clinical Staging	Clinical stage 3, Month 24	2 Participants
HIV+/Gardasil Group	Number of HIV+ Subjects by WHO HIV Clinical Staging	Clinical stage 1, Month 12	112 Participants
HIV+/Gardasil Group	Number of HIV+ Subjects by WHO HIV Clinical Staging	Clinical stage 3, Month 18	2 Participants
HIV+/Gardasil Group	Number of HIV+ Subjects by WHO HIV Clinical Staging	Clinical stage 2, Month 12	1 Participants
HIV+/Gardasil Group	Number of HIV+ Subjects by WHO HIV Clinical Staging	Clinical stage 2, Month 24	1 Participants
HIV+/Gardasil Group	Number of HIV+ Subjects by WHO HIV Clinical Staging	Clinical stage 3, Month 12	2 Participants
HIV+/Gardasil Group	Number of HIV+ Subjects by WHO HIV Clinical Staging	Clinical stage 4, Month 18	4 Participants
HIV+/Gardasil Group	Number of HIV+ Subjects by WHO HIV Clinical Staging	Clinical stage 4, Month 12	4 Participants
HIV+/Gardasil Group	Number of HIV+ Subjects by WHO HIV Clinical Staging	Clinical stage 4, Month 24	4 Participants
HIV+/Gardasil Group	Number of HIV+ Subjects by WHO HIV Clinical Staging	Clinical stage 1, Month 18	110 Participants
HIV+/Gardasil Group	Number of HIV+ Subjects by WHO HIV Clinical Staging	Clinical stage 1, Month 24	110 Participants
HIV+/Gardasil Group	Number of HIV+ Subjects by WHO HIV Clinical Staging	Clinical stage 2, Month 18	1 Participants

Secondary

Number of HIV- Subjects With Any and Grade 3 Solicited Local Symptoms

Time frame: During the 7-day follow-up period (from the day of vaccination up to 6 subsequent days) after each vaccine dose and across doses

Population: The analysis was performed on the Total Vaccinated cohort, which included all vaccinated subjects for whom data were available and who had available symptom sheets completed.

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
HIV+/Cervarix Group	Number of HIV- Subjects With Any and Grade 3 Solicited Local Symptoms	Any Pain, Dose 1	127 Participants
HIV+/Cervarix Group	Number of HIV- Subjects With Any and Grade 3 Solicited Local Symptoms	Any Pain, Dose 3	94 Participants
HIV+/Cervarix Group	Number of HIV- Subjects With Any and Grade 3 Solicited Local Symptoms	Any Swelling, Dose 3	29 Participants
HIV+/Cervarix Group	Number of HIV- Subjects With Any and Grade 3 Solicited Local Symptoms	Grade 3 Swelling, Dose 3	0 Participants
HIV+/Cervarix Group	Number of HIV- Subjects With Any and Grade 3 Solicited Local Symptoms	Grade 3 Swelling, Across Doses	0 Participants
HIV+/Cervarix Group	Number of HIV- Subjects With Any and Grade 3 Solicited Local Symptoms	Grade 3 Pain, Dose 1	10 Participants
HIV+/Cervarix Group	Number of HIV- Subjects With Any and Grade 3 Solicited Local Symptoms	Any Redness, Dose 1	32 Participants
HIV+/Cervarix Group	Number of HIV- Subjects With Any and Grade 3 Solicited Local Symptoms	Grade 3 Redness, Dose 1	0 Participants
HIV+/Cervarix Group	Number of HIV- Subjects With Any and Grade 3 Solicited Local Symptoms	Any Swelling, Dose 1	23 Participants
HIV+/Cervarix Group	Number of HIV- Subjects With Any and Grade 3 Solicited Local Symptoms	Grade 3 Swelling, Dose 1	0 Participants
HIV+/Cervarix Group	Number of HIV- Subjects With Any and Grade 3 Solicited Local Symptoms	Any Pain, Dose 2	108 Participants
HIV+/Cervarix Group	Number of HIV- Subjects With Any and Grade 3 Solicited Local Symptoms	Grade 3 Pain, Dose 2	6 Participants
HIV+/Cervarix Group	Number of HIV- Subjects With Any and Grade 3 Solicited Local Symptoms	Any Redness, Dose 2	29 Participants
HIV+/Cervarix Group	Number of HIV- Subjects With Any and Grade 3 Solicited Local Symptoms	Grade 3 Redness, Dose 2	0 Participants
HIV+/Cervarix Group	Number of HIV- Subjects With Any and Grade 3 Solicited Local Symptoms	Any Swelling, Dose 2	24 Participants
HIV+/Cervarix Group	Number of HIV- Subjects With Any and Grade 3 Solicited Local Symptoms	Grade 3 Swelling, Dose 2	0 Participants
HIV+/Cervarix Group	Number of HIV- Subjects With Any and Grade 3 Solicited Local Symptoms	Grade 3 Pain, Dose 3	10 Participants
HIV+/Cervarix Group	Number of HIV- Subjects With Any and Grade 3 Solicited Local Symptoms	Any Redness, Dose 3	28 Participants
HIV+/Cervarix Group	Number of HIV- Subjects With Any and Grade 3 Solicited Local Symptoms	Grade 3 Redness, Dose 3	0 Participants
HIV+/Cervarix Group	Number of HIV- Subjects With Any and Grade 3 Solicited Local Symptoms	Any Pain, Across Doses	133 Participants
HIV+/Cervarix Group	Number of HIV- Subjects With Any and Grade 3 Solicited Local Symptoms	Grade 3 Pain, Across Doses	22 Participants
HIV+/Cervarix Group	Number of HIV- Subjects With Any and Grade 3 Solicited Local Symptoms	Any Redness, Across Doses	52 Participants
HIV+/Cervarix Group	Number of HIV- Subjects With Any and Grade 3 Solicited Local Symptoms	Grade 3 Redness, Across Doses	0 Participants
HIV+/Cervarix Group	Number of HIV- Subjects With Any and Grade 3 Solicited Local Symptoms	Any Swelling, Across Doses	47 Participants
HIV+/Gardasil Group	Number of HIV- Subjects With Any and Grade 3 Solicited Local Symptoms	Grade 3 Redness, Across Doses	0 Participants
HIV+/Gardasil Group	Number of HIV- Subjects With Any and Grade 3 Solicited Local Symptoms	Any Redness, Dose 2	29 Participants
HIV+/Gardasil Group	Number of HIV- Subjects With Any and Grade 3 Solicited Local Symptoms	Any Pain, Dose 3	82 Participants
HIV+/Gardasil Group	Number of HIV- Subjects With Any and Grade 3 Solicited Local Symptoms	Grade 3 Redness, Dose 3	0 Participants
HIV+/Gardasil Group	Number of HIV- Subjects With Any and Grade 3 Solicited Local Symptoms	Any Swelling, Dose 3	19 Participants
HIV+/Gardasil Group	Number of HIV- Subjects With Any and Grade 3 Solicited Local Symptoms	Grade 3 Redness, Dose 2	0 Participants
HIV+/Gardasil Group	Number of HIV- Subjects With Any and Grade 3 Solicited Local Symptoms	Grade 3 Swelling, Dose 3	0 Participants
HIV+/Gardasil Group	Number of HIV- Subjects With Any and Grade 3 Solicited Local Symptoms	Any Redness, Across Doses	42 Participants
HIV+/Gardasil Group	Number of HIV- Subjects With Any and Grade 3 Solicited Local Symptoms	Grade 3 Swelling, Across Doses	0 Participants
HIV+/Gardasil Group	Number of HIV- Subjects With Any and Grade 3 Solicited Local Symptoms	Any Pain, Dose 1	91 Participants
HIV+/Gardasil Group	Number of HIV- Subjects With Any and Grade 3 Solicited Local Symptoms	Any Swelling, Dose 2	27 Participants
HIV+/Gardasil Group	Number of HIV- Subjects With Any and Grade 3 Solicited Local Symptoms	Grade 3 Pain, Dose 1	1 Participants
HIV+/Gardasil Group	Number of HIV- Subjects With Any and Grade 3 Solicited Local Symptoms	Any Pain, Across Doses	119 Participants
HIV+/Gardasil Group	Number of HIV- Subjects With Any and Grade 3 Solicited Local Symptoms	Any Redness, Dose 1	21 Participants
HIV+/Gardasil Group	Number of HIV- Subjects With Any and Grade 3 Solicited Local Symptoms	Grade 3 Swelling, Dose 2	0 Participants
HIV+/Gardasil Group	Number of HIV- Subjects With Any and Grade 3 Solicited Local Symptoms	Grade 3 Redness, Dose 1	0 Participants
HIV+/Gardasil Group	Number of HIV- Subjects With Any and Grade 3 Solicited Local Symptoms	Any Swelling, Across Doses	39 Participants
HIV+/Gardasil Group	Number of HIV- Subjects With Any and Grade 3 Solicited Local Symptoms	Any Swelling, Dose 1	14 Participants
HIV+/Gardasil Group	Number of HIV- Subjects With Any and Grade 3 Solicited Local Symptoms	Grade 3 Pain, Dose 3	6 Participants
HIV+/Gardasil Group	Number of HIV- Subjects With Any and Grade 3 Solicited Local Symptoms	Grade 3 Swelling, Dose 1	0 Participants
HIV+/Gardasil Group	Number of HIV- Subjects With Any and Grade 3 Solicited Local Symptoms	Grade 3 Pain, Across Doses	8 Participants
HIV+/Gardasil Group	Number of HIV- Subjects With Any and Grade 3 Solicited Local Symptoms	Any Pain, Dose 2	92 Participants
HIV+/Gardasil Group	Number of HIV- Subjects With Any and Grade 3 Solicited Local Symptoms	Any Redness, Dose 3	19 Participants
HIV+/Gardasil Group	Number of HIV- Subjects With Any and Grade 3 Solicited Local Symptoms	Grade 3 Pain, Dose 2	2 Participants

Secondary

Number of HIV- Subjects With Any, Grade 3 and Related Solicited General Symptoms

Time frame: During the 7-day follow-up period (from the day of vaccination up to 6 subsequent days) after each vaccine dose and across doses

Population: The analysis was performed on the Total Vaccinated cohort, which included all vaccinated subjects for whom data were available and who had available symptom sheets completed.

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
HIV+/Cervarix Group	Number of HIV- Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Myalgia, Dose 2	1 Participants
HIV+/Cervarix Group	Number of HIV- Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Fatigue, Dose 1	29 Participants
HIV+/Cervarix Group	Number of HIV- Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Gastrointestinal, Dose 1	1 Participants
HIV+/Cervarix Group	Number of HIV- Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Headache, Dose 1	45 Participants
HIV+/Cervarix Group	Number of HIV- Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Myalgia, Dose 1	1 Participants
HIV+/Cervarix Group	Number of HIV- Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Temperature, Dose 1	0 Participants
HIV+/Cervarix Group	Number of HIV- Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Fatigue, Dose 2	34 Participants
HIV+/Cervarix Group	Number of HIV- Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Fatigue, Dose 2	19 Participants
HIV+/Cervarix Group	Number of HIV- Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Headache, Dose 2	5 Participants
HIV+/Cervarix Group	Number of HIV- Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Fatigue, Dose 3	32 Participants
HIV+/Cervarix Group	Number of HIV- Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Gastrointestinal, Dose 3	6 Participants
HIV+/Cervarix Group	Number of HIV- Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Myalgia, Dose 3	22 Participants
HIV+/Cervarix Group	Number of HIV- Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Arthralgia, Across Doses	31 Participants
HIV+/Cervarix Group	Number of HIV- Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Gastrointestinal, Across Doses	17 Participants
HIV+/Cervarix Group	Number of HIV- Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Headache, Across Doses	69 Participants
HIV+/Cervarix Group	Number of HIV- Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Fatigue, Dose 2	2 Participants
HIV+/Cervarix Group	Number of HIV- Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Gastrointestinal, Dose 2	9 Participants
HIV+/Cervarix Group	Number of HIV- Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Gastrointestinal, Dose 2	1 Participants
HIV+/Cervarix Group	Number of HIV- Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Gastrointestinal, Dose 2	7 Participants
HIV+/Cervarix Group	Number of HIV- Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Headache, Dose 2	35 Participants
HIV+/Cervarix Group	Number of HIV- Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Headache, Dose 2	23 Participants
HIV+/Cervarix Group	Number of HIV- Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Myalgia, Dose 2	36 Participants
HIV+/Cervarix Group	Number of HIV- Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Arthralgia, Dose 1	17 Participants
HIV+/Cervarix Group	Number of HIV- Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Myalgia, Dose 2	28 Participants
HIV+/Cervarix Group	Number of HIV- Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Rash, Dose 2	2 Participants
HIV+/Cervarix Group	Number of HIV- Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Rash, Dose 2	0 Participants
HIV+/Cervarix Group	Number of HIV- Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Rash, Dose 2	1 Participants
HIV+/Cervarix Group	Number of HIV- Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Temperature, Dose 2	10 Participants
HIV+/Cervarix Group	Number of HIV- Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Temperature, Dose 2	1 Participants
HIV+/Cervarix Group	Number of HIV- Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Temperature, Dose 2	5 Participants
HIV+/Cervarix Group	Number of HIV- Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Urticaria, Dose 2	1 Participants
HIV+/Cervarix Group	Number of HIV- Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Headache, Dose 3	3 Participants
HIV+/Cervarix Group	Number of HIV- Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Urticaria, Dose 2	0 Participants
HIV+/Cervarix Group	Number of HIV- Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Urticaria, Dose 2	1 Participants
HIV+/Cervarix Group	Number of HIV- Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Arthralgia, Dose 3	9 Participants
HIV+/Cervarix Group	Number of HIV- Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Arthralgia, Dose 3	0 Participants
HIV+/Cervarix Group	Number of HIV- Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Arthralgia, Dose 3	9 Participants
HIV+/Cervarix Group	Number of HIV- Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Fatigue, Dose 3	1 Participants
HIV+/Cervarix Group	Number of HIV- Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Fatigue, Dose 3	29 Participants
HIV+/Cervarix Group	Number of HIV- Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Gastrointestinal, Dose 3	7 Participants
HIV+/Cervarix Group	Number of HIV- Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Gastrointestinal, Dose 3	1 Participants
HIV+/Cervarix Group	Number of HIV- Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Headache, Dose 3	33 Participants
HIV+/Cervarix Group	Number of HIV- Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Headache, Dose 3	26 Participants
HIV+/Cervarix Group	Number of HIV- Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Myalgia, Dose 3	26 Participants
HIV+/Cervarix Group	Number of HIV- Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Myalgia, Dose 3	2 Participants
HIV+/Cervarix Group	Number of HIV- Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Rash, Dose 3	2 Participants
HIV+/Cervarix Group	Number of HIV- Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Rash, Dose 3	0 Participants
HIV+/Cervarix Group	Number of HIV- Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Rash, Dose 3	2 Participants
HIV+/Cervarix Group	Number of HIV- Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Temperature, Dose 3	9 Participants
HIV+/Cervarix Group	Number of HIV- Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Temperature, Dose 3	2 Participants
HIV+/Cervarix Group	Number of HIV- Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Temperature, Dose 3	7 Participants
HIV+/Cervarix Group	Number of HIV- Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Urticaria, Dose 3	2 Participants
HIV+/Cervarix Group	Number of HIV- Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Urticaria, Dose 3	0 Participants
HIV+/Cervarix Group	Number of HIV- Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Urticaria, Dose 3	2 Participants
HIV+/Cervarix Group	Number of HIV- Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Arthralgia, Across Doses	0 Participants
HIV+/Cervarix Group	Number of HIV- Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Arthralgia, Across Doses	20 Participants
HIV+/Cervarix Group	Number of HIV- Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Fatigue, Across Doses	65 Participants
HIV+/Cervarix Group	Number of HIV- Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Fatigue, Across Doses	5 Participants
HIV+/Cervarix Group	Number of HIV- Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Fatigue, Across Doses	45 Participants
HIV+/Cervarix Group	Number of HIV- Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Gastrointestinal, Across Doses	28 Participants
HIV+/Cervarix Group	Number of HIV- Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Gastrointestinal, Across Doses	2 Participants
HIV+/Cervarix Group	Number of HIV- Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Headache, Across Doses	7 Participants
HIV+/Cervarix Group	Number of HIV- Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Headache, Across Doses	51 Participants
HIV+/Cervarix Group	Number of HIV- Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Myalgia, Across Doses	64 Participants
HIV+/Cervarix Group	Number of HIV- Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Myalgia, Across Doses	3 Participants
HIV+/Cervarix Group	Number of HIV- Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Myalgia, Across Doses	44 Participants
HIV+/Cervarix Group	Number of HIV- Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Rash, Across Doses	5 Participants
HIV+/Cervarix Group	Number of HIV- Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Rash, Across Doses	0 Participants
HIV+/Cervarix Group	Number of HIV- Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Rash, Across Doses	5 Participants
HIV+/Cervarix Group	Number of HIV- Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Temperature, Across Doses	22 Participants
HIV+/Cervarix Group	Number of HIV- Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Temperature, Across Doses	3 Participants
HIV+/Cervarix Group	Number of HIV- Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Temperature, Across Doses	16 Participants
HIV+/Cervarix Group	Number of HIV- Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Urticaria, Across Doses	4 Participants
HIV+/Cervarix Group	Number of HIV- Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Urticaria, Across Doses	0 Participants
HIV+/Cervarix Group	Number of HIV- Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Urticaria, Across Doses	4 Participants
HIV+/Cervarix Group	Number of HIV- Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Arthralgia, Dose 1	0 Participants
HIV+/Cervarix Group	Number of HIV- Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Arthralgia, Dose 1	9 Participants
HIV+/Cervarix Group	Number of HIV- Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Fatigue, Dose 1	45 Participants
HIV+/Cervarix Group	Number of HIV- Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Fatigue, Dose 1	3 Participants
HIV+/Cervarix Group	Number of HIV- Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Gastrointestinal, Dose 1	19 Participants
HIV+/Cervarix Group	Number of HIV- Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Gastrointestinal, Dose 1	8 Participants
HIV+/Cervarix Group	Number of HIV- Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Headache, Dose 1	0 Participants
HIV+/Cervarix Group	Number of HIV- Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Headache, Dose 1	29 Participants
HIV+/Cervarix Group	Number of HIV- Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Myalgia, Dose 1	44 Participants
HIV+/Cervarix Group	Number of HIV- Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Myalgia, Dose 1	28 Participants
HIV+/Cervarix Group	Number of HIV- Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Rash, Dose 1	2 Participants
HIV+/Cervarix Group	Number of HIV- Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Rash, Dose 1	0 Participants
HIV+/Cervarix Group	Number of HIV- Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Rash, Dose 1	2 Participants
HIV+/Cervarix Group	Number of HIV- Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Temperature, Dose 1	11 Participants
HIV+/Cervarix Group	Number of HIV- Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Temperature, Dose 1	7 Participants
HIV+/Cervarix Group	Number of HIV- Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Urticaria, Dose 1	3 Participants
HIV+/Cervarix Group	Number of HIV- Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Urticaria, Dose 1	0 Participants
HIV+/Cervarix Group	Number of HIV- Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Urticaria, Dose 1	3 Participants
HIV+/Cervarix Group	Number of HIV- Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Arthralgia, Dose 2	14 Participants
HIV+/Cervarix Group	Number of HIV- Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Arthralgia, Dose 2	0 Participants
HIV+/Cervarix Group	Number of HIV- Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Arthralgia, Dose 2	9 Participants
HIV+/Gardasil Group	Number of HIV- Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Rash, Dose 3	0 Participants
HIV+/Gardasil Group	Number of HIV- Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Arthralgia, Dose 1	0 Participants
HIV+/Gardasil Group	Number of HIV- Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Fatigue, Dose 1	34 Participants
HIV+/Gardasil Group	Number of HIV- Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Headache, Dose 1	22 Participants
HIV+/Gardasil Group	Number of HIV- Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Fatigue, Dose 1	17 Participants
HIV+/Gardasil Group	Number of HIV- Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Gastrointestinal, Dose 1	14 Participants
HIV+/Gardasil Group	Number of HIV- Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Rash, Dose 3	0 Participants
HIV+/Gardasil Group	Number of HIV- Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Temperature, Across Doses	1 Participants
HIV+/Gardasil Group	Number of HIV- Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Headache, Dose 1	2 Participants
HIV+/Gardasil Group	Number of HIV- Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Temperature, Dose 3	10 Participants
HIV+/Gardasil Group	Number of HIV- Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Temperature, Dose 1	8 Participants
HIV+/Gardasil Group	Number of HIV- Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Temperature, Dose 1	0 Participants
HIV+/Gardasil Group	Number of HIV- Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Temperature, Dose 1	5 Participants
HIV+/Gardasil Group	Number of HIV- Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Arthralgia, Dose 2	12 Participants
HIV+/Gardasil Group	Number of HIV- Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Temperature, Across Doses	16 Participants
HIV+/Gardasil Group	Number of HIV- Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Fatigue, Dose 2	34 Participants
HIV+/Gardasil Group	Number of HIV- Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Temperature, Dose 3	6 Participants
HIV+/Gardasil Group	Number of HIV- Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Fatigue, Dose 2	19 Participants
HIV+/Gardasil Group	Number of HIV- Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Headache, Dose 2	31 Participants
HIV+/Gardasil Group	Number of HIV- Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Myalgia, Dose 1	36 Participants
HIV+/Gardasil Group	Number of HIV- Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Rash, Dose 2	0 Participants
HIV+/Gardasil Group	Number of HIV- Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Temperature, Dose 2	10 Participants
HIV+/Gardasil Group	Number of HIV- Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Urticaria, Dose 3	3 Participants
HIV+/Gardasil Group	Number of HIV- Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Gastrointestinal, Dose 3	0 Participants
HIV+/Gardasil Group	Number of HIV- Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Urticaria, Across Doses	6 Participants
HIV+/Gardasil Group	Number of HIV- Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Urticaria, Dose 3	0 Participants
HIV+/Gardasil Group	Number of HIV- Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Myalgia, Dose 3	21 Participants
HIV+/Gardasil Group	Number of HIV- Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Temperature, Dose 3	1 Participants
HIV+/Gardasil Group	Number of HIV- Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Myalgia, Dose 1	2 Participants
HIV+/Gardasil Group	Number of HIV- Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Arthralgia, Across Doses	18 Participants
HIV+/Gardasil Group	Number of HIV- Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Fatigue, Across Doses	33 Participants
HIV+/Gardasil Group	Number of HIV- Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Gastrointestinal, Across Doses	1 Participants
HIV+/Gardasil Group	Number of HIV- Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Urticaria, Dose 3	3 Participants
HIV+/Gardasil Group	Number of HIV- Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Arthralgia, Across Doses	34 Participants
HIV+/Gardasil Group	Number of HIV- Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Arthralgia, Dose 2	5 Participants
HIV+/Gardasil Group	Number of HIV- Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Fatigue, Dose 2	0 Participants
HIV+/Gardasil Group	Number of HIV- Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Arthralgia, Across Doses	2 Participants
HIV+/Gardasil Group	Number of HIV- Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Gastrointestinal, Dose 2	15 Participants
HIV+/Gardasil Group	Number of HIV- Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Urticaria, Across Doses	6 Participants
HIV+/Gardasil Group	Number of HIV- Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Gastrointestinal, Dose 2	1 Participants
HIV+/Gardasil Group	Number of HIV- Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Arthralgia, Dose 1	21 Participants
HIV+/Gardasil Group	Number of HIV- Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Gastrointestinal, Dose 2	6 Participants
HIV+/Gardasil Group	Number of HIV- Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Fatigue, Across Doses	56 Participants
HIV+/Gardasil Group	Number of HIV- Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Headache, Dose 2	2 Participants
HIV+/Gardasil Group	Number of HIV- Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Myalgia, Dose 1	21 Participants
HIV+/Gardasil Group	Number of HIV- Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Headache, Dose 2	19 Participants
HIV+/Gardasil Group	Number of HIV- Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Fatigue, Across Doses	4 Participants
HIV+/Gardasil Group	Number of HIV- Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Myalgia, Dose 2	26 Participants
HIV+/Gardasil Group	Number of HIV- Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Urticaria, Dose 1	3 Participants
HIV+/Gardasil Group	Number of HIV- Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Myalgia, Dose 2	0 Participants
HIV+/Gardasil Group	Number of HIV- Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Arthralgia, Dose 1	11 Participants
HIV+/Gardasil Group	Number of HIV- Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Myalgia, Dose 2	19 Participants
HIV+/Gardasil Group	Number of HIV- Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Gastrointestinal, Across Doses	26 Participants
HIV+/Gardasil Group	Number of HIV- Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Rash, Dose 2	4 Participants
HIV+/Gardasil Group	Number of HIV- Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Rash, Dose 1	6 Participants
HIV+/Gardasil Group	Number of HIV- Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Gastrointestinal, Across Doses	17 Participants
HIV+/Gardasil Group	Number of HIV- Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Rash, Dose 2	1 Participants
HIV+/Gardasil Group	Number of HIV- Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Headache, Across Doses	67 Participants
HIV+/Gardasil Group	Number of HIV- Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Urticaria, Dose 1	3 Participants
HIV+/Gardasil Group	Number of HIV- Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Temperature, Dose 2	0 Participants
HIV+/Gardasil Group	Number of HIV- Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Headache, Across Doses	5 Participants
HIV+/Gardasil Group	Number of HIV- Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Temperature, Dose 2	8 Participants
HIV+/Gardasil Group	Number of HIV- Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Fatigue, Dose 1	2 Participants
HIV+/Gardasil Group	Number of HIV- Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Urticaria, Dose 2	1 Participants
HIV+/Gardasil Group	Number of HIV- Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Headache, Across Doses	40 Participants
HIV+/Gardasil Group	Number of HIV- Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Rash, Dose 1	0 Participants
HIV+/Gardasil Group	Number of HIV- Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Urticaria, Dose 2	0 Participants
HIV+/Gardasil Group	Number of HIV- Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Myalgia, Across Doses	53 Participants
HIV+/Gardasil Group	Number of HIV- Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Urticaria, Dose 2	1 Participants
HIV+/Gardasil Group	Number of HIV- Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Gastrointestinal, Dose 1	1 Participants
HIV+/Gardasil Group	Number of HIV- Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Arthralgia, Dose 3	14 Participants
HIV+/Gardasil Group	Number of HIV- Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Myalgia, Across Doses	4 Participants
HIV+/Gardasil Group	Number of HIV- Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Arthralgia, Dose 3	2 Participants
HIV+/Gardasil Group	Number of HIV- Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Arthralgia, Dose 2	0 Participants
HIV+/Gardasil Group	Number of HIV- Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Arthralgia, Dose 3	11 Participants
HIV+/Gardasil Group	Number of HIV- Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Fatigue, Dose 3	20 Participants
HIV+/Gardasil Group	Number of HIV- Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Myalgia, Across Doses	40 Participants
HIV+/Gardasil Group	Number of HIV- Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Fatigue, Dose 3	2 Participants
HIV+/Gardasil Group	Number of HIV- Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Gastrointestinal, Dose 1	11 Participants
HIV+/Gardasil Group	Number of HIV- Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Fatigue, Dose 3	15 Participants
HIV+/Gardasil Group	Number of HIV- Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Rash, Across Doses	8 Participants
HIV+/Gardasil Group	Number of HIV- Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Gastrointestinal, Dose 3	9 Participants
HIV+/Gardasil Group	Number of HIV- Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Urticaria, Across Doses	0 Participants
HIV+/Gardasil Group	Number of HIV- Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Gastrointestinal, Dose 3	6 Participants
HIV+/Gardasil Group	Number of HIV- Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Headache, Dose 1	45 Participants
HIV+/Gardasil Group	Number of HIV- Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Headache, Dose 3	25 Participants
HIV+/Gardasil Group	Number of HIV- Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Headache, Dose 3	2 Participants
HIV+/Gardasil Group	Number of HIV- Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Rash, Across Doses	0 Participants
HIV+/Gardasil Group	Number of HIV- Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Headache, Dose 3	17 Participants
HIV+/Gardasil Group	Number of HIV- Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Rash, Dose 1	2 Participants
HIV+/Gardasil Group	Number of HIV- Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Myalgia, Dose 3	28 Participants
HIV+/Gardasil Group	Number of HIV- Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Rash, Across Doses	3 Participants
HIV+/Gardasil Group	Number of HIV- Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Myalgia, Dose 3	2 Participants
HIV+/Gardasil Group	Number of HIV- Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Urticaria, Dose 1	0 Participants
HIV+/Gardasil Group	Number of HIV- Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Rash, Dose 3	0 Participants
HIV+/Gardasil Group	Number of HIV- Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Temperature, Across Doses	24 Participants

Secondary

Number of HIV- Subjects With Medically Significant Conditions (MSCs)

Time frame: From Day 0 up to Month 7 (from Day 0 up to 30 days after the last vaccination dose at Month 6)

Population: The analysis was performed on the Total Vaccinated cohort for analysis of safety, which included all subjects with at least one vaccine administration documented.

Arm	Measure	Value (COUNT_OF_PARTICIPANTS)
HIV+/Cervarix Group	Number of HIV- Subjects With Medically Significant Conditions (MSCs)	7 Participants
HIV+/Gardasil Group	Number of HIV- Subjects With Medically Significant Conditions (MSCs)	14 Participants

Secondary

Number of HIV- Subjects With Potential Immune-mediated Disease (pIMDs)

Time frame: From Day 0 up to Month 7 (from Day 0 up to 30 days after the last vaccination dose at Month 6)

Population: The analysis was performed on the Total Vaccinated cohort for analysis of safety, which included all subjects with at least one vaccine administration documented.

Arm	Measure	Value (COUNT_OF_PARTICIPANTS)
HIV+/Cervarix Group	Number of HIV- Subjects With Potential Immune-mediated Disease (pIMDs)	0 Participants
HIV+/Gardasil Group	Number of HIV- Subjects With Potential Immune-mediated Disease (pIMDs)	0 Participants

Secondary

Number of HIV- Subjects With Serious Adverse Events (SAEs)

Time frame: From Day 0 up to Month 7 (from Day 0 up to 30 days after the last vaccination dose at Month 6)

Population: The analysis was performed on the Total Vaccinated cohort for analysis of safety, which included all subjects with at least one vaccine administration documented.

Arm	Measure	Value (COUNT_OF_PARTICIPANTS)
HIV+/Cervarix Group	Number of HIV- Subjects With Serious Adverse Events (SAEs)	1 Participants
HIV+/Gardasil Group	Number of HIV- Subjects With Serious Adverse Events (SAEs)	0 Participants

Secondary

Number of HIV- Subjects With Unsolicited Adverse Events (AEs)

Time frame: During the 30-day follow-up period (from the day of vaccination up to 29 subsequent days) after any vaccination

Population: The analysis was performed on the Total Vaccinated cohort for analysis of safety, which included all subjects with at least one vaccine administration documented.

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
HIV+/Cervarix Group	Number of HIV- Subjects With Unsolicited Adverse Events (AEs)	Any AE(s)	26 Participants
HIV+/Cervarix Group	Number of HIV- Subjects With Unsolicited Adverse Events (AEs)	Grade 3 AE(s)	1 Participants
HIV+/Cervarix Group	Number of HIV- Subjects With Unsolicited Adverse Events (AEs)	Related AE(s)	4 Participants
HIV+/Gardasil Group	Number of HIV- Subjects With Unsolicited Adverse Events (AEs)	Any AE(s)	32 Participants
HIV+/Gardasil Group	Number of HIV- Subjects With Unsolicited Adverse Events (AEs)	Grade 3 AE(s)	3 Participants
HIV+/Gardasil Group	Number of HIV- Subjects With Unsolicited Adverse Events (AEs)	Related AE(s)	2 Participants

Secondary

Number of Subjects Reporting Pregnancies and Outcomes of Reported Pregnancies

Time frame: During the entire study period (from Day 0 up to Month 24)

Population: The analysis was performed on the Total Vaccinated cohort, which included all vaccinated subjects who reported any pregnancies and outcomes of reported pregnancies.

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
HIV+/Cervarix Group	Number of Subjects Reporting Pregnancies and Outcomes of Reported Pregnancies	Spontaneous abortion NO apparent congen. anomaly	1 Participants
HIV+/Cervarix Group	Number of Subjects Reporting Pregnancies and Outcomes of Reported Pregnancies	Ectopic pregnancy	0 Participants
HIV+/Cervarix Group	Number of Subjects Reporting Pregnancies and Outcomes of Reported Pregnancies	Elective termin. congenital anomaly	0 Participants
HIV+/Cervarix Group	Number of Subjects Reporting Pregnancies and Outcomes of Reported Pregnancies	Missing	0 Participants
HIV+/Cervarix Group	Number of Subjects Reporting Pregnancies and Outcomes of Reported Pregnancies	Pregnancy ongoing	0 Participants
HIV+/Cervarix Group	Number of Subjects Reporting Pregnancies and Outcomes of Reported Pregnancies	Live infant congenital anomaly	0 Participants
HIV+/Cervarix Group	Number of Subjects Reporting Pregnancies and Outcomes of Reported Pregnancies	Live infant NO apparent congenital anomaly	8 Participants
HIV+/Cervarix Group	Number of Subjects Reporting Pregnancies and Outcomes of Reported Pregnancies	Lost to follow-up	0 Participants
HIV+/Cervarix Group	Number of Subjects Reporting Pregnancies and Outcomes of Reported Pregnancies	Stillbirth congenital anomaly	0 Participants
HIV+/Cervarix Group	Number of Subjects Reporting Pregnancies and Outcomes of Reported Pregnancies	Elective termin. NO apparent congenital anomaly	1 Participants
HIV+/Cervarix Group	Number of Subjects Reporting Pregnancies and Outcomes of Reported Pregnancies	Stillbirth NO apparent congenital anomaly	0 Participants
HIV+/Gardasil Group	Number of Subjects Reporting Pregnancies and Outcomes of Reported Pregnancies	Elective termin. NO apparent congenital anomaly	0 Participants
HIV+/Gardasil Group	Number of Subjects Reporting Pregnancies and Outcomes of Reported Pregnancies	Live infant NO apparent congenital anomaly	7 Participants
HIV+/Gardasil Group	Number of Subjects Reporting Pregnancies and Outcomes of Reported Pregnancies	Live infant congenital anomaly	0 Participants
HIV+/Gardasil Group	Number of Subjects Reporting Pregnancies and Outcomes of Reported Pregnancies	Elective termin. congenital anomaly	0 Participants
HIV+/Gardasil Group	Number of Subjects Reporting Pregnancies and Outcomes of Reported Pregnancies	Ectopic pregnancy	0 Participants
HIV+/Gardasil Group	Number of Subjects Reporting Pregnancies and Outcomes of Reported Pregnancies	Spontaneous abortion NO apparent congen. anomaly	1 Participants
HIV+/Gardasil Group	Number of Subjects Reporting Pregnancies and Outcomes of Reported Pregnancies	Stillbirth NO apparent congenital anomaly	0 Participants
HIV+/Gardasil Group	Number of Subjects Reporting Pregnancies and Outcomes of Reported Pregnancies	Stillbirth congenital anomaly	0 Participants
HIV+/Gardasil Group	Number of Subjects Reporting Pregnancies and Outcomes of Reported Pregnancies	Lost to follow-up	0 Participants
HIV+/Gardasil Group	Number of Subjects Reporting Pregnancies and Outcomes of Reported Pregnancies	Pregnancy ongoing	0 Participants
HIV+/Gardasil Group	Number of Subjects Reporting Pregnancies and Outcomes of Reported Pregnancies	Missing	0 Participants
HIV-/Cervarix Group	Number of Subjects Reporting Pregnancies and Outcomes of Reported Pregnancies	Pregnancy ongoing	0 Participants
HIV-/Cervarix Group	Number of Subjects Reporting Pregnancies and Outcomes of Reported Pregnancies	Spontaneous abortion NO apparent congen. anomaly	0 Participants
HIV-/Cervarix Group	Number of Subjects Reporting Pregnancies and Outcomes of Reported Pregnancies	Stillbirth congenital anomaly	0 Participants
HIV-/Cervarix Group	Number of Subjects Reporting Pregnancies and Outcomes of Reported Pregnancies	Stillbirth NO apparent congenital anomaly	0 Participants
HIV-/Cervarix Group	Number of Subjects Reporting Pregnancies and Outcomes of Reported Pregnancies	Live infant NO apparent congenital anomaly	3 Participants
HIV-/Cervarix Group	Number of Subjects Reporting Pregnancies and Outcomes of Reported Pregnancies	Live infant congenital anomaly	0 Participants
HIV-/Cervarix Group	Number of Subjects Reporting Pregnancies and Outcomes of Reported Pregnancies	Lost to follow-up	0 Participants
HIV-/Cervarix Group	Number of Subjects Reporting Pregnancies and Outcomes of Reported Pregnancies	Elective termin. congenital anomaly	0 Participants
HIV-/Cervarix Group	Number of Subjects Reporting Pregnancies and Outcomes of Reported Pregnancies	Missing	0 Participants
HIV-/Cervarix Group	Number of Subjects Reporting Pregnancies and Outcomes of Reported Pregnancies	Ectopic pregnancy	0 Participants
HIV-/Cervarix Group	Number of Subjects Reporting Pregnancies and Outcomes of Reported Pregnancies	Elective termin. NO apparent congenital anomaly	0 Participants
HIV-/Gardasil Group	Number of Subjects Reporting Pregnancies and Outcomes of Reported Pregnancies	Missing	0 Participants
HIV-/Gardasil Group	Number of Subjects Reporting Pregnancies and Outcomes of Reported Pregnancies	Elective termin. NO apparent congenital anomaly	0 Participants
HIV-/Gardasil Group	Number of Subjects Reporting Pregnancies and Outcomes of Reported Pregnancies	Spontaneous abortion NO apparent congen. anomaly	0 Participants
HIV-/Gardasil Group	Number of Subjects Reporting Pregnancies and Outcomes of Reported Pregnancies	Lost to follow-up	0 Participants
HIV-/Gardasil Group	Number of Subjects Reporting Pregnancies and Outcomes of Reported Pregnancies	Pregnancy ongoing	0 Participants
HIV-/Gardasil Group	Number of Subjects Reporting Pregnancies and Outcomes of Reported Pregnancies	Live infant NO apparent congenital anomaly	7 Participants
HIV-/Gardasil Group	Number of Subjects Reporting Pregnancies and Outcomes of Reported Pregnancies	Stillbirth NO apparent congenital anomaly	0 Participants
HIV-/Gardasil Group	Number of Subjects Reporting Pregnancies and Outcomes of Reported Pregnancies	Live infant congenital anomaly	0 Participants
HIV-/Gardasil Group	Number of Subjects Reporting Pregnancies and Outcomes of Reported Pregnancies	Ectopic pregnancy	0 Participants
HIV-/Gardasil Group	Number of Subjects Reporting Pregnancies and Outcomes of Reported Pregnancies	Stillbirth congenital anomaly	0 Participants
HIV-/Gardasil Group	Number of Subjects Reporting Pregnancies and Outcomes of Reported Pregnancies	Elective termin. congenital anomaly	0 Participants

Secondary

Number of Subjects With Medically Significant Conditions (MSCs)

Time frame: From Day 0 up to Month 18 (from Day 0 up to 12 months after the last vaccination dose at Month 6)

Population: The analysis was performed on the Total Vaccinated cohort for analysis of safety, which included all subjects with at least one vaccine administration documented.

Arm	Measure	Value (COUNT_OF_PARTICIPANTS)
HIV+/Cervarix Group	Number of Subjects With Medically Significant Conditions (MSCs)	25 Participants
HIV+/Gardasil Group	Number of Subjects With Medically Significant Conditions (MSCs)	37 Participants
HIV-/Cervarix Group	Number of Subjects With Medically Significant Conditions (MSCs)	10 Participants
HIV-/Gardasil Group	Number of Subjects With Medically Significant Conditions (MSCs)	17 Participants

Secondary

Number of Subjects With Potential Immune-mediated Diseases (pIMDs)

Time frame: From Day 0 up to Month 18 (from Day 0 up to 12 months after the last vaccination dose at Month 6)

Population: The analysis was performed on the Total Vaccinated cohort for analysis of safety, which included all subjects with at least one vaccine administration documented.

Arm	Measure	Value (COUNT_OF_PARTICIPANTS)
HIV+/Cervarix Group	Number of Subjects With Potential Immune-mediated Diseases (pIMDs)	1 Participants
HIV+/Gardasil Group	Number of Subjects With Potential Immune-mediated Diseases (pIMDs)	0 Participants
HIV-/Cervarix Group	Number of Subjects With Potential Immune-mediated Diseases (pIMDs)	0 Participants
HIV-/Gardasil Group	Number of Subjects With Potential Immune-mediated Diseases (pIMDs)	0 Participants

Secondary

Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters

Among assessed haematological and biochemical parameters were: alanine aminotransferase \[ALAT\], basophils \[BSPH\], creatinine \[CRT\], eosinophils \[ESPH\]. Unknown = value unknown for the specified visit and laboratory parameter; Below = value below the laboratory reference range defined for the specified visit and laboratory parameter; Within = value within the laboratory reference range defined for the specified visit and laboratory parameter; Above = value above the laboratory reference range defined for the specified visit and laboratory parameter.

Time frame: At Day 0, Week 6, Week 10, Month 6, Month 7, Month 12, Month 18 and Month 24

Population: The analysis was performed on the Total Vaccinated cohort, which included all vaccinated subjects for whom data were available at Day 0, Week 6, Week 10, Month 6, Month 7\*, Month 12, Month 18 and Month 24.~\* Month 7 data for HIV+/Cervarix and HIV+/Gardasil groups are also reported in the Primary outcome measure.

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	CRT, Week 6, Above	0 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	ESPH, Week 10, Below	11 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	CRT, Week 10, Above	0 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	BSPH, Day 0, Above	0 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	BSPH, Week 10, Unknown	0 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	CRT, Month 6, Above	1 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	CRT, Month 18, Unknown	0 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	BSPH, Month 18, Below	0 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	ESPH, Week 6, Below	10 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	CRT, Month 7, Above	1 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	BSPH, Week 6, Above	0 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	CRT, Month 12, Above	3 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	CRT, Month 18, Above	3 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	ESPH, Week 6, Above	9 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	ESPH, Month 12, Above	7 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	CRT, Day 0, Unknown	0 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	BSPH, Week 6, Below	0 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	BSPH, Week 10, Above	1 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	ALAT, Month 18, Above	4 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	ESPH, Week 6, Within	109 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	ESPH, Month 7, Unknown	0 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	ESPH, Month 24, Above	5 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	ESPH, Day 0, Below	15 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	BSPH, Week 10, Below	0 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	CRT, Day 0, Above	1 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	ESPH, Month 24, Below	7 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	ESPH, Month 6, Below	9 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	ALAT, Day 0, Unknown	0 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	ESPH, Day 0, Above	6 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	ESPH, Month 7, Below	9 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	BSPH, Month 12, Below	0 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	ALAT, Week 6, Unknown	0 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	BSPH, Month 6, Below	0 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	ALAT, Month 24, Above	4 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	BSPH, Month 12, Unknown	1 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	ALAT, Week 10, Unknown	1 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	CRT, Month 24, Unknown	0 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	ALAT, Month 7, Within	110 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	ESPH, Month 12, Below	9 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	ALAT, Month 6, Unknown	0 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	CRT, Week 10, Within	95 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	ESPH, Month 7, Within	108 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	BSPH, Month 7, Below	0 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	ALAT, Month 7, Unknown	0 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	BSPH, Week 10, Within	127 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	ALAT, Week 10, Above	8 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	ESPH, Month 6, Unknown	0 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	BSPH, Week 6, Unknown	0 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	CRT, Day 0, Below	31 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	ALAT, Month 18, Unknown	0 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	BSPH, Day 0, Unknown	0 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	CRT, Week 6, Below	35 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	ESPH, Week 10, Unknown	0 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	ALAT, Month 24, Unknown	0 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	ALAT, Month 6, Below	3 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	ESPH, Month 24, Within	103 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	CRT, Week 10, Below	33 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	ALAT, Day 0, Below	9 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	BSPH, Month 6, Unknown	0 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	ESPH, Month 7, Above	4 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	BSPH, Month 6, Within	123 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	ALAT, Week 6, Below	4 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	ESPH, Week 10, Within	112 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	BSPH, Month 6, Above	0 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	CRT, Month 6, Below	33 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	ESPH, Month 24, Unknown	1 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	BSPH, Month 18, Unknown	0 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	ALAT, Week 10, Below	2 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	ALAT, Month 7, Below	4 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	ALAT, Month 6, Above	8 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	ESPH, Month 6, Within	103 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	ALAT, Month 12, Below	6 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	CRT, Month 7, Below	29 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	CRT, Month 6, Unknown	0 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	ESPH, Month 18, Unknown	0 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	ALAT, Month 18, Below	2 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	BSPH, Month 7, Within	120 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	ESPH, Month 18, Within	111 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	ALAT, Month 24, Below	0 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	CRT, Month 12, Below	25 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	BSPH, Month 7, Above	1 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	ESPH, Month 12, Unknown	1 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	ALAT, Day 0, Within	109 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	CRT, Month 24, Below	27 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	CRT, Month 12, Unknown	0 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	ESPH, Week 6, Unknown	0 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	ALAT, Week 6, Within	119 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	CRT, Week 6, Unknown	0 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	BSPH, Month 12, Within	121 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	ESPH, Day 0, Unknown	0 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	ALAT, Week 10, Within	117 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	ESPH, Month 12, Within	105 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	BSPH, Month 12, Above	0 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	CRT, Month 24, Above	1 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	ALAT, Month 6, Within	112 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	CRT, Month 12, Within	94 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	BSPH, Month 24, Unknown	1 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	CRT, Month 7, Unknown	0 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	CRT, Month 6, Within	89 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	CRT, Week 6, Within	93 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	ALAT, Month 12, Within	104 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	BSPH, Month 18, Within	120 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	ESPH, Month 18, Above	6 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	ESPH, Week 10, Above	5 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	ALAT, Month 18, Within	115 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	CRT, Month 7, Within	91 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	BSPH, Month 24, Below	0 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	ESPH, Month 6, Above	11 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	CRT, Week 10, Unknown	0 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	ALAT, Month 24, Within	112 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	BSPH, Month 18, Above	1 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	ALAT, Month 7, Above	7 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	ESPH, Month 18, Below	4 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	ALAT, Month 12, Unknown	0 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	ALAT, Day 0, Above	11 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	ESPH, Day 0, Within	108 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	ALAT, Week 6, Above	5 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	CRT, Month 18, Within	93 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	BSPH, Day 0, Within	129 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	BSPH, Month 24, Within	115 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	CRT, Month 18, Below	25 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	CRT, Month 24, Within	88 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	BSPH, Week 6, Within	128 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	BSPH, Month 7, Unknown	0 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	BSPH, Month 24, Above	0 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	ALAT, Month 12, Above	12 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	CRT, Day 0, Within	97 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	BSPH, Day 0, Below	0 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	ALAT, Month 24, Above	6 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	CRT, Month 24, Below	30 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	BSPH, Day 0, Unknown	0 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	BSPH, Week 6, Unknown	0 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	ALAT, Week 6, Above	6 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	BSPH, Week 10, Unknown	0 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	CRT, Week 6, Above	0 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	BSPH, Month 6, Unknown	0 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	CRT, Day 0, Above	1 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	BSPH, Month 7, Unknown	0 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	BSPH, Month 12, Unknown	0 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	ESPH, Week 6, Above	11 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	CRT, Month 12, Within	91 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	BSPH, Month 18, Unknown	0 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	BSPH, Month 24, Unknown	0 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	CRT, Week 6, Unknown	0 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	CRT, Week 6, Below	28 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	BSPH, Day 0, Below	1 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	CRT, Day 0, Below	26 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	BSPH, Week 6, Below	1 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	CRT, Week 10, Unknown	0 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	BSPH, Week 10, Within	124 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	CRT, Month 7, Unknown	0 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	CRT, Month 6, Unknown	0 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	BSPH, Month 6, Within	122 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	BSPH, Month 7, Within	121 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	CRT, Day 0, Unknown	0 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	BSPH, Month 12, Within	119 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	CRT, Month 12, Unknown	0 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	ALAT, Week 10, Below	8 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	BSPH, Month 24, Within	117 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	ESPH, Day 0, Above	8 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	BSPH, Month 18, Below	0 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	BSPH, Day 0, Above	0 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	BSPH, Week 6, Above	0 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	CRT, Month 18, Unknown	0 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	BSPH, Month 12, Below	0 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	BSPH, Week 10, Below	0 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	BSPH, Month 6, Below	0 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	BSPH, Month 7, Below	0 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	CRT, Month 24, Unknown	0 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	ESPH, Month 24, Within	99 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	ALAT, Week 10, Above	9 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	CRT, Week 10, Below	30 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	ESPH, Month 18, Above	2 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	CRT, Month 6, Below	32 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	ESPH, Month 18, Within	106 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	CRT, Month 7, Below	36 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	ALAT, Month 6, Above	9 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	CRT, Month 12, Below	23 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	ESPH, Month 12, Within	104 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	CRT, Month 18, Below	17 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	CRT, Week 6, Within	97 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	CRT, Week 10, Within	96 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	ESPH, Month 7, Within	106 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	ESPH, Week 10, Within	108 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	CRT, Month 6, Within	89 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	ESPH, Day 0, Within	102 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	CRT, Month 7, Within	84 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	CRT, Month 18, Within	98 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	ESPH, Month 12, Above	5 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	CRT, Month 24, Within	85 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	ESPH, Week 10, Below	12 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	CRT, Week 10, Above	0 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	ESPH, Week 6, Below	13 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	CRT, Month 6, Above	1 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	ALAT, Month 12, Above	6 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	ALAT, Month 12, Unknown	0 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	CRT, Month 24, Above	1 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	ESPH, Week 6, Within	102 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	ESPH, Day 0, Unknown	0 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	ESPH, Month 6, Unknown	0 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	ALAT, Month 18, Above	6 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	ESPH, Day 0, Below	18 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	ESPH, Month 24, Below	15 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	ALAT, Day 0, Unknown	0 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	ESPH, Month 18, Below	9 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	ALAT, Week 6, Unknown	0 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	ESPH, Month 12, Below	10 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	ALAT, Week 10, Unknown	0 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	ALAT, Month 6, Unknown	0 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	ESPH, Month 7, Below	10 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	ALAT, Month 7, Unknown	0 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	ESPH, Month 7, Above	5 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	BSPH, Month 18, Within	117 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	ESPH, Week 10, Unknown	0 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	ALAT, Month 18, Unknown	0 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	BSPH, Week 10, Above	3 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	ALAT, Month 24, Unknown	0 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	ALAT, Day 0, Above	6 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	ESPH, Week 6, Unknown	0 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	ALAT, Day 0, Below	4 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	ESPH, Month 24, Unknown	0 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	ALAT, Week 6, Below	5 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	BSPH, Month 6, Above	1 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	ALAT, Month 6, Below	4 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	ALAT, Month 7, Below	3 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	ESPH, Month 18, Unknown	0 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	ALAT, Month 12, Below	1 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	ESPH, Month 6, Within	108 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	ALAT, Month 18, Below	2 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	ESPH, Month 12, Unknown	0 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	ALAT, Month 24, Below	1 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	ALAT, Day 0, Within	118 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	BSPH, Month 7, Above	0 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	ALAT, Week 6, Within	115 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	ESPH, Month 6, Above	2 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	ALAT, Week 10, Within	110 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	ALAT, Month 6, Within	110 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	ESPH, Month 7, Unknown	0 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	ALAT, Month 7, Within	105 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	BSPH, Month 12, Above	0 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	ALAT, Month 12, Within	112 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	ESPH, Month 24, Above	3 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	CRT, Month 18, Above	1 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	ALAT, Month 18, Within	109 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	ESPH, Month 6, Below	13 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	CRT, Month 12, Above	4 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	ALAT, Month 24, Within	110 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	BSPH, Month 18, Above	0 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	BSPH, Month 24, Below	0 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	CRT, Day 0, Within	100 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	BSPH, Day 0, Within	127 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	ESPH, Week 10, Above	7 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	CRT, Month 7, Above	0 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	BSPH, Week 6, Within	125 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	ALAT, Month 7, Above	13 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	BSPH, Month 24, Above	0 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	ESPH, Month 7, Within	103 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	ALAT, Month 7, Below	20 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	ALAT, Month 18, Below	23 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	ALAT, Month 6, Within	101 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	ALAT, Day 0, Above	2 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	ALAT, Week 6, Above	5 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	ALAT, Week 10, Above	4 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	ALAT, Month 6, Above	2 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	ALAT, Month 7, Above	1 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	ALAT, Month 12, Above	2 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	ALAT, Month 18, Above	2 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	BSPH, Day 0, Unknown	0 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	BSPH, Week 10, Unknown	0 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	BSPH, Week 10, Above	1 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	BSPH, Month 6, Above	0 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	BSPH, Month 12, Above	0 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	BSPH, Month 18, Above	1 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	BSPH, Month 24, Above	0 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	CRT, Month 12, Unknown	0 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	CRT, Month 18, Unknown	0 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	CRT, Month 24, Unknown	0 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	CRT, Day 0, Below	27 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	CRT, Week 6, Below	36 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	CRT, Week 10, Below	27 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	CRT, Month 6, Below	25 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	CRT, Month 7, Below	22 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	CRT, Week 10, Within	108 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	CRT, Month 6, Within	103 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	CRT, Month 7, Within	93 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	CRT, Month 12, Within	83 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	CRT, Month 18, Within	98 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	CRT, Month 24, Within	86 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	CRT, Month 6, Above	0 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	CRT, Month 7, Above	0 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	CRT, Month 24, Above	0 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	ESPH, Month 6, Unknown	0 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	ESPH, Month 24, Unknown	0 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	ALAT, Day 0, Unknown	0 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	ALAT, Week 6, Unknown	0 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	ALAT, Week 10, Unknown	0 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	ALAT, Month 6, Unknown	0 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	ALAT, Month 7, Unknown	0 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	ALAT, Month 12, Unknown	0 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	ALAT, Month 18, Unknown	0 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	ALAT, Month 24, Unknown	0 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	ALAT, Day 0, Below	33 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	ALAT, Week 6, Below	35 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	ALAT, Week 10, Below	27 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	ALAT, Month 6, Below	25 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	ALAT, Month 12, Below	20 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	ALAT, Month 24, Below	14 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	ALAT, Day 0, Within	109 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	ALAT, Week 6, Within	97 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	ALAT, Week 10, Within	104 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	ALAT, Month 7, Within	94 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	ALAT, Month 12, Within	86 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	ALAT, Month 18, Within	85 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	ESPH, Month 6, Below	4 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	ALAT, Month 24, Within	87 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	BSPH, Month 24, Below	7 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	BSPH, Day 0, Within	123 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	BSPH, Week 6, Within	127 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	ALAT, Month 24, Above	2 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	BSPH, Week 6, Unknown	2 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	BSPH, Month 6, Unknown	0 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	BSPH, Month 7, Unknown	0 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	BSPH, Month 12, Unknown	0 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	BSPH, Month 18, Unknown	0 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	BSPH, Month 24, Unknown	0 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	BSPH, Day 0, Below	21 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	BSPH, Week 6, Below	8 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	BSPH, Week 10, Within	119 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	BSPH, Month 6, Within	116 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	BSPH, Month 7, Within	109 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	BSPH, Month 12, Within	102 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	BSPH, Month 18, Within	99 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	BSPH, Month 24, Within	96 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	BSPH, Day 0, Above	0 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	BSPH, Week 6, Above	0 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	BSPH, Month 7, Above	0 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	BSPH, Week 10, Below	15 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	BSPH, Month 6, Below	12 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	BSPH, Month 7, Below	6 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	BSPH, Month 12, Below	6 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	BSPH, Month 18, Below	10 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	CRT, Week 10, Unknown	0 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	CRT, Day 0, Unknown	0 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	CRT, Week 6, Unknown	0 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	CRT, Month 6, Unknown	0 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	CRT, Month 7, Unknown	0 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	CRT, Day 0, Above	2 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	CRT, Month 12, Below	24 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	CRT, Week 6, Above	0 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	CRT, Week 10, Above	0 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	CRT, Month 18, Below	11 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	ESPH, Month 7, Unknown	0 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	CRT, Month 24, Below	17 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	CRT, Day 0, Within	115 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	CRT, Month 12, Above	1 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	CRT, Week 6, Within	101 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	CRT, Month 18, Above	1 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	ESPH, Day 0, Unknown	0 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	ESPH, Month 12, Unknown	0 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	ESPH, Month 18, Unknown	0 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	ESPH, Week 6, Unknown	2 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	ESPH, Week 10, Unknown	0 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	ESPH, Month 12, Below	3 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	ESPH, Month 18, Below	6 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	ESPH, Month 24, Below	3 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	ESPH, Day 0, Below	3 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	ESPH, Week 6, Below	7 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	ESPH, Week 10, Below	3 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	ESPH, Month 7, Below	6 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	ESPH, Day 0, Within	130 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	ESPH, Month 12, Within	98 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	ESPH, Month 18, Within	96 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	ESPH, Week 6, Within	115 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	ESPH, Week 10, Within	125 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	ESPH, Month 24, Within	99 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	ESPH, Day 0, Above	11 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	ESPH, Week 6, Above	13 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	ESPH, Week 10, Above	7 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	ESPH, Month 6, Above	6 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	ESPH, Month 6, Within	118 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	ESPH, Month 7, Above	6 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	ESPH, Month 12, Above	7 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	ESPH, Month 18, Above	8 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	ESPH, Month 24, Above	1 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	ALAT, Month 18, Above	2 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	BSPH, Day 0, Within	125 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	BSPH, Month 24, Below	8 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	ESPH, Week 6, Above	7 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	CRT, Day 0, Within	123 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	CRT, Month 7, Above	1 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	ESPH, Month 6, Below	4 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	BSPH, Month 24, Above	1 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	CRT, Month 12, Above	1 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	ALAT, Month 18, Within	98 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	ALAT, Month 12, Within	95 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	ALAT, Month 7, Within	98 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	ALAT, Month 6, Within	102 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	BSPH, Month 18, Above	1 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	ALAT, Week 6, Above	4 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	CRT, Month 18, Above	3 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	ALAT, Week 10, Within	109 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	ALAT, Week 6, Within	106 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	ESPH, Week 10, Above	5 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	ESPH, Day 0, Unknown	0 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	ALAT, Day 0, Within	106 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	ESPH, Month 7, Unknown	0 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	ALAT, Month 24, Below	14 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	ALAT, Month 18, Below	17 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	BSPH, Month 12, Above	0 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	ESPH, Month 12, Unknown	0 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	ALAT, Month 12, Below	22 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	ALAT, Month 7, Below	23 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	BSPH, Month 7, Above	1 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	ESPH, Month 18, Unknown	0 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	ALAT, Week 10, Below	26 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	ALAT, Day 0, Below	35 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	ALAT, Month 24, Unknown	0 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	ALAT, Day 0, Above	4 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	ESPH, Week 6, Unknown	3 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	ALAT, Month 18, Unknown	0 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	ALAT, Month 12, Unknown	1 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	BSPH, Month 6, Above	1 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	ESPH, Week 10, Unknown	0 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	ALAT, Month 7, Unknown	0 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	ALAT, Month 6, Unknown	0 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	ESPH, Month 7, Below	6 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	ALAT, Week 10, Unknown	0 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	ALAT, Week 6, Unknown	0 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	ALAT, Week 6, Below	32 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	ESPH, Month 12, Below	6 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	ALAT, Day 0, Unknown	0 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	ESPH, Month 6, Within	124 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	ESPH, Month 18, Below	4 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	ESPH, Week 10, Below	1 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	ESPH, Day 0, Below	4 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	ESPH, Month 6, Above	6 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	ESPH, Month 6, Unknown	0 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	CRT, Month 24, Above	1 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	ESPH, Month 24, Unknown	0 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	BSPH, Week 10, Above	0 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	CRT, Month 6, Above	1 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	CRT, Week 10, Above	0 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	BSPH, Week 6, Below	7 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	ESPH, Week 6, Below	6 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	CRT, Week 6, Above	1 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	CRT, Day 0, Above	1 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	ESPH, Month 24, Above	6 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	CRT, Month 12, Within	95 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	ESPH, Month 7, Above	7 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	CRT, Month 7, Within	107 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	CRT, Month 6, Within	107 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	ALAT, Month 12, Above	0 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	ESPH, Day 0, Within	133 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	CRT, Week 10, Within	107 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	ESPH, Month 24, Below	6 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	ESPH, Month 7, Within	112 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	CRT, Week 6, Within	113 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	CRT, Month 12, Below	22 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	ALAT, Month 7, Above	4 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	ESPH, Month 12, Within	107 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	CRT, Month 7, Below	17 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	CRT, Month 6, Below	26 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	ALAT, Month 24, Within	95 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	ESPH, Month 12, Above	5 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	ESPH, Week 6, Within	126 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	CRT, Week 10, Below	29 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	BSPH, Month 6, Below	13 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	ALAT, Month 6, Above	5 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	BSPH, Month 7, Below	8 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	BSPH, Week 10, Below	17 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	BSPH, Week 6, Above	1 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	ESPH, Month 18, Within	105 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	BSPH, Month 12, Below	7 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	BSPH, Day 0, Above	0 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	BSPH, Month 24, Within	102 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	CRT, Week 6, Below	28 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	BSPH, Month 18, Below	12 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	BSPH, Month 18, Within	104 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	BSPH, Month 12, Within	111 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	CRT, Month 24, Unknown	0 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	BSPH, Month 7, Within	116 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	ALAT, Week 10, Above	1 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	ESPH, Week 10, Within	130 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	CRT, Week 10, Unknown	0 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	BSPH, Month 6, Within	120 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	BSPH, Week 10, Within	119 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	ESPH, Month 24, Within	99 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	CRT, Month 18, Unknown	0 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	CRT, Month 6, Unknown	0 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	BSPH, Week 6, Within	131 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	BSPH, Day 0, Below	20 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	CRT, Day 0, Below	21 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	BSPH, Month 24, Unknown	0 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	BSPH, Month 18, Unknown	0 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	BSPH, Month 12, Unknown	0 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	CRT, Month 18, Within	102 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	CRT, Month 24, Within	93 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	BSPH, Month 7, Unknown	0 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	BSPH, Month 6, Unknown	0 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	CRT, Month 12, Unknown	0 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	ALAT, Month 6, Below	27 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	BSPH, Week 10, Unknown	0 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	CRT, Month 7, Unknown	0 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	BSPH, Week 6, Unknown	3 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	ESPH, Day 0, Above	8 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	CRT, Week 6, Unknown	0 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	CRT, Month 18, Below	12 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	CRT, Day 0, Unknown	0 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	BSPH, Day 0, Unknown	0 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	ALAT, Month 24, Above	2 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	ESPH, Month 18, Above	8 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters	CRT, Month 24, Below	17 Participants

Secondary

Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters

Among assessed haematological parameters were: haematocrit \[HTCR\], haemoglobin \[HGB\], lymphocytes \[LYMP\] and monocytes \[MONO\]. Unknown = value unknown for the specified visit and laboratory parameter; Below = value below the laboratory reference range defined for the specified visit and laboratory parameter; Within = value within the laboratory reference range defined for the specified visit and laboratory parameter; Above = value above the laboratory reference range defined for the specified visit and laboratory parameter.

Time frame: At Day 0, Week 6, Week 10, Month 6, Month 7, Month 12, Month 18 and Month 24

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	HGB, Month 12, Below	29 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	MONO, Month 12, Above	15 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	HTCR, Month 18, Above	0 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	MONO, Month 24, Within	98 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	MONO, Month 12, Unknown	1 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	MONO, Month 18, Above	10 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	MONO, Week 6, Within	117 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	LYMP, Day 0, Below	7 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	HGB, Month 18, Below	34 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	MONO, Month 24, Above	12 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	LYMP, Month 12, Within	104 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	LYMP, Day 0, Above	17 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	HGB, Month 18, Above	3 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	HTCR, Day 0, Unknown	0 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	MONO, Month 24, Below	5 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	MONO, Month 6, Unknown	0 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	LYMP, Month 24, Above	9 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	HTCR, Week 6, Unknown	0 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	HGB, Month 24, Below	27 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	LYMP, Week 6, Below	6 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	MONO, Month 18, Unknown	0 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	HTCR, Week 10, Unknown	0 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	HGB, Month 18, Unknown	0 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	MONO, Month 18, Below	3 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	LYMP, Month 18, Unknown	0 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	HTCR, Month 6, Unknown	0 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	HGB, Day 0, Within	88 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	LYMP, Week 6, Unknown	0 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	MONO, Day 0, Above	11 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	HTCR, Month 7, Unknown	0 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	HGB, Week 10, Unknown	0 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	LYMP, Week 10, Below	11 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	LYMP, Month 6, Within	98 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	HTCR, Month 12, Unknown	1 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	MONO, Week 10, Unknown	0 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	HGB, Week 6, Within	88 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	MONO, Month 24, Unknown	1 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	HTCR, Month 18, Unknown	0 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	HGB, Month 24, Unknown	1 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	LYMP, Week 6, Above	13 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	MONO, Week 10, Within	116 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	HTCR, Month 24, Unknown	1 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	HGB, Week 10, Within	89 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	LYMP, Month 7, Within	96 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	LYMP, Month 6, Below	6 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	HTCR, Day 0, Below	32 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	LYMP, Month 12, Unknown	1 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	MONO, Month 6, Above	13 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	HGB, Month 6, Within	85 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	HTCR, Week 6, Below	22 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	HGB, Day 0, Below	38 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	MONO, Month 18, Within	108 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	MONO, Day 0, Below	7 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	HTCR, Week 10, Below	30 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	MONO, Month 12, Within	104 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	LYMP, Month 7, Below	12 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	MONO, Month 7, Above	11 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	HTCR, Month 6, Below	26 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	HGB, Month 7, Within	92 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	HTCR, Month 12, Above	2 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	LYMP, Week 10, Unknown	0 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	HTCR, Month 7, Below	19 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	LYMP, Week 10, Above	16 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	LYMP, Month 18, Within	105 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	LYMP, Month 12, Below	6 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	HTCR, Month 12, Below	24 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	HGB, Month 12, Within	91 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	HGB, Month 6, Unknown	0 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	MONO, Week 6, Below	4 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	HTCR, Month 18, Below	30 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	HGB, Week 6, Below	38 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	MONO, Month 6, Within	107 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	HGB, Month 18, Within	84 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	HTCR, Month 24, Below	24 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	HGB, Day 0, Unknown	0 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	MONO, Week 6, Above	7 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	LYMP, Month 18, Below	4 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	HTCR, Day 0, Within	96 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	LYMP, Month 7, Unknown	0 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	MONO, Day 0, Within	111 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	MONO, Day 0, Unknown	0 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	HTCR, Week 6, Within	106 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	HGB, Month 24, Within	88 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	HGB, Week 10, Below	38 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	MONO, Week 10, Below	4 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	HTCR, Week 10, Within	97 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	MONO, Month 12, Below	2 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	LYMP, Month 6, Above	19 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	HGB, Day 0, Above	3 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	HTCR, Month 6, Within	97 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	HGB, Month 7, Unknown	0 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	LYMP, Month 24, Below	8 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	MONO, Week 6, Unknown	0 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	HTCR, Month 7, Within	101 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	LYMP, Month 24, Unknown	1 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	LYMP, Month 6, Unknown	0 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	HGB, Week 6, Above	2 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	HTCR, Month 12, Within	95 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	HGB, Month 6, Below	38 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	HGB, Week 6, Unknown	0 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	MONO, Month 6, Below	3 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	HTCR, Month 18, Within	91 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	MONO, Month 7, Within	106 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	LYMP, Day 0, Within	105 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	HGB, Week 10, Above	1 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	HTCR, Month 24, Within	91 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	LYMP, Month 24, Within	98 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	LYMP, Month 7, Above	13 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	HTCR, Month 24, Above	0 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	HTCR, Day 0, Above	1 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	HGB, Month 6, Above	0 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	MONO, Month 7, Unknown	0 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	LYMP, Week 6, Within	109 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	HTCR, Week 6, Above	0 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	HGB, Month 7, Below	28 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	HGB, Month 12, Unknown	1 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	MONO, Month 7, Below	4 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	HTCR, Week 10, Above	1 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	LYMP, Day 0, Unknown	0 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	HGB, Month 24, Above	0 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	HGB, Month 7, Above	1 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	HTCR, Month 6, Above	0 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	HGB, Month 12, Above	1 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	MONO, Week 10, Above	8 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	LYMP, Week 10, Within	101 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	HTCR, Month 7, Above	1 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	LYMP, Month 18, Above	12 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	LYMP, Month 12, Above	11 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	LYMP, Week 10, Within	102 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	HTCR, Month 12, Above	0 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	HTCR, Month 18, Above	3 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	MONO, Week 10, Above	15 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	MONO, Month 12, Below	5 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	HTCR, Month 24, Above	1 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	LYMP, Month 6, Within	104 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	HGB, Day 0, Unknown	0 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	LYMP, Month 7, Unknown	0 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	HGB, Week 6, Unknown	0 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	HGB, Month 24, Above	1 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	HGB, Week 10, Unknown	0 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	MONO, Month 18, Below	6 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	HGB, Month 6, Unknown	0 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	LYMP, Month 7, Within	97 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	MONO, Month 6, Unknown	0 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	HGB, Month 7, Unknown	0 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	MONO, Month 7, Unknown	0 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	MONO, Week 6, Unknown	0 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	HGB, Month 12, Unknown	0 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	HGB, Month 18, Unknown	0 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	LYMP, Month 12, Within	95 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	MONO, Month 24, Below	5 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	HGB, Month 24, Unknown	0 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	HGB, Day 0, Below	37 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	LYMP, Month 18, Within	103 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	HGB, Week 6, Below	35 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	LYMP, Month 12, Unknown	0 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	HGB, Week 10, Below	35 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	MONO, Month 6, Above	14 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	MONO, Day 0, Within	117 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	HGB, Month 6, Below	36 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	LYMP, Month 24, Within	97 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	HGB, Month 7, Below	37 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	HGB, Month 12, Below	35 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	HGB, Month 18, Below	32 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	MONO, Week 6, Within	112 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	HGB, Month 24, Below	27 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	LYMP, Day 0, Above	14 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	HGB, Day 0, Within	89 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	LYMP, Month 18, Unknown	0 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	HGB, Week 6, Within	88 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	HGB, Week 10, Within	90 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	LYMP, Week 6, Above	6 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	MONO, Week 10, Within	108 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	HGB, Month 6, Within	86 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	HGB, Month 7, Within	83 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	MONO, Week 10, Unknown	0 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	HGB, Month 12, Within	83 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	LYMP, Week 10, Above	16 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	HGB, Month 18, Within	82 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	MONO, Month 24, Within	99 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	MONO, Month 6, Within	104 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	HGB, Month 24, Within	89 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	MONO, Month 7, Above	17 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	HGB, Day 0, Above	2 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	LYMP, Month 6, Above	11 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	HGB, Week 6, Above	3 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	LYMP, Month 24, Unknown	0 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	HGB, Week 10, Above	2 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	MONO, Month 7, Within	97 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	HGB, Month 6, Above	1 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	LYMP, Month 7, Above	13 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	HGB, Month 7, Above	1 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	LYMP, Month 18, Above	10 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	LYMP, Month 12, Above	14 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	MONO, Month 12, Above	13 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	LYMP, Day 0, Unknown	0 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	MONO, Month 18, Above	12 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	MONO, Month 12, Unknown	0 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	MONO, Month 24, Above	13 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	LYMP, Day 0, Below	9 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	HTCR, Day 0, Unknown	0 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	HTCR, Week 6, Unknown	1 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	HTCR, Week 10, Unknown	0 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	LYMP, Week 6, Below	11 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	MONO, Month 18, Unknown	0 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	HTCR, Month 6, Unknown	0 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	HTCR, Month 7, Unknown	0 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	LYMP, Month 24, Above	11 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	HTCR, Month 12, Unknown	0 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	LYMP, Week 10, Below	9 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	HTCR, Month 18, Unknown	0 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	LYMP, Week 6, Unknown	0 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	MONO, Month 24, Unknown	0 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	HTCR, Month 24, Unknown	0 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	MONO, Day 0, Above	7 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	HTCR, Day 0, Below	23 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	LYMP, Month 6, Below	8 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	HGB, Month 18, Above	3 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	HTCR, Week 6, Below	17 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	HTCR, Week 10, Below	22 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	MONO, Day 0, Below	4 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	HTCR, Month 6, Below	27 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	LYMP, Month 7, Below	11 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	HTCR, Month 7, Below	27 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	LYMP, Week 10, Unknown	0 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	HTCR, Month 12, Below	25 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	LYMP, Month 12, Below	10 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	HTCR, Month 18, Below	22 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	HGB, Month 12, Above	1 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	MONO, Week 6, Below	4 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	HTCR, Month 24, Below	24 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	HTCR, Day 0, Within	102 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	LYMP, Month 18, Below	4 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	HTCR, Week 6, Within	105 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	MONO, Month 18, Within	99 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	HTCR, Week 10, Within	103 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	MONO, Week 6, Above	10 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	MONO, Week 10, Below	4 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	HTCR, Month 6, Within	95 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	LYMP, Month 24, Below	9 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	HTCR, Month 7, Within	92 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	MONO, Day 0, Unknown	0 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	HTCR, Month 12, Within	94 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	LYMP, Month 6, Unknown	0 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	HTCR, Month 18, Within	92 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	MONO, Month 6, Below	5 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	HTCR, Month 24, Within	92 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	LYMP, Day 0, Within	105 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	MONO, Month 12, Within	101 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	HTCR, Day 0, Above	3 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	HTCR, Week 6, Above	3 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	LYMP, Week 6, Within	109 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	HTCR, Week 10, Above	2 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	MONO, Month 7, Below	7 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	HTCR, Month 6, Above	1 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	HTCR, Month 7, Above	2 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	HGB, Month 7, Above	0 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	HGB, Month 12, Above	0 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	HGB, Month 18, Above	1 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	HGB, Month 24, Above	0 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	MONO, Month 12, Within	101 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	LYMP, Day 0, Unknown	0 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	LYMP, Week 6, Unknown	2 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	LYMP, Week 10, Unknown	0 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	LYMP, Month 6, Unknown	0 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	MONO, Month 18, Within	101 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	LYMP, Month 7, Unknown	0 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	LYMP, Month 12, Unknown	0 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	LYMP, Month 18, Unknown	0 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	LYMP, Month 24, Unknown	0 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	MONO, Month 24, Within	95 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	LYMP, Day 0, Below	11 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	MONO, Month 6, Unknown	0 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	LYMP, Week 6, Below	12 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	LYMP, Week 10, Below	13 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	LYMP, Month 6, Below	9 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	MONO, Day 0, Above	1 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	LYMP, Month 7, Below	6 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	LYMP, Month 18, Above	10 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	LYMP, Month 12, Below	6 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	LYMP, Month 18, Below	6 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	LYMP, Month 24, Below	6 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	MONO, Week 6, Above	3 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	LYMP, Day 0, Within	120 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	LYMP, Week 6, Within	113 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	LYMP, Week 10, Within	110 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	LYMP, Month 6, Within	106 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	MONO, Week 10, Above	4 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	LYMP, Month 7, Within	103 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	LYMP, Month 12, Within	92 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	LYMP, Month 18, Within	94 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	LYMP, Month 24, Within	88 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	MONO, Month 6, Above	6 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	LYMP, Day 0, Above	13 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	MONO, Month 7, Unknown	0 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	LYMP, Week 6, Above	10 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	LYMP, Week 10, Above	12 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	LYMP, Month 6, Above	13 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	MONO, Month 7, Above	3 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	LYMP, Month 7, Above	6 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	MONO, Month 12, Above	2 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	MONO, Month 18, Above	4 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	MONO, Month 24, Above	1 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	MONO, Month 12, Unknown	0 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	HTCR, Day 0, Unknown	0 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	HTCR, Week 6, Unknown	0 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	HTCR, Week 10, Unknown	0 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	HTCR, Month 6, Unknown	0 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	MONO, Month 18, Unknown	0 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	HTCR, Month 7, Unknown	0 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	HTCR, Month 12, Unknown	0 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	HTCR, Month 18, Unknown	0 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	HTCR, Month 24, Unknown	0 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	MONO, Month 24, Unknown	0 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	HTCR, Day 0, Below	24 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	LYMP, Month 24, Above	9 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	HTCR, Week 6, Below	18 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	HTCR, Week 10, Below	11 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	HTCR, Month 6, Below	13 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	MONO, Day 0, Below	10 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	HTCR, Month 7, Below	13 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	LYMP, Month 12, Above	10 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	HTCR, Month 12, Below	15 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	HTCR, Month 18, Below	17 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	HTCR, Month 24, Below	21 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	MONO, Week 6, Below	3 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	HTCR, Day 0, Within	120 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	HTCR, Week 6, Within	119 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	HTCR, Week 10, Within	123 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	HTCR, Month 6, Within	115 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	MONO, Week 10, Below	2 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	HTCR, Month 7, Within	102 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	HTCR, Month 12, Within	93 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	HTCR, Month 18, Within	90 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	HTCR, Month 24, Within	82 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	MONO, Month 6, Below	0 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	HTCR, Day 0, Above	0 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	MONO, Day 0, Unknown	0 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	HTCR, Week 6, Above	0 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	HTCR, Week 10, Above	1 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	HTCR, Month 6, Above	0 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	MONO, Month 7, Below	5 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	HTCR, Month 7, Above	0 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	HTCR, Month 12, Above	0 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	HTCR, Month 18, Above	3 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	HTCR, Month 24, Above	0 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	MONO, Month 12, Below	5 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	HGB, Day 0, Unknown	0 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	HGB, Week 6, Unknown	0 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	HGB, Week 10, Unknown	0 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	HGB, Month 6, Unknown	0 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	MONO, Month 18, Below	5 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	HGB, Month 7, Unknown	0 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	HGB, Month 12, Unknown	0 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	HGB, Month 18, Unknown	0 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	HGB, Month 24, Unknown	0 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	MONO, Month 24, Below	7 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	HGB, Day 0, Below	40 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	MONO, Week 6, Unknown	2 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	HGB, Week 6, Below	40 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	HGB, Week 10, Below	37 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	HGB, Month 6, Below	45 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	MONO, Day 0, Within	133 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	HGB, Month 7, Below	36 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	HGB, Month 12, Below	39 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	HGB, Month 18, Below	32 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	HGB, Month 24, Below	28 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	MONO, Week 6, Within	129 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	HGB, Day 0, Within	104 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	HGB, Week 6, Within	97 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	HGB, Week 10, Within	98 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	HGB, Month 6, Within	83 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	MONO, Week 10, Within	129 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	HGB, Month 7, Within	79 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	HGB, Month 12, Within	69 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	HGB, Month 18, Within	77 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	HGB, Month 24, Within	75 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	MONO, Month 6, Within	113 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	HGB, Day 0, Above	0 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	MONO, Week 10, Unknown	0 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	HGB, Week 6, Above	0 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	HGB, Week 10, Above	0 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	HGB, Month 6, Above	0 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	MONO, Month 7, Within	107 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	HGB, Month 7, Below	38 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	LYMP, Month 12, Above	12 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	LYMP, Month 18, Above	7 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	LYMP, Month 24, Above	3 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	MONO, Day 0, Unknown	0 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	MONO, Week 6, Unknown	3 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	MONO, Week 10, Unknown	0 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	MONO, Month 6, Unknown	0 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	MONO, Month 7, Unknown	0 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	MONO, Month 12, Unknown	0 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	MONO, Month 18, Unknown	0 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	MONO, Month 24, Unknown	0 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	MONO, Day 0, Below	17 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	MONO, Week 6, Below	4 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	MONO, Week 10, Below	6 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	MONO, Month 6, Below	7 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	MONO, Month 7, Below	2 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	MONO, Month 12, Below	2 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	MONO, Month 18, Below	4 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	MONO, Month 24, Below	10 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	MONO, Day 0, Within	126 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	MONO, Week 6, Within	133 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	MONO, Week 10, Within	127 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	MONO, Month 6, Within	121 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	MONO, Month 7, Within	118 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	MONO, Month 12, Within	113 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	MONO, Month 18, Within	109 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	MONO, Month 24, Within	99 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	MONO, Day 0, Above	2 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	MONO, Week 6, Above	2 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	MONO, Week 10, Above	3 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	MONO, Month 6, Above	6 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	MONO, Month 7, Above	5 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	MONO, Month 12, Above	3 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	MONO, Month 18, Above	4 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	MONO, Month 24, Above	2 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	HTCR, Day 0, Unknown	0 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	HTCR, Week 6, Unknown	0 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	HTCR, Week 10, Unknown	0 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	HTCR, Month 6, Unknown	0 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	HTCR, Month 7, Unknown	1 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	HTCR, Month 12, Unknown	0 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	HTCR, Month 18, Unknown	0 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	HTCR, Month 24, Unknown	0 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	HTCR, Day 0, Below	24 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	HTCR, Week 6, Below	13 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	HTCR, Week 10, Below	7 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	HTCR, Month 6, Below	17 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	HTCR, Month 7, Below	14 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	HTCR, Month 12, Below	17 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	HTCR, Month 18, Below	16 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	HTCR, Month 24, Below	17 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	HTCR, Day 0, Within	118 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	HTCR, Week 6, Within	125 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	HTCR, Week 10, Within	126 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	HTCR, Month 6, Within	117 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	HTCR, Month 7, Within	108 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	HTCR, Month 12, Within	100 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	HTCR, Month 18, Within	101 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	HTCR, Month 24, Within	93 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	HTCR, Day 0, Above	3 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	HTCR, Week 6, Above	4 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	HTCR, Week 10, Above	3 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	HTCR, Month 6, Above	0 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	HTCR, Month 7, Above	2 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	HTCR, Month 12, Above	1 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	HTCR, Month 18, Above	0 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	HTCR, Month 24, Above	1 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	HGB, Day 0, Unknown	0 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	HGB, Week 6, Unknown	0 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	HGB, Week 10, Unknown	0 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	HGB, Month 6, Unknown	0 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	HGB, Month 7, Unknown	0 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	HGB, Month 12, Unknown	0 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	HGB, Month 18, Unknown	0 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	HGB, Month 24, Unknown	0 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	HGB, Day 0, Below	45 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	HGB, Week 6, Below	50 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	HGB, Week 10, Below	38 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	HGB, Month 6, Below	38 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	LYMP, Month 7, Above	8 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	HGB, Month 12, Below	39 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	HGB, Month 18, Below	35 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	HGB, Month 24, Below	26 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	HGB, Day 0, Within	98 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	HGB, Week 6, Within	88 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	HGB, Week 10, Within	97 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	HGB, Month 6, Within	96 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	HGB, Month 7, Within	86 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	HGB, Month 12, Within	79 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	HGB, Month 18, Within	82 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	HGB, Month 24, Within	84 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	HGB, Day 0, Above	2 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	HGB, Week 6, Above	4 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	HGB, Week 10, Above	1 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	HGB, Month 6, Above	0 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	HGB, Month 7, Above	1 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	HGB, Month 12, Above	0 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	HGB, Month 18, Above	0 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	HGB, Month 24, Above	1 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	LYMP, Day 0, Unknown	0 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	LYMP, Week 6, Unknown	3 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	LYMP, Week 10, Unknown	0 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	LYMP, Month 6, Unknown	0 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	LYMP, Month 7, Unknown	0 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	LYMP, Month 12, Unknown	0 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	LYMP, Month 18, Unknown	0 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	LYMP, Month 24, Unknown	0 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	LYMP, Day 0, Below	6 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	LYMP, Week 6, Below	6 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	LYMP, Week 10, Below	6 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	LYMP, Month 6, Below	11 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	LYMP, Month 7, Below	6 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	LYMP, Month 12, Below	8 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	LYMP, Month 18, Below	4 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	LYMP, Month 24, Below	7 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	LYMP, Day 0, Within	132 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	LYMP, Week 6, Within	121 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	LYMP, Week 10, Within	124 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	LYMP, Month 6, Within	115 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	LYMP, Month 7, Within	111 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	LYMP, Month 12, Within	98 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	LYMP, Month 18, Within	106 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	LYMP, Month 24, Within	101 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	LYMP, Day 0, Above	7 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	LYMP, Week 6, Above	12 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	LYMP, Week 10, Above	6 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters	LYMP, Month 6, Above	8 Participants

Secondary

Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters

Among assessed haematological parameters were: neutrophils \[NTPH\], platelets \[PLAT\], red blood cells \[RBC\] and white blood cells \[WBC\]. Unknown = value unknown for the specified visit and laboratory parameter; Below = value below the laboratory reference range defined for the specified visit and laboratory parameter; Within = value within the laboratory reference range defined for the specified visit and laboratory parameter; Above = value above the laboratory reference range defined for the specified visit and laboratory parameter.

Time frame: At Day 0, Week 6, Week 10, Month 6, Month 7, Month 12, Month 18 and Month 24

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	RBC, Day 0, Unknown	0 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	PLAT, Month 24, Above	5 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	PLAT, Month 18, Above	1 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	PLAT, Day 0, Unknown	0 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	WBC, Week 6, Within	118 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	PLAT, Month 12, Above	5 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	PLAT, Month 7, Above	2 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	PLAT, Week 6, Unknown	0 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	WBC, Day 0, Within	118 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	PLAT, Month 6, Above	5 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	PLAT, Week 10, Above	5 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	PLAT, Week 10, Unknown	0 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	NTPH, Day 0, Below	14 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	PLAT, Week 6, Above	3 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	PLAT, Day 0, Above	6 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	PLAT, Month 6, Unknown	0 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	WBC, Month 7, Above	5 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	PLAT, Month 24, Within	109 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	PLAT, Month 18, Within	117 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	PLAT, Month 7, Unknown	0 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	WBC, Month 24, Below	11 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	PLAT, Month 12, Within	113 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	PLAT, Month 7, Within	118 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	PLAT, Month 12, Unknown	1 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	WBC, Month 18, Below	12 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	PLAT, Month 6, Within	116 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	PLAT, Week 10, Within	122 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	PLAT, Month 18, Unknown	0 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	NTPH, Week 6, Below	16 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	PLAT, Week 6, Within	124 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	PLAT, Day 0, Within	123 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	PLAT, Month 24, Unknown	1 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	NTPH, Week 10, Unknown	0 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	PLAT, Month 24, Below	1 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	PLAT, Month 18, Below	3 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	PLAT, Day 0, Below	0 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	WBC, Month 12, Below	14 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	PLAT, Month 12, Below	3 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	PLAT, Month 7, Below	1 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	PLAT, Week 6, Below	1 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	WBC, Month 7, Below	10 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	PLAT, Month 6, Below	2 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	PLAT, Week 10, Below	1 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	NTPH, Week 10, Below	18 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	WBC, Week 6, Unknown	0 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	WBC, Month 6, Below	12 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	WBC, Week 10, Below	9 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	NTPH, Month 6, Below	18 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	WBC, Month 6, Above	5 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	WBC, Week 6, Below	9 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	WBC, Day 0, Below	8 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	NTPH, Month 7, Below	16 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	WBC, Week 10, Above	3 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	WBC, Month 24, Unknown	1 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	WBC, Month 18, Unknown	0 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	NTPH, Month 12, Below	19 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	NTPH, Month 6, Unknown	0 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	WBC, Month 12, Unknown	1 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	WBC, Month 7, Unknown	0 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	NTPH, Month 18, Below	15 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	WBC, Month 24, Above	2 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	WBC, Month 6, Unknown	0 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	WBC, Week 10, Unknown	0 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	NTPH, Month 24, Below	14 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	WBC, Week 6, Above	1 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	WBC, Day 0, Unknown	0 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	RBC, Month 24, Above	3 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	NTPH, Day 0, Within	106 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	WBC, Day 0, Above	3 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	RBC, Month 18, Above	2 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	RBC, Month 12, Above	3 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	NTPH, Week 6, Within	101 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	NTPH, Month 7, Unknown	0 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	RBC, Month 7, Above	3 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	RBC, Month 6, Above	4 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	NTPH, Week 10, Within	103 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	WBC, Month 18, Above	3 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	RBC, Week 10, Above	2 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	RBC, Week 6, Above	3 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	NTPH, Month 6, Within	100 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	WBC, Month 24, Within	102 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	RBC, Day 0, Above	3 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	RBC, Month 24, Within	74 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	NTPH, Month 7, Within	97 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	WBC, Month 18, Within	106 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	RBC, Month 18, Within	81 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	RBC, Month 12, Within	79 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	NTPH, Month 12, Within	92 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	NTPH, Month 12, Unknown	1 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	RBC, Month 7, Within	82 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	RBC, Month 6, Within	79 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	NTPH, Month 18, Within	98 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	NTPH, Week 6, Unknown	0 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	RBC, Week 10, Within	78 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	RBC, Week 6, Within	81 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	NTPH, Month 24, Within	92 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	WBC, Month 12, Within	103 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	RBC, Day 0, Within	83 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	RBC, Month 24, Below	38 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	NTPH, Day 0, Above	9 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	WBC, Month 7, Within	106 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	RBC, Month 18, Below	38 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	RBC, Month 12, Below	39 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	NTPH, Week 6, Above	11 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	NTPH, Month 18, Unknown	0 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	RBC, Month 7, Below	36 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	RBC, Month 6, Below	40 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	NTPH, Week 10, Above	7 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	NTPH, Day 0, Unknown	0 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	RBC, Week 10, Below	48 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	RBC, Week 6, Below	44 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	NTPH, Month 6, Above	5 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	WBC, Month 6, Within	106 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	RBC, Day 0, Below	43 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	RBC, Month 24, Unknown	1 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	NTPH, Month 7, Above	8 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	WBC, Week 10, Within	116 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	RBC, Month 18, Unknown	0 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	RBC, Month 12, Unknown	1 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	NTPH, Month 12, Above	10 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	NTPH, Month 24, Unknown	1 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	RBC, Month 7, Unknown	0 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	RBC, Month 6, Unknown	0 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	NTPH, Month 18, Above	8 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	WBC, Month 12, Above	4 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	RBC, Week 10, Unknown	0 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	RBC, Week 6, Unknown	0 Participants
HIV+/Cervarix Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	NTPH, Month 24, Above	9 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	NTPH, Month 24, Above	11 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	WBC, Month 12, Unknown	0 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	NTPH, Day 0, Unknown	0 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	NTPH, Week 6, Unknown	0 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	NTPH, Week 10, Unknown	0 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	NTPH, Month 6, Unknown	0 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	NTPH, Month 7, Unknown	0 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	NTPH, Month 12, Unknown	0 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	NTPH, Month 18, Unknown	0 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	NTPH, Month 24, Unknown	0 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	NTPH, Day 0, Below	12 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	NTPH, Week 6, Below	13 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	NTPH, Week 10, Below	17 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	NTPH, Month 6, Below	14 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	NTPH, Month 7, Below	17 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	NTPH, Month 12, Below	16 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	NTPH, Month 18, Below	15 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	NTPH, Month 24, Below	11 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	NTPH, Day 0, Within	99 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	NTPH, Week 6, Within	95 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	NTPH, Week 10, Within	100 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	NTPH, Month 6, Within	98 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	NTPH, Month 7, Within	93 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	NTPH, Month 12, Within	93 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	NTPH, Month 18, Within	89 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	NTPH, Month 24, Within	95 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	NTPH, Day 0, Above	17 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	NTPH, Week 6, Above	18 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	NTPH, Week 10, Above	10 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	NTPH, Month 6, Above	11 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	NTPH, Month 7, Above	11 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	NTPH, Month 12, Above	10 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	NTPH, Month 18, Above	13 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	PLAT, Day 0, Unknown	0 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	PLAT, Week 6, Unknown	0 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	PLAT, Week 10, Unknown	0 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	PLAT, Month 6, Unknown	0 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	PLAT, Month 7, Unknown	0 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	PLAT, Month 12, Unknown	0 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	PLAT, Month 18, Unknown	0 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	PLAT, Month 24, Unknown	0 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	PLAT, Day 0, Below	0 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	PLAT, Week 6, Below	0 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	PLAT, Week 10, Below	1 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	PLAT, Month 6, Below	2 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	PLAT, Month 7, Below	3 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	PLAT, Month 12, Below	1 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	PLAT, Month 18, Below	4 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	PLAT, Month 24, Below	2 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	PLAT, Day 0, Within	122 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	PLAT, Week 6, Within	119 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	PLAT, Week 10, Within	124 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	PLAT, Month 6, Within	118 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	PLAT, Month 7, Within	114 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	PLAT, Month 12, Within	114 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	PLAT, Month 18, Within	110 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	PLAT, Month 24, Within	110 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	PLAT, Day 0, Above	6 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	PLAT, Week 6, Above	7 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	PLAT, Week 10, Above	2 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	PLAT, Month 6, Above	3 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	PLAT, Month 7, Above	4 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	PLAT, Month 12, Above	4 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	PLAT, Month 18, Above	3 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	PLAT, Month 24, Above	5 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	RBC, Day 0, Unknown	0 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	RBC, Week 6, Unknown	0 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	RBC, Week 10, Unknown	0 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	RBC, Month 6, Unknown	0 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	RBC, Month 7, Unknown	0 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	RBC, Month 12, Unknown	0 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	RBC, Month 18, Unknown	0 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	RBC, Month 24, Unknown	0 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	RBC, Day 0, Below	38 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	RBC, Week 6, Below	36 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	RBC, Week 10, Below	37 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	RBC, Month 6, Below	39 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	RBC, Month 7, Below	34 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	RBC, Month 12, Below	31 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	RBC, Month 18, Below	31 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	RBC, Month 24, Below	34 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	RBC, Day 0, Within	87 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	RBC, Week 6, Within	85 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	RBC, Week 10, Within	87 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	RBC, Month 6, Within	81 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	RBC, Month 7, Within	84 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	RBC, Month 12, Within	86 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	RBC, Month 18, Within	80 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	RBC, Month 24, Within	83 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	RBC, Day 0, Above	3 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	RBC, Week 6, Above	5 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	RBC, Week 10, Above	3 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	RBC, Month 6, Above	3 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	RBC, Month 7, Above	3 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	RBC, Month 12, Above	2 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	RBC, Month 18, Above	6 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	RBC, Month 24, Above	0 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	WBC, Day 0, Unknown	0 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	WBC, Week 6, Unknown	0 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	WBC, Week 10, Unknown	0 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	WBC, Month 6, Unknown	0 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	WBC, Month 7, Unknown	0 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	WBC, Month 18, Unknown	0 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	WBC, Month 24, Unknown	0 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	WBC, Day 0, Below	7 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	WBC, Week 6, Below	11 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	WBC, Week 10, Below	9 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	WBC, Month 6, Below	6 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	WBC, Month 7, Below	9 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	WBC, Month 12, Below	13 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	WBC, Month 18, Below	10 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	WBC, Month 24, Below	5 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	WBC, Day 0, Within	116 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	WBC, Week 6, Within	111 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	WBC, Week 10, Within	113 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	WBC, Month 6, Within	116 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	WBC, Month 7, Within	108 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	WBC, Month 12, Within	103 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	WBC, Month 18, Within	107 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	WBC, Month 24, Within	107 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	WBC, Day 0, Above	5 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	WBC, Week 6, Above	4 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	WBC, Week 10, Above	5 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	WBC, Month 6, Above	1 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	WBC, Month 7, Above	4 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	WBC, Month 12, Above	3 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	WBC, Month 18, Above	0 Participants
HIV+/Gardasil Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	WBC, Month 24, Above	5 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	RBC, Month 24, Above	2 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	RBC, Month 24, Below	10 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	NTPH, Month 24, Below	9 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	PLAT, Month 24, Above	4 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	WBC, Day 0, Unknown	0 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	NTPH, Month 24, Within	83 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	WBC, Day 0, Above	3 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	WBC, Week 6, Unknown	0 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	NTPH, Week 6, Unknown	2 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	RBC, Day 0, Within	118 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	NTPH, Month 6, Above	15 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	WBC, Week 10, Unknown	0 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	WBC, Month 7, Above	3 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	NTPH, Month 18, Below	9 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	NTPH, Month 6, Unknown	0 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	WBC, Month 6, Unknown	0 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	WBC, Month 7, Within	106 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	RBC, Week 6, Within	118 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	WBC, Month 24, Above	5 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	WBC, Month 7, Unknown	0 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	RBC, Day 0, Below	18 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	NTPH, Month 12, Below	12 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	WBC, Month 12, Unknown	0 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	NTPH, Month 18, Within	86 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	NTPH, Month 12, Above	12 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	WBC, Week 6, Above	7 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	WBC, Month 18, Unknown	0 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	RBC, Week 10, Within	120 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	NTPH, Month 7, Below	10 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	NTPH, Day 0, Unknown	0 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	WBC, Month 24, Unknown	0 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	WBC, Week 10, Within	131 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	NTPH, Month 12, Unknown	0 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	RBC, Month 6, Within	111 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	WBC, Day 0, Below	5 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	RBC, Week 6, Below	14 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	NTPH, Month 6, Below	15 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	WBC, Month 18, Above	5 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	WBC, Week 6, Below	5 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	NTPH, Month 12, Within	84 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	RBC, Month 7, Unknown	0 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	WBC, Week 10, Above	1 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	WBC, Week 10, Below	2 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	RBC, Month 7, Within	100 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	NTPH, Week 10, Above	19 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	PLAT, Week 10, Below	0 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	NTPH, Month 18, Above	15 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	PLAT, Week 6, Below	1 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	NTPH, Week 10, Below	12 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	PLAT, Month 6, Below	0 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	WBC, Month 12, Within	100 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	RBC, Month 12, Within	88 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	RBC, Week 10, Below	11 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	PLAT, Month 7, Below	1 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	NTPH, Month 7, Within	92 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	PLAT, Day 0, Below	3 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	WBC, Month 6, Below	2 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	PLAT, Month 12, Below	0 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	RBC, Day 0, Unknown	0 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	RBC, Month 18, Within	97 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	WBC, Week 6, Within	124 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	PLAT, Month 18, Below	1 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	NTPH, Month 18, Unknown	0 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	PLAT, Month 24, Unknown	0 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	RBC, Month 6, Below	14 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	PLAT, Month 24, Below	2 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	RBC, Month 24, Within	91 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	RBC, Month 12, Unknown	0 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	NTPH, Week 10, Unknown	0 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	PLAT, Day 0, Within	133 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	NTPH, Month 6, Within	98 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	PLAT, Month 18, Unknown	0 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	WBC, Month 7, Below	5 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	PLAT, Week 6, Within	130 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	WBC, Month 12, Above	4 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	RBC, Day 0, Above	5 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	NTPH, Week 6, Above	20 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	PLAT, Week 10, Within	131 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	RBC, Week 10, Unknown	0 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	PLAT, Month 12, Unknown	1 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	NTPH, Week 6, Below	8 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	PLAT, Month 6, Within	127 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	WBC, Month 18, Within	100 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	RBC, Week 6, Above	4 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	RBC, Month 7, Below	15 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	PLAT, Month 7, Within	110 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	NTPH, Week 10, Within	104 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	PLAT, Month 7, Unknown	1 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	WBC, Month 12, Below	3 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	PLAT, Month 12, Within	103 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	NTPH, Month 7, Above	13 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	RBC, Week 10, Above	3 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	WBC, Day 0, Within	135 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	PLAT, Month 18, Within	106 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	WBC, Month 6, Within	122 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	PLAT, Month 6, Unknown	0 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	NTPH, Month 7, Unknown	0 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	PLAT, Month 24, Within	97 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	RBC, Month 6, Above	2 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	NTPH, Week 6, Within	107 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	WBC, Month 6, Above	3 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	PLAT, Day 0, Above	8 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	RBC, Month 12, Below	19 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	PLAT, Week 10, Unknown	1 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	WBC, Month 18, Below	4 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	PLAT, Week 6, Above	5 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	RBC, Month 7, Above	0 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	RBC, Month 18, Unknown	2 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	NTPH, Day 0, Above	16 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	PLAT, Week 10, Above	3 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	WBC, Month 24, Within	94 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	PLAT, Week 6, Unknown	1 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	NTPH, Day 0, Below	11 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	PLAT, Month 6, Above	1 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	RBC, Month 12, Above	1 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	RBC, Week 6, Unknown	0 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	NTPH, Day 0, Within	117 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	PLAT, Month 7, Above	3 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	RBC, Month 18, Below	9 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	PLAT, Day 0, Unknown	0 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	WBC, Month 24, Below	3 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	PLAT, Month 12, Above	4 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	RBC, Month 18, Above	2 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	NTPH, Month 24, Unknown	0 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	RBC, Month 6, Unknown	0 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	PLAT, Month 18, Above	3 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	RBC, Month 24, Unknown	0 Participants
HIV-/Cervarix Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	NTPH, Month 24, Above	11 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	NTPH, Month 6, Below	14 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	PLAT, Month 24, Above	5 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	RBC, Month 6, Above	4 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	NTPH, Week 6, Unknown	3 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	RBC, Day 0, Unknown	0 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	NTPH, Month 18, Above	11 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	RBC, Week 6, Unknown	1 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	WBC, Day 0, Within	140 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	RBC, Week 10, Unknown	0 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	NTPH, Month 12, Above	13 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	RBC, Month 6, Unknown	1 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	RBC, Month 7, Unknown	0 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	NTPH, Month 7, Above	10 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	RBC, Month 12, Unknown	1 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	WBC, Week 6, Within	135 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	RBC, Month 18, Unknown	3 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	NTPH, Month 6, Above	16 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	NTPH, Month 18, Unknown	0 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	RBC, Month 24, Unknown	0 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	RBC, Day 0, Below	13 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	NTPH, Week 10, Above	13 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	RBC, Week 6, Below	12 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	WBC, Week 10, Within	129 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	RBC, Week 10, Below	8 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	NTPH, Week 6, Above	10 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	RBC, Month 6, Below	12 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	WBC, Month 7, Above	4 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	RBC, Month 7, Below	19 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	NTPH, Day 0, Above	16 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	RBC, Month 12, Below	14 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	WBC, Month 6, Within	128 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	RBC, Month 18, Below	13 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	NTPH, Month 24, Within	89 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	NTPH, Month 12, Unknown	0 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	RBC, Month 24, Below	9 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	RBC, Day 0, Within	123 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	NTPH, Month 18, Within	92 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	RBC, Week 6, Within	120 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	WBC, Month 7, Within	120 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	RBC, Week 10, Within	122 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	NTPH, Month 12, Within	94 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	RBC, Month 6, Within	117 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	WBC, Month 24, Above	6 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	RBC, Month 7, Within	100 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	NTPH, Month 7, Within	106 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	RBC, Month 12, Within	100 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	WBC, Month 12, Within	115 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	RBC, Month 18, Within	96 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	NTPH, Month 6, Within	104 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	NTPH, Month 7, Unknown	0 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	RBC, Month 24, Within	98 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	RBC, Day 0, Above	5 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	NTPH, Week 10, Within	113 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	RBC, Week 6, Above	6 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	WBC, Month 18, Within	107 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	RBC, Week 10, Above	5 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	NTPH, Week 6, Within	116 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	WBC, Month 12, Above	1 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	RBC, Month 7, Above	6 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	NTPH, Day 0, Within	122 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	RBC, Month 12, Above	3 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	WBC, Month 24, Within	101 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	RBC, Month 18, Above	4 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	NTPH, Month 24, Below	10 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	NTPH, Month 6, Unknown	0 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	RBC, Month 24, Above	4 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	NTPH, Day 0, Unknown	0 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	WBC, Day 0, Unknown	0 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	WBC, Week 6, Unknown	0 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	NTPH, Month 18, Below	14 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	WBC, Day 0, Above	3 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	WBC, Week 10, Unknown	0 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	WBC, Month 6, Unknown	0 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	NTPH, Month 12, Below	11 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	WBC, Month 7, Unknown	0 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	WBC, Month 12, Unknown	0 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	NTPH, Month 7, Below	9 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	WBC, Month 18, Unknown	0 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	WBC, Week 6, Above	3 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	WBC, Month 24, Unknown	0 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	NTPH, Month 24, Unknown	0 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	NTPH, Week 10, Unknown	0 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	WBC, Day 0, Below	2 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	WBC, Week 6, Below	4 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	NTPH, Week 10, Below	10 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	PLAT, Week 6, Below	0 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	WBC, Week 10, Below	3 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	PLAT, Week 10, Below	0 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	PLAT, Month 6, Below	0 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	PLAT, Day 0, Below	0 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	WBC, Week 10, Above	4 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	PLAT, Month 7, Below	1 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	PLAT, Month 12, Below	2 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	PLAT, Month 24, Unknown	0 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	WBC, Month 6, Below	2 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	PLAT, Month 18, Below	2 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	NTPH, Week 6, Below	13 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	PLAT, Month 24, Below	3 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	PLAT, Month 18, Unknown	0 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	PLAT, Day 0, Within	138 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	PLAT, Week 6, Within	137 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	PLAT, Month 12, Unknown	0 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	WBC, Month 7, Below	1 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	PLAT, Week 10, Within	132 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	PLAT, Month 6, Within	131 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	PLAT, Month 7, Unknown	0 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	WBC, Month 18, Above	5 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	PLAT, Month 7, Within	121 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	PLAT, Month 12, Within	111 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	PLAT, Month 6, Unknown	0 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	WBC, Month 12, Below	2 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	PLAT, Month 18, Within	111 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	NTPH, Day 0, Below	7 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	PLAT, Month 24, Within	103 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	PLAT, Week 10, Unknown	0 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	PLAT, Day 0, Above	7 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	PLAT, Week 6, Above	4 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	PLAT, Week 6, Unknown	1 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	WBC, Month 18, Below	5 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	PLAT, Week 10, Above	4 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	PLAT, Month 6, Above	3 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	PLAT, Day 0, Unknown	0 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	WBC, Month 6, Above	4 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	PLAT, Month 7, Above	3 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	PLAT, Month 12, Above	5 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	NTPH, Month 24, Above	12 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	WBC, Month 24, Below	4 Participants
HIV-/Gardasil Group	Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters	PLAT, Month 18, Above	4 Participants

Secondary

Number of Subjects With SAEs

Time frame: During the entire study period (from Day 0 up to Month 24)

Population: The analysis was performed on the Total Vaccinated cohort for analysis of safety, which included all subjects with at least one vaccine administration documented.

Arm	Measure	Value (COUNT_OF_PARTICIPANTS)
HIV+/Cervarix Group	Number of Subjects With SAEs	9 Participants
HIV+/Gardasil Group	Number of Subjects With SAEs	9 Participants
HIV-/Cervarix Group	Number of Subjects With SAEs	4 Participants
HIV-/Gardasil Group	Number of Subjects With SAEs	1 Participants

Secondary

Pseudovirion-Based Neutralization Assay (PBNA) Titers of Anti-HPV-16/18 Antibodies in HIV- Subjects, Based on TVC

Titers of anti-HPV-16/18 antibodies, expressed as Geometric Mean Titers (GMTs), with cut-offs greater than or equal to (≥) 40 estimated dose giving 50% signal reduction when compared to a control without serum (ED50), as assessed by the Pseudovirion-Based Neutralization Assay \[PBNA\], for HIV- subjects. Between-group comparisons to assess superiority were performed on the TVC (by PBNA, regardless of HPV serostatus at baseline).

Time frame: At Month 7 (30 days after the last vaccination dose at Month 6)

Arm	Measure	Group	Value (GEOMETRIC_MEAN)
HIV+/Cervarix Group	Pseudovirion-Based Neutralization Assay (PBNA) Titers of Anti-HPV-16/18 Antibodies in HIV- Subjects, Based on TVC	Anti-HPV-16	60550.6 Titers
HIV+/Cervarix Group	Pseudovirion-Based Neutralization Assay (PBNA) Titers of Anti-HPV-16/18 Antibodies in HIV- Subjects, Based on TVC	Anti-HPV-18	32118.1 Titers
HIV+/Gardasil Group	Pseudovirion-Based Neutralization Assay (PBNA) Titers of Anti-HPV-16/18 Antibodies in HIV- Subjects, Based on TVC	Anti-HPV-16	19634.8 Titers
HIV+/Gardasil Group	Pseudovirion-Based Neutralization Assay (PBNA) Titers of Anti-HPV-16/18 Antibodies in HIV- Subjects, Based on TVC	Anti-HPV-18	5773.4 Titers

Comparison: Adjusted GMT ratio for anti-HPV-18 neutra antibody (ED50): To demonstrate that the immunogenicity of Cervarix vaccine (HIV-/Cervarix Group) was superior to that of Gardasil vaccine (HIV-/Gardasil Group), in terms of geometric mean titers (GMTs) against HPV-18, measured by Pseudovirion-based neutralization assay (PBNA) in HIV- subjects.p-value: <0.000197.5% CI: [3.2, 9.06]ANOVA

Comparison: Adjusted GMT ratio for anti-HPV-16 neutra antibody (ED50): To demonstrate that the immunogenicity of Cervarix vaccine (HIV-/Cervarix Group) was superior to that of Gardasil vaccine (HIV-/Gardasil Group), in terms of geometric mean titers (GMTs) against HPV-16, measured by Pseudovirion-based neutralization assay (PBNA) in HIV- subjects.p-value: <0.000197.5% CI: [1.84, 5.06]ANOVA

Source: ClinicalTrials.gov · Data processed: Mar 24, 2026

Evaluation of Safety and Immunogenicity of a Human Papillomavirus (HPV) Vaccine in Human Immunodeficiency Virus (HIV) Infected Females

Conditions

Keywords

Brief summary

Related papers

Interventions

Sponsors

Study design

Eligibility

Inclusion criteria

Exclusion criteria

Design outcomes

Primary

Secondary

Countries

Participant flow

Recruitment details

Pre-assignment details

Participants by arm

Withdrawals & dropouts

Baseline characteristics

Adverse events

Outcome results

Cluster of Differentiation 4 (CD4+) Cell Count in HIV+ Subjects at Month 7

HIV Viral Load (VL) in HIV+ Subjects at Month 7

Number of HIV+ Subjects by World Health Organization (WHO) HIV Clinical Staging

Number of HIV+ Subjects Reporting Pregnancies and Outcomes of Reported Pregnancies

Number of HIV+ Subjects With Any, Grade 3 and Related Solicited General Symptoms

Number of HIV+ Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs)

Number of HIV+ Subjects With Haematological and Biochemical Parameter Abnormalities

Number of HIV+ Subjects With Medically Significant Conditions (MSCs)

Number of HIV+ Subjects With Potential Immune-mediated Diseases (pIMDs)

Number of HIV+ Subjects With Serious Adverse Events (SAEs)

Number of Human Immunodeficiency Virus Positive Subjects (HIV+) With Any and Grade 3 Solicited Local Symptoms

Pseudovirion-Based Neutralization Assay (PBNA) Titers of Anti-HPV-16/18 Antibodies in HIV+ Subjects, Based on Adapted According-to-protocol (ATP) Cohort for Immunogenicity

Pseudovirion-Based Neutralization Assay (PBNA) Titers of Anti-HPV-16/18 Antibodies in HIV+ Subjects, Based on Total Vaccinated Cohort (TVC)

Anti-HPV-16 and Anti-HPV-18 Antibody Concentrations by ELISA in Cervicovaginal Secretion (CVS)

Anti-HPV-16 and Anti-HPV-18 Antibody Concentrations by Enzyme-linked Immunosorbent Assay (ELISA) in Serum

Cluster of Differentiation 4 (CD4+) Cell Count in HIV+ Subjects at Months 12, 18 and 24

Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response

Frequency of Specific B-cells for HPV-16/18 Antigens

HIV Viral Load (VL) in HIV+ Subjects at Months 12, 18 and 24

Number of HIV+ Subjects by WHO HIV Clinical Staging

Number of HIV- Subjects With Any and Grade 3 Solicited Local Symptoms

Number of HIV- Subjects With Any, Grade 3 and Related Solicited General Symptoms

Number of HIV- Subjects With Medically Significant Conditions (MSCs)

Number of HIV- Subjects With Potential Immune-mediated Disease (pIMDs)

Number of HIV- Subjects With Serious Adverse Events (SAEs)

Number of HIV- Subjects With Unsolicited Adverse Events (AEs)

Number of Subjects Reporting Pregnancies and Outcomes of Reported Pregnancies

Number of Subjects With Medically Significant Conditions (MSCs)

Number of Subjects With Potential Immune-mediated Diseases (pIMDs)

Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters

Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters

Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters

Number of Subjects With SAEs

Pseudovirion-Based Neutralization Assay (PBNA) Titers of Anti-HPV-16/18 Antibodies in HIV- Subjects, Based on TVC